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ABSTRACT 
This project investigated the effect of β2-adrenergic receptor (β2-AR) stimulation on the 
function of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells in vitro. 
Catecholamines have been previously shown to increase efflux of these cells into the blood, 
but the effects on cell function are unclear. In this thesis three aspects of function have been 
addressed. The results of the studies presented in this thesis showed that: 
(1) β2-adrenergic stimulation by salmeterol reduced the percentage of IFN-γ producing CD4+ 
and CD8+ T cells activated by Staphylococcus Aureus enterotoxin type B (SEB) 
superantigen, cytomegalovirus lysate (CMV) or CMV pp65 (pp65) recombinant protein.  
(2) salmeterol, at high concentrations, increased rolling behaviour and decreased stationary 
behaviour of peripheral blood lymphocytes (PBLs) on human microvascular cell line 
(HMEC-1) and on vascular cell adhesion molecule-1 (VCAM-1), in both flow and static 
assays. 
(3) adrenergic stimulation impaired the activation and cytotoxic function of CD8+ T and NK 
cells, as indicated by lower expression of CD107a (a marker of CD8+ T and NK cell 
activation and function) following incubation of peripheral blood mononuclear cells (PBMCs) 
with human erythromyeloblastoid leukemia (K562) cell line or MHC class I chain-related 
gene A (MICA*009) transfected Chinese hamster ovary cells (T-CHO) was analysed.  
The results presented in this thesis showed that adrenergic stimulation influences a number of 
cellular functions, such as those related to migration, cytokine production and cytotoxic 
function. Together the above studies may contribute to our understanding about how stress 
affects the ability of the cytotoxic cells. 
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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
1.1 The Immune System 
The mammalian immune system is a complex system consisting of two different arms - innate 
and adaptive immunity, each with distinct cell types and functions. The cooperative 
interactions of these two arms are required for the elimination of infective pathogens with 
high efficiency (Kawai and Akira, 2009). The innate immune response represents the first line 
of defence towards invading pathogens and mounts an immediate and non-specific immune 
response (Sternberg, 2006). In order to be able to sense these microbial infections, the innate 
sentinel cells (i.e., phagocytes including neutrophils, natural killer cells (NK), macrophages 
and dendritic cells) express pattern recognition receptors (PRRs) that recognise pathogen-
associated molecular patterns (PAMPs). Since PAMPs are broadly expressed on many 
different types of pathogens (bacteria, viruses or fungi) but are not present in host cells, PRRs 
can discriminate between self and non-self cells (Iwasaki and Medzhitov, 2010; Kawai and 
Akira, 2009). Following binding of PRRs to PAMPs, neutrophils, monocytes (or 
macrophages once located in the tissue) and dendritic cells engulf and destroy the foreign 
micro-organism by the process of phagocytosis and induce inflammatory responses. The 
inflammatory responses are characterized by an increase in local blood flow and increased 
vascular permeability (i.e. of blood vessels and tissues) to allow the escape of leukocytes from 
the blood stream to the site of injury and infection. This recruitment of leukocytes to the sites 
of injury and infection is extremely important in promoting the antigen clearance and wound 
healing. 
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1.1.1 Introduction to NK Cells 
Originally, NK cells were described as large granular lymphocytes that had natural 
cytotoxicity against tumour cells, viruses, bacteria, parasites, all of which cause stress in 
affected cells (Anfossi et al., 2006; Bosch et al., 2005a; Cooper et al., 2001; Evans et al., 
2011; Loza et al., 2002; Paust and von Andrian, 2011; Vivier et al., 2008). It was not until 
later that they were recognised as a separate lymphocyte lineage with both cytotoxicity and 
cytokine effector functions (Vivier et al., 2008). 
NK cells represent only a minor fraction of total lymphocytes (2 %-18 %) in peripheral blood 
of humans and are located throughout lymphoid and non-lymphoid tissues. These front line 
defenders have the capacity to migrate quickly in and out of tissues enabling them to be 
among the first immune cells to arrive at sites of tissue damage and infection (Bosch et al., 
2005b). The importance of NK cells in human host immunity is clearly observed in patients 
with isolated genetic deficiencies in NK cells who contract severe infectious diseases despite 
the presence of functional T cells and B cells (Paust and von Andrian, 2011).  
 In humans, NK are recognised by the expression of CD56 and CD16 cell surface antigens, in 
combination with absence of the pan-T cell marker CD3. Whereas, CD56 is expressed on all 
NK cells, CD16 is not. CD16 is a low affinity fragment crystallisable (Fc) receptor that 
enables NK to detect antibody-coated target cells and thus to exert antibody dependent cell 
cytotoxicity (ADCC) (Cooper et al., 2001; Paust and von Andrian, 2011; Vivier et al., 2008), 
a mechanism of cell-mediated immunity that causes the lysis of target cells coated with 
antibody, by effector cells with cytolytic activity. 
There are two major subsets of NK cells; CD56dim (low expression of CD56) or CD56bright 
(high expression of CD56) (Bosch et al., 2005a; Cooper et al., 2001; Suzui et al., 2004; Vivier 
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et al., 2008). These NK populations differ in their trafficking (Evans et al., 2011) and 
cytotoxic properties (Anfossi et al., 2006). The CD56dim cells compromise 90% of the 
peripheral blood and spleen NK cells and are cytotoxic related to their high expression levels 
of perforin. In contrast, most of the CD56bright CD16–  NK cells reside in lymph nodes and 
tonsils, lack perforin, and produce cytokines such as interferon-gamma (IFN-γ) (Vivier et al., 
2008). Also, while CD56dim NK cells express high levels of CXCR1 (CXC chemokine 
receptor 1) and CX3CR1 (CX3C chemokine receptor 1), which are required for their 
migration to peripheral inflammatory sites, CD56bright NK cells express migration markers 
that facilitate traffic to secondary lymphoid organs (SLO) such as CCR7 (lymphoid CC-
chemokine receptor 7), CXCR3 (CXC chemokine receptor 3) and CD62L (L-selectin). With 
the inclusion of CD16 human peripheral blood NK cells can be separated into five different 
subpopulations of NK cells according to the cell surface density (Poli et al., 2009). These are 
(1) CD56dim CD16bright, (2) CD56dim CD16-, (3) CD56bright CD16dim, (4) CD56bright CD16-, (5) 
CD56- CD16bright. Out of these different NK cell subpopulations, the majority of functionally 
distinct NK cell subsets include CD56dim CD16bright and CD56bright CD16dim/- (Fig.1.1.). 
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Figure 1.1. Two main NK cell subsets. Schematic representation of human CD56dim CD16+ and CD56bright CD16- NK cells including their 
surface phenotype and functional properties. Figure was taken from (Hanna and Mandelboim, 2007).
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1.1.2 NK Cell Receptors 
On the bases of their structural homologies, natural killer cell surface receptors can be divided 
into two groups. The first group includes killer cell immunoglobulin-like receptors (KIRs) 
and leukocyte immunoglobulin-like receptors (LILRs). These consist of type 1 
transmembrane glycoproteins with two or three extracellular immunoglobulin like domains 
responsible for ligand recognition (Campbell and Purdy, 2011; Farag et al., 2002; Lanier, 
2008; Strong and McFarland, 2004). The second family of human NK receptors includes the 
C-type lectin family and is characterized by a C-type lectin extracellular domain. One 
example of the C-type lectin NK receptor is the heterodimeric CD94-NKG2A. This is 
composed of a (CD94) glycoprotein that is covalently (disulfide) bonded to a chain encoded 
by a gene of the C-type lectin NKG2 family (Farag et al., 2002; Lanier, 1998; Radaev and 
Sun, 2003). 
1.1.3 Inhibitory Receptors 
All NK cells undergo a maturation step which serves as an education process which enables 
NK cells to become competent and recognise self-MHC class 1 molecules through which they 
become “tolerant to self” or the lack of self-MHC class 1 molecules otherwise referred to as 
the “missing self” (Fig.1.2). The recognition of the self-MHC class 1 occurs by the specific 
inhibitory receptors, KIR in humans, equivalent to the lectin-like Ly49 dimers in mice. When 
NK cells encounter cells with decreased expression of MHC class 1 molecules (i.e. virally-
infected or tumour cells), they are no longer controlled by inhibitory signals and NK cell 
cytotoxicity and cytokine production will be promoted (Anfossi et al., 2006; Vivier et al., 
2008). 
 
 
6 
 
It is important to note that despite their structural diversity, all inhibitory NK receptors have 
long cytoplasmic domains with an immunoreceptor tyrosine-based inhibitory motifs (ITIMs) 
which are directly phosphorylated to induce inhibitory signals (Campbell and Purdy, 2011; 
Lanier, 2008). More specifically, it is thought that when the ITIM bearing receptors bind their 
MHC-I ligands, the tyrosine residues in the ITIMs, are phosphorylated by a Src family kinase, 
and provide docking sites for cytoplasmic phosphatases having a Src homology 2 (SH-2) 
domain,  SHP-1 and SHP-2, which dephosphorylate critical tyrosine phosphoproteins that 
propagate activation signalling thereby inhibiting the NK cell activation towards  target cell 
(Campbell and Purdy, 2011; Lanier, 2008; Treanor et al., 2006) (Fig.1.3.).   
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Figure 1.2. NK cell self-tolerance and the “missing self hypothesis”. A-Upon 
interaction with a normal target cell, a NK cell might receive activating signals. Despite 
this, the inhibitory signals from the ligated MHC-binding receptor at the surface of NK 
cells prevent the autologous target cell lysis, because the target cell expresses the 
appropriate self-MHC class I alleles. B-Viral infection and transformation causes the 
target cell to lose the expression of MHC class I molecules and thereby results in the 
disengagement of the MHC-binding inhibitory receptor at the surface of NK cell. With 
no inhibitory signals received to prevent the autologous target cell lysis, the target cell is 
perceived by the NK cell to be missing self. C-In the case of an allogeneic transplant, 
NK cells of the host interact with donor target cells that express foreign MHC class I 
alleles. However, due to the fact that the foreign non-self MHC class I molecules do not 
engage all of the inhibitory receptors at the surface of a host NK cell, allogeneic cells 
are lysed by NK cells. Figure was taken from (Kumar and McNerney, 2005). 
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Figure 1.3. NK cell effector signalling pathways. ITAM-associated NK cell activating 
receptors as well as inhibitory receptors are presented.  Figure was taken from (Vivier et 
al., 2004).  
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1.1.4 Activating Receptors 
Since receptor inhibition of NK cell function prevents killing of self- MHC class I cells, to be 
able to exert their cytolytic activity, NK cells require activating signals generated upon 
effector/target cell interaction (Fauriat et al., 2010; Lanier, 2005; Moretta et al., 2011b; 
Verheyden and Demanet, 2008).   
Several NK cell activating receptors involved in activation of NK-cell effector functions have 
been identified. These include the natural cytotoxicity receptors, (NCR- NKp46, NKp30, and 
NKp44) (Moretta et al., 2001a; Moretta et al., 2001b; Moretta et al., 2011a), the C-type lectin 
surface receptors (CD94/NKG2C; CD94/NKG2E and NKG2D); activatory KIRs (KIR2Ds, 
KIR3Ds), and the low affinity immunoglobulin gamma Fc region receptor III-A (FcRIIIA) 
(Moretta et al., 2001b; Moretta et al., 2011a; Moretta et al., 2011b; Vivier et al., 2004; Vivier 
et al., 2008). In contrast to the inhibitory receptors, all activating receptors lack ITIMs and 
carry short cytoplasmic domains, which upon non-covalent  association with adapter 
polypeptides that carry an immuno-receptor tyrosine-based activation motifs (ITAMs), enable 
the transmission of the activating signals (with exception of NKG2D). NK cells express 
constitutively several ITAM-bearing adapter proteins including CD3 (CD3 zeta chain), 
FcRI (Fc epsilon receptor gamma chain) and DAP12 (DNAX-activating protein of 12 kDa). 
In humans, CD3 and FcRI associate with NKp30, NKp46, and CD16, whereas DAP12 
pairs with several members of activating killer cell immunoglobulin receptors (KIRs); and C-
type lectin like receptors, as well as NKp44 (Lanier, 2003; Lopez-Larrea et al., 2008; Vivier 
et al., 2004).  
1.1.5 NKG2D 
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NKG2D is a type II transmembrane-anchored C-lectin-like protein encoded by a gene located 
on human chromosome 12p13 and mouse chromosome 6. It acts as an activating cell surface 
receptor and is expressed by NK cells, T (gamma-delta T) cells, NKT (Natural killer T) 
cells, some cytolytic CD8+ T (alpha-beta T) cells and CD4+ T cells (Billadeau et al., 2003; 
Lanier, 2003, 2005, 2008; Radaev and Sun, 2003). The NKG2D receptor is implicated as a 
key trigger for some forms of NK cell-mediated cytotoxicity and has generated tremendous 
interest due to the finding that it allows activation of NK cells following recognition of viral 
infected and transformed cells that have upregulated expression of “stress induced” NKG2D 
ligands (Billadeau et al., 2003; Lanier, 2003; Radaev and Sun, 2003). 
 Stress induced ligands recognised by NKG2D include MHC class I related chains (MICs) 
(i.e. MICA, MICB) and UL16 binding proteins (ULBPs) in humans, and retinoic acid early  
transcripts-1 (Rae-1),  minor histocompatibility antigen H60 and ULBP-like transcript-1 in 
mice (Ashiru et al., 2009; Billadeau et al., 2003; Endt et al., 2007). MICA and MICB are 
often expressed in epithelial tumours in lung, breast, kidney, ovary, prostate and colon 
carcinomas (Bauer et al., 1999; Groh et al., 2006). In mice the anomalous expression of MIC 
homologue Rae in local tissues, strongly stimulates antitumor immunity leading to tumor 
rejection by NK and CD8+ T cells, whereas in humans elevated levels of the soluble MICA 
(resulting from proteolytic shedding of the MICA by tumour cells) correlated with the 
progression of the prostate cancer (Holdenrieder et al., 2006). Following interaction with its 
specific ligand, NKG2D associates with a transmembrane–anchored adapter protein (DAP10). 
DAP10 (which is expressed as a disulfide linked homodimer) has a short (21 amino acids) 
cytoplasmic domain which contains an YxxM –signalling motif (where x donates any amino 
acid). Phosphorylation of this motif results in its association with p85 subunit of 
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phosphatidylinositol-3 kinase (PI3 kinase) and Growth factor receptor-bound protein 2 (Grb2) 
(Lanier, 2003, 2008) (Fig.1.4.). 
The importance of NKG2D in antiviral immunity is best observed in human and mouse 
cytomegalovirus (CMV) (Lanier, 2005). The human CMV encodes a recombinant UL16 
protein, which upon intracellular interaction with NKG2D ligands, prevents their expression 
on the surface of the infected cells. As result, the susceptibility of the infected cells to 
NKG2D-dependent NK effector functions are diminished. A second human CMV encoded 
protein UL142 down modulates the expression of MICA by retaining it in the cis-Golgi 
apparatus (Ashiru et al., 2009). Recently the importance of NKG2D has also been 
demonstrated in gastric cancer patients who exhibit decreased expression of this receptor 
(Saito et al., 2011).  
Despite its essential role in antiviral and anti-tumour immunity, ligation of NKG2D receptor 
alone is not adequate to induce the activation of NK cells. In fact with exception of CD16, the 
binding of a single activating receptor is not sufficient to trigger the NK cell effector 
functions. This was clearly demonstrated by Bryceson et al. (2006) who used agonistic 
antibodies directed against various surface activating receptors and observed that when 
NKp46, NKG2D, CD2, or DNAM-1 (DNAX-accessory molecule-1) activating receptors were 
used in isolation, stimulating any of these receptors produced little or no target lysis. In 
contrast, simultaneous cross-linking of different pairs or combinations of receptors by agonist 
antibodies, induced a combinative effect on both cytokine production and lytic activity 
(Bryceson et al., 2006; Lanier, 2008) suggesting that the triggering of NK cell effector 
functions is a result of several signalling pathways originated from a number of activating 
receptors (Lanier, 2008; Vivier et al., 2004). 
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NK cells also utilise other methods to detect and kill the tumour and viral infected cells. NK 
cells recognise infectious nonself ligands (the CMV-encoded m157) by toll like receptors 
(TLRs). Indeed, NK cells express several TLRs which induce IFN-γ production and enhance 
cytotoxicity in vitro (Vivier et al., 2008). As stated above, NK cells also detect target cells 
that are coated with antibody by their expression of their low affinity Fc receptor CD16 
(Bosch et al., 2005a; Vivier et al., 2008), CD56dim NK cell have high level expression of KIRs 
and IL-2 which may control and regulate their cytotoxic properties, the expression of these 
inhibitory receptors is low or absent in the CD56bright NK cell (Hanna and Mandelboim, 2007; 
Jacobs et al., 2001). Instead CD56bright NK subset has high expression of CD94/NKG2A 
inhibitory receptors, which are expressed at low levels in CD56dim NK cell subset. In contrast, 
both NK subsets express the activatory NKG2D receptor. Therefore most cells are protected 
by normal expression of MHC class I, while a cell lacking MHC class I will be killed. If cells 
express both MHC class I and NKG2D ligands it will depend on the balance of signals 
between stimulation and inhibition of the killing response. Finally, NK cell can be activated 
through the surface receptors Fas ligand (FasL) or TNF-related apoptosis-inducing ligand 
(TRAIL-R) directly on target cells to induce their lysis and apoptosis in a cell-contact 
dependent manner. 
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Figure 1.4. Two pathways of NK cells cytotoxicity. The elimination of transformed 
cells occurs through one of the two contact-dependent mechanisms. A-Granule 
exocytosis; following recognition of the target cell, NK cells release the cytotoxic 
granule contents, perforin and granzymes. Upon entry into target cells cytoplasm, 
granzymes induce apoptotic cell death either via the activation of cellular caspases or 
via caspase-independent pathways. B-Death receptor engagement; Following the 
activation of NK cells with cytokines and the triggering of the activation receptors, NK 
cells express on their surface Fas ligand (FasL), tumor necrosis factor-alpha (TNF-α), 
and TNF-related apoptosis-inducing ligand (TRAIL).Upon engagement and aggregation 
of target cell death ligands by their specific receptors (Fas, TNF, TRAIL-R1/TRAIL-R2 
respectively), NK cells induce apoptosis of the target cells in a caspase dependent 
mechanism. Figure was taken from (Smyth et al., 2005). 
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1.1.6 NK Cell Killing 
Following recognition of the tumor and virally infected cells, NK cells mediate killing by two 
major effector functions. Firstly, NK cells release cytotoxic granules such as granzymes and 
perforin. Perforin is a membrane disrupting protein, which plays an essential role in target-cell 
apoptosis mediated by cytotoxic T lymphocytes CTLs and NK cells. More specifically, its 
indispensable role in the apoptosis of viral and transformed cells involves mediating the entry 
of granzymes into their (target-cell) cytoplasm. Granzymes are a family of structurally related 
serine proteases, released from the secretory granule contents of the cytotoxic lymphocytes 
through the process of exocytosis and are responsible for promoting target cell apoptosis. 
Human NK cells express five different granzymes. These include granzymes A, B, K, H and 
M. Two models of perforin action have been described. Firstly, that perforin polymerized in 
response to calcium and placed itself into the membrane of transformed cells, creating a 
channel which allowed the passage of granzymes (Lieberman, 2003; Motyka et al., 2000). 
Secondly that granzymes enters the cytosol of the target cells in a perforin independent 
manner through either interaction with a cell surface receptor(s) (i.e. granzyme B requires the 
interaction and binding with the cation-independent mannose 6-phosphate/insulin-like growth 
factor receptor (CI-MPR) to be taken up and induce the apoptosis of target cells) or through 
the activation of clathrin- and dynamin-dependent endocytosis (which removes perforin and 
granzymes from the plasma membrane to early endosomes) (Thiery et al., 2010; Trapani et 
al., 2003). 
NK cells express on their surface at least three tumour necrosis factor (TNF)-family death 
ligands including FasL, TNF-α, and TRAIL. Upon engagement and aggregation of target cell 
death ligands by their specific receptors (Fas, TNF, TRAIL-R1/TRAIL-R2 respectively) NK 
cells induce apoptosis of the target cells in a caspase dependent mechanism (Screpanti et al., 
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2005; Trapani and Smyth, 2002). The increased susceptibility to virus induced death and 
tumor development after neutralisation of TRAIL in vivo (Takeda et al., 2002), indicates the 
contribution of death-receptor mediated apoptosis to NK cell cytotoxicity. In addition to 
conferring cytotoxicity, the production of IFN-γ by the NK cells, also participates to the 
shaping of the adaptive immune response (Anfossi et al., 2006; Martin-Fontecha et al., 2004). 
Overall, NK cell activity is regulated by the dynamic balance between signals that either 
activate or inhibit each-other (Anfossi et al., 2006; Vivier et al., 2008).  
1.2 The Adaptive Immune Response 
Although the innate immune system has evolved to rapidly sense and effect the elimination of 
a wide range of pathogens, it is not always able to completely eliminate a foreign invader 
(Bonilla and Oettgen, 2010).  This has led to the evolution of adaptive immune system which 
is a more specialised antigen-specific response. Adaptive immune system responses are 
primarily generated by B cells and T cells. Following development in the primary lymphoid 
organs (bone marrow and thymus), B and T lymphocytes traffic to secondary lymphoid 
organs such as lymph nodes and spleen in order to sample antigens from lymph and blood 
(Bonilla and Oettgen, 2010).  To be able to recognise and interact with pathogens, both B and 
T cells possess the expression of enormous repertoire of antigen receptors on their surface 
with a potentially unique specificity for a particular pathogen or protein fragment (a peptide) 
(Chaplin, 2006). B cell receptors (BCR) interact directly with free antigen, whereas T cell 
receptors (TCR) can only interact with peptide antigens displayed by the major 
histocompatibility complex (MHC) molecules expressed by antigen presenting cells (APCs). 
APCs include dendritic cells, macrophages and B cells. These are specialised samplers of 
environmental antigens and danger signals (Bonilla and Oettgen, 2010) mainly present as 
immature APCs in the skin and mucosal sites where pathogen encounter is more likely to 
 
 
16 
 
occur. Following antigen recognition during an infection via TLRs for example, APCs 
phagocytose pathogens and present processed microbial antigens on their surface in 
combination with MHC class II. Maturation follows as the cells migrate towards lymph 
nodes, via the lymphatic system, where they present the antigens to migrating T cells by 
MHC molecules. These T cells, scan the foreign antigen-MHC complex in a such way that if 
a T lymphocyte has an antigen receptor complimentary to the presented antigen, it will bind to 
the MHC/peptide complex, and begin to clonally expand giving rise to effector T 
lymphocytes (including cytotoxic-T cells, T-helper cells, and memory cells). This clonal 
expansion represents the fundamental basis of acquired immunity providing large number of 
effector cells to migrate to the original site of infection in order to eliminate it. Upon 
resolution of the infection, most antigen-specific cells die, and are cleared away by 
phagocytes. However, a small number of these antigen-specific lymphocytes are retained as 
long lived memory cells for subsequent encounters with the same antigen (Alberts et al., 
2002). Thus one of the crucial characteristics of the adaptive immune system is its ability to 
retain an “immunological memory”, and mount a secondary immune response. Unlike the 
primary immune response (a response to a pathogen not encountered before by the immune 
system), which is slow and becomes apparent several days after the initial infection, (during 
an initial antigen encounter the production of antigen-specific population can take up to 6 
days) this secondary immune response is very rapid and efficient (immune response can occur 
as early as 2 days) and prevents any clinical indications of the re-infection thereby rendering 
the immunological memory one of the main advantages of the adaptive immune system. 
1.2.1 T Lymphocyte Populations 
T cells can be classified in two different main categories, CD4+ T lymphocytes (CD4+ TLs), 
otherwise referred to as T-helpers (Th) and CD8+ T lymphocytes (CD8+ TLs) also known as 
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cytotoxic T lymphocytes (CTLs). The main function of CD4+ TLs is to regulate and assist in 
active immune responses by releasing cytokines. Cytokines are chemical messengers between 
the immune cells which play a crucial role in maintaining the homeostasis within the immune 
system by mediating inflammatory and immune responses.  CD4+ TLs can be divided into 
various different types, with distinct cytokine secretion phenotype giving rise to unique 
functional characteristics for each type, including Th-1, Th-2 , Th-17 and T regulatory cells 
(Kaiko et al., 2008). Th-1 are involved in the secretion of IFN-γ, IL-2, and TNF-β, which 
promote cellular immunity and stimulate the functional activity of  CD8+ TLs, and activated 
macrophages to destroy intracellular bacteria (Elenkov et al., 2008). Th-2 cells primarily secrete 
IL-4, IL-10, and IL-13 which promote allergic inflammation, up-regulate antibody production 
and target parasitic organisms (Elenkov et al., 2008; Kaiko et al., 2008). Th-17 represent a 
distinct class of CD4+ T effector cells that do not fall into either Th-1 or Th-2 category. As their 
name suggests, Th-17 are involved in production of proinflammatory molecules of the IL-17 
family including IL-17A-F. IL-17A-F promotes tissue inflammation in response to extracellular 
bacteria and fungi, by inducing proinflammatory cytokines and chemokines that attract and 
activate granulocytes, macrophages and neutrophils (Kurts, 2008). In contrast to the 
aforementioned T helper subsets, Treg are regulatory T cells which suppress the activity of 
effector and autoreactive T cells in vivo by several mechanisms including production of IL-10 
and transforming growth factor-β (TGF-β) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) 
(Nelson, 2004; Rudensky, 2011; Sansom and Walker, 2006).   
1.2.2 Subsets of Human CD8+ T Cells 
Nowadays, it is possible to discriminate up to 14 CD8+ TLs cell subsets rendering the CD8+ 
TLs population indeed very heterogeneous (Chen et al., 2001; Monteiro et al., 2007; Sallusto 
et al., 2004; Sallusto et al., 1999; van Lier et al., 2003). The different subsets of human 
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memory CD8+ TLs can be identified on the basis of differential expression of the surface 
markers and homing receptors both of which are related to their activation and function (Chen 
et al., 2001). The three main subpopulations of CD8+ T cell compartment include naïve, 
effector and memory subsets. For example, naïve cells are characterized by the expression of 
CCR7 (lymph node homing marker) and CD62L (high endothelial venules homing marker) 
because they continuously travel between the lymph nodes, where the antigen is presented by 
the APCs. In addition they express co-stimulatory molecules CD27 and CD28 which are 
important for their activation but do not reacquire markers of effector cells like perforin or Fas 
ligand as they have never encountered an antigen before and thus do not exhibit effector 
functions.  
Von Andrian and Mackay described function and migration of T cells as “two sides of the 
same coin”. This makes sense when considering the fact that in addition to the migratory 
potential, the CCR7 marker is also related to the specific functional capacity of that cell. For 
example CCR7– cells have a superior ability to produce effector cytokines (i.e. IFN-γ) 
following stimulation compared to CCR7+ cells. In addition to the markers described above, 
naïve cells can also be discriminated by their expression of the CD45RA marker (leukocyte 
common antigen isoform). This is one of the four isoforms of the CD45, with each isoform 
being characterized by a specific molecular weight. The CD45R marker is unusual as it is 
converted into the CD45RO isoform after antigenic stimulation of the naïve T cells and then 
following further stimulation is reversibly re-expressed in CD45RA+ effector memory cells.  
Since both, naïve cells and CD45RA+ effector memory cells express this marker; CD45RA+ 
cannot, on its own be used to distinguish between naïve cells and CD45RA+ effector memory 
cells, but is used in combination with other markers previously described. This is extremely 
important in terms of distinguishing between two different CD8+ TLs subsets as for example 
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unlike the naïve cells; CD45RA+ effector memory cells lack the surface expression of the co-
stimulatory molecules CD27 and CD28 respectively. Like naïve cells, central memory cells, 
(CM; CD45RA−, CCR7, CD28-, CD27+) which have previously responded to an infection 
also express CCR7 in order to interact with the APCs in the lymph node, but lack the co 
stimulatory receptor CD28- and are therefore referred to as the intermediate cells, a name that 
relates to their position along the linear pathway of differentiation (Appay et al., 2002). 
Following activation, CM cells differentiate into effector memory (EM; CD45RA−, CCR7−, 
CD28-, CD27-); and further CD45RA+ effector memory (EMRA; CD45RA+, CCR7−, CD28-, 
CD27-) (Appay et al., 2002; Chen et al., 2001; Sallusto et al., 2004; Sallusto et al., 1999). 
CD8+ EM cells have a potent lytic and cytotoxic activity as result of their rapid production of 
high levels of perforin, granzyme a, IFN-γ and TNF-α cytokines. Referred to as the “late”  
differentiated cells due to their lack of the CD28 and CD27 co-stimulatory molecules for  
activation, they show immediate effector functions in the peripheral tissues where the 
infection takes place.  As they are localised in the inflamed tissues, they do not express the 
lymph node homing marker CCR7, but instead express receptors that allows them to home to 
inflamed areas. In addition to the general CD8+ TLs population, in the recent years, even the 
effector memory (EM; CD45RA−, CCR7−, CD28-, CD27-) CD8+ TLs population has been 
described heterogeneous (Monteiro et al., 2007; Romero et al., 2007). By combining the 
simultaneous analysis of surface markers, the multiparameter flow cytometry revealed four 
distinct subsets of effector memory cells. These include: CD28+CD27+ EM1 and EMRA1 
sub-types; CD28−CD27+ EM2 and EMRA2 sub-types; CD28−CD27− EM3 and EMRA3 sub-
types; and the CD28+CD27− EM4 sub-type, with increasing differentiation and cytolytic 
activity from EM-1 to EM-4.  
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1.2.3 Viral Infection and CD8+ TLs Differentiation 
CD8+ TLs play a crucial role in defense against infected cells and tumors. The understanding 
of the mechanisms through which the immune system controls such pathological situation, 
depends on the understanding of mechanisms involved in CD8+ TLs differentiation and the 
development of distinct memory subsets following an initial encounter with the antigen 
(Monteiro et al., 2007; Schluns and Lefrancois, 2003). To date, the precise pathways involved 
in CD8+ TLs differentiation and distinct memory subsets development have been the subject 
of intense debate and are not completely understood (Schluns and Lefrancois, 2003; van Lier 
et al., 2003). There are now data indicating that the frequency of antigenic stimulation and 
environmental cytokines, in particular IL-7 and IL-15 act at each stage of the immune 
response and are crucial factors to promoting proliferation and survival of CD8+ TLs 
(Gamadia et al., 2004; Kaech et al., 2003; Schluns and Lefrancois, 2003; Weng et al., 2002).  
Studies of CD8+ TLs demonstrate that response is related to its infection history, as T cells 
with specificities for different persistent viruses vary in phenotype and function (Appay et al., 
2002; Gamadia et al., 2004; van Lier et al., 2003; Waller et al., 2008). The response to CMV 
results in an immunological response largely characterised by terminally differentiated-
effector-memory subsets (CCR7-CD27-CD28-CD45RA+) (Khan et al., 2002; Klenerman and 
Dunbar, 2008; van Lier et al., 2003). CMV is a major -herpes virus infecting above 70% of 
the world’s wide population (Fletcher et al., 2005; Gillespie et al., 2000; Khan et al., 2002; 
Osawa and Singh, 2009). As with any other virus, once CMV enters the cell, it causes a 
primary infection. However because of the host’s inability to eliminate the virus, it will lead 
to a latent infection whereby the presence of the virus in the host will be permanent 
throughout the host’s lifetime. The CD8+ TLs differentiation phenotype observed following 
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the CMV infection is thought to occur as result of repeating activation of CMV specific CD8+ 
TLs due to the intermittent reactivation of CMV in the host’s body. 
In contrast to infection with CMV, Epstein-Barr virus (EBV) (a latent herpes virus infecting 
90% of population) infection gives rise to an early or intermediate effector-memory 
phenotype (CCR7-CD27+CD28+CD45RA-) (Appay et al., 2002; van Lier et al., 2003), 
whereas infection with influenza (a virus that does not cause chronic infections) exhibits an 
early-effector memory phenotype (CCR7+CD27+CD28+CD45RA-) (van Lier et al., 2003). The 
fact that these individual viruses have the ability to induce different responses in the memory 
and latency phase indicates that the immune system has developed means to establish 
protection during co-evolution with viruses depending both on the viral load and the 
biological properties of the virus (van Lier et al., 2003). 
1.3 STRESS AND IMMUNE FUNCTION 
1.3.1 The Birth of Psychoneuroimmunology 
The term psychoneuroimmunology was coined by Robert Ader (a psychologist) and Nicholas 
Cohen (an immunologist) who demonstrated that immune system could be classically 
conditioned (Ader and Cohen, 1975). In an experiment of classical conditioning of rats Ader 
and Cohen (1975) fed rats with a combination of saccharin-laced water (the conditioned 
stimulus) and the drug Cytoxan which unconditionally induces nausea and taste aversion, and 
suppression of the immune system. As a result, mice learned to avoid saccharin. What was 
considered a surprising discovery reflected the fact that when the experiment was repeated 
without the injection of drug to reverse the aversion, high proportion of rats died  when 
receiving saccharin alone (Ader and Cohen, 1975). Thus, conditioning of rats was adequate 
enough to cause the death of high proportions of rats and Ader and Cohen explained this 
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finding by proposing that rats had been immunosuppressed after receiving the conditioned 
stimulus. To test this hypothesis, they deliberately immunized conditioned and unconditioned 
animals, and exposed these and other control groups to the conditioned taste stimulus and 
measured the amount of antibody produced. The results showed that conditioned rats exposed 
to the conditioned stimulus were indeed immunosupressed indicating that a signal via the 
nervous system (taste) was affecting the immune system. This was one of the first scientific 
experiments that demonstrated that the immune system can be affected by the nervous system 
(Ader and Cohen, 1975). 
The field growth continued and in 1981, David Felten provided one of the first indications of 
how neuro-immune interaction occurs by discovering a network of nerve fibers innervating  
the blood vessels as well as cells of the immune system (Felten et al., 1981).  These nerves 
were also found in the thymus and spleen terminating near clusters of lymphocytes, 
macrophages, and mast cells, which play an important role in controlling the immune function 
(Felten et al., 1985). 
The field of psychoneuroimmunology was further developed in 1985, by 
neuropharmacologist Candace Pert who revealed that neuropeptide specific receptors are 
present on both the cell walls of the brain and in the immune system (Pert et al., 1985). He 
demonstrated that neuropeptides and neurotransmitters act directly upon the immune system 
showing their close association with  emotions and suggesting  mechanisms through which 
emotions and immunology are deeply interdependent (Pert et al., 1985). 
Existing advances in psychiatry, immunology, neurology and other integrated disciplines of 
medicine has promoted enormous growth for psychoneuroimmunology. Besides, it is possible 
that the mechanisms underlying behaviorally induced alterations of immune function, and 
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immune alterations inducing behavioral changes, could involve clinical and therapeutic 
implications that will not be fully appreciated until more is known about the extent of these 
interrelationships in normal and pathophysiological states. 
1.3.2 What Is Stress? 
The scientific literature defines stress in various ways. One of the most broad psychological 
definitions has been that stress occurs when an individual perceives that the demands from the 
environment exceed their adaptive capacity or ability to cope (Chen and Miller, 2007; Cohen 
et al., 2007; Dhabhar, 2002; Glaser and Kiecolt-Glaser, 2005). A more specific definition of 
stress, describes it as a process consisting of a series of steps. First, a stressor (1. a stimulus 
from academic examinations to bereavement) initiates a conscious or sub-conscious reaction 
in the brain that once perceived (2. stress perception), initiates an emotional (i.e. anxiety and 
embarrassment), or behavioural, (fight/flight) response (3. stress response) (Chen and Miller, 
2007; Dhabhar, 2002). Within this conceptualization of stress, two different types of stress 
have been distinguished. These are the acute stress and chronic stress. Acute stress represents 
the reaction to an immediate threat, commonly referred to as the fight or flight response. This 
type of stress is time-limited in duration lasting for a period of minutes to hours and can come 
any time through life experiences. Thus, acute stress deals with unexpected situations which 
may be experienced consciously and unconsciously, real or imagined as a danger thing. 
Example of common acute stessors include: noise, crowding, isolation, hunger, danger, 
infection, imagining a threat or remembering a dangerous event.  It is important to note that 
generally once the acute threat has passed, levels of stress hormones return to normal and the 
individual reaches the relaxation response. 
In contrast to the short-lived acute stress response, chronic stress refers to on-going stressful 
situations eliciting prolonged responses persisting for months, as result of stable life 
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difficulties. Examples of common chronic stressors include: long term relationship problems, 
on-going highly pressured work, loneliness and persistant financial worries. Both categories 
of stress influence the immune function in various ways (Chen and Miller, 2007; Dhabhar, 
2002; Glaser and Kiecolt-Glaser, 2005) (see section 1.3.3). The physical changes in response 
to both types of stress are understood by researchers since in prehistoric times, to be an 
essential adaptation for meeting natural threats. Thus in modern times, stress response can be 
an asset for raising levels of performance during critical events such as a competitive sports 
activity, an important job interview, or in unexpected situations of actual danger or crisis. 
1.3.3 Acute and Chronic Stress 
Acute psychological stress has a number of characteristic effects on human cellular immune 
system that enhance the innate immune response. Previous animal studies have shown that 
acute stress is associated with enhanced skin delayed-type hypersensitivity responses, 
enhanced inflammatory phase of both innate and adaptive immune responses, an increase in 
the T cell dependent antibody production (mainly IgG), an increase in the leukocyte 
trafficking in the site of infection, faster wound healing and enhanced vaccination responses 
(Atanackovic et al., 2006; Dhabhar, 2002; Dhabhar and McEwen, 1997; Silberman et al., 
2003). Whereas some immunoenhancement effects of the acute stress may increase the 
severity of inflammatory (i.e. cardiovascular disease) or autoimmune diseases (arthritis or 
multiple sclerosis), others could be potentially beneficial as for example in the context of 
wound healing, vaccination or resistance to infection. Furthermore, the effect of acute stress is 
also important in preparing the immune system for responding immediately to the 
immunological challenge (i.e. wounding or infection) imposed by the action of a stressor (a 
predator) (Atanackovic et al., 2006; Dhabhar, 2002; Dhabhar and McEwen, 1997; 
Viswanathan et al., 2005; Viswanathan and Dhabhar, 2005). 
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In contrast to the acute stress which is associated with immunoenhancement, chronic stress 
induces changes in the immune system that result in immunosuppression which has negative 
health consequences (Dhabhar and McEwen, 1996). For example caregiving for a spouse with 
dementia is associated with poor antibody and virus specific T cell responses to influenza 
virus vaccination and can also significantly inhibit the IgG antibody response to a 
pneumococcal bacterial vaccine when compared to non-caregiving control (Glaser, 2005; 
Glaser and Kiecolt-Glaser, 2005; Glaser et al., 2000; Kiecolt-Glaser et al., 1996). 
Furthermore, evidence has associated chronic stress with slower wound healing (Glaser and 
Kiecolt-Glaser, 2005; Kiecolt-Glaser et al., 2010; Kiecolt-Glaser et al., 2009; Kiecolt-Glaser 
et al., 2005) and with increased susceptibility to the common cold and upper respiratory 
infections thus indicating its potential clinical relevance which possibly reflects the wide 
emphasis of chronic stress in the literature (Zorrilla et al., 2001). 
1.3.4 Effect of Acute Stress on Leukocyte Distribution in Blood 
Acute psychological stressors causes large, rapid and reversible changes in the distribution of 
peripheral blood leukocyte subpopulations which may determine the ability of the immune 
system to induce an antigen specific, cell mediated immune response in vivo and thus perform 
its surveillance (Benschop et al., 1996b; Bosch et al., 2003; Bosch et al., 2005b; Dhabhar et 
al., 1996; Silberman et al., 2003). Previous studies have reported that both the psychological 
and physical acute stress cause a transient increase in lymphocyte numbers termed 
lymphocytosis (within 10 minutes) (Anane et al., 2009; Anane et al., 2010; Atanackovic et al., 
2006; Benschop et al., 1996b; Campbell et al., 2009; Dhabhar et al., 1995; Dimitrov et al., 
2010; Silberman et al., 2003; Simpson et al., 2007; Viswanathan and Dhabhar, 2005). The 
lymphocytosis phenomena is characterised by a large increase (400%) in relative percentages 
of NK cells and other lymphocytes (150 % in T cells and B cells) as well as an increase in the 
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absolute number of monocytes and granulocytes. These immunological alterations are 
catecholamine-mediated (Atanackovic et al., 2006; Benschop et al., 1996b; Dhabhar and 
McEwen, 1997; Silberman et al., 2003).  
Catecholamines (CAs) are neuro-endocrine signalling substances that participate in regulation 
of the activities of key life support systems, such as that of the immune system. Example of 
CAs include, epinephrine (EPI), norepinephrine (NE), dopamine etc., which among other 
things are used to treat cardiac arrest and low blood pressure. CAs are synthesized from the 
amino acid precursor L-tyrosine and are released from the adrenal medulla and sympathetic 
nerve terminals into the blood, during stressful stimulations like strenuous exercise, physical 
trauma, inflammation, and psychological stress. Upon their entry into the blood from the site 
of release (Kvetnansky et al., 2009) CAs modulate the immune response via receptors 
expressed on the immune cells (Szelenyi and Vizi, 2007). Indeed CAs, EPI and NE exert their 
effects by binding to 7 transmembrane spanning G-protein-coupled cell surface receptors 
termed adrenoreceptors.   
The four major types of adrenoreceptors by which the CAs mediate their effects are (1, 2, 
1, 2). These are all expressed on the surface of many different cell types throughout the 
body. It is now reported that whereas -adrenoreceptors are responsible for the changes on 
granulocyte trafficking, the changes in lymphocyte trafficking are driven by -
adrenoreceptors (-AR) which mediate endothelial detachment and subsequent re-circulation 
(Anane et al., 2009a; Anane et al., 2010a; Benschop et al., 1996b; Bosch et al., 2003; Bosch et 
al., 2005a; Campbell et al., 2009; Dimitrov et al., 2010; Silberman et al., 2003; Viswanathan 
and Dhabhar, 2005). This is confirmed by the fact that when -AR are blocked with 
propranolol (a nonselective -blocker) prior to infusion with EPI, lymphocytosis is 
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completely inhibited (Benschop et al., 1996b; Gader, 1974). Similarly, administration of -
AR antagonists also abrogates exercise or psychological stress induced lymphocytosis 
(Benschop et al., 1996a; Benschop et al., 1994a). Studies have indicated that of all -AR, 
lymphocytosis is mainly underlined by the involvement and activation of 2AR in particular. 
For example, adhesion of NK cells to endothelial cells in vitro can be reversed in a 2AR 
specific way and mobilization of NK cells, during catecholamine infusion is inhibited by 
2AR selective antagonists (Benschop et al., 1996a; Benschop et al., 1994b; Benschop et al., 
1996b). 
While all lymphocyte express 2AR on their surface, lymphocytosis in psychological and 
physical acute stress is largely governed by a selective increase in the cytotoxic lymphocytes, 
which express high density 2AR on their surface. Of all cytotoxic cells, NK cells have the 
highest β2AR expression, followed by CD8+ TLs and  TLs which display intermediate 
2AR expression and ultimately CD4+ TLs and B cells with low 2AR expression (Anane et 
al., 2009; Anane et al., 2010; Campbell et al., 2009).  
Aside from the 2AR expression, the selective mobilisation of leukocytes is also determined 
by the specific profile of adhesion molecules expressed on the cells as well as the cell’s 
cytotoxic potential. Based on this context, studies have reported that within the cytotoxic 
lymphocyte category, acute stress mostly mobilises cytotoxic cells that have a great capacity 
to migrate to sites of infection as well as display a differentiated memory phenotype. These 
include CD45RA+ EMRA effector memory cells (e.g.  and CD8+ T cells), cytotoxic cells 
possessing high tissue migratory potential (CD11ahigh and CD62Llow/neg) and cytotoxic cells 
(e.g. CD8+ TLs) that have shortened telomeres and exhibit high expression of NK receptors 
KLRG-1 and CD57+ (features of replicative senescence) (Anane et al., 2009; Anane et al., 
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2010; Bosch et al., 2003; Campbell et al., 2009). It is important to emphasize that is through 
these important phenotypic characteristics that cytotoxic cells gain the potential to quickly 
destroy foreign antigens present in the body’s peripheral tissue. 
1.3.5 Possible Mechanisms of Lymphocytosis 
To be able to understand what regulates and controls the levels of circulating lymphocytes, 
there’s need for understanding the mechanisms involved in lymphocytosis. Several agents 
have been utilised to cause an increase in the number of blood lymphocytes count in 
experimental animals, including heparin and heparinoid compounds which induce the 
lymphocytosis as a result of mobilisation of cells from lymphoid organs (Rai et al., 1971); 
partially purified lymphocytosis-promoting factor (LPF)  (Adler and Morse, 1973); as well as 
Bordetella pertussis toxin which has been mostly used to investigate lymphocyte physiology 
(Rai et al., 1971). Bordetella pertussis is a gram-negative coccobacillus of the genus 
Bordetella, responsible for the whooping cough. In previous studies Bordetella pertussis has 
been used as a nonspecific immune stimulant to increase the immunological activity in mice 
(Rai et al., 1971). It has been reported that the significant lymphocytosis induced by 
Bordetella pertussis could involve one or several mechanisms and disrupt the normal 
lymphocyte circulation pathway, including (1), an increased rate of lymphocytes entry to into 
the circulation via the efferent lymphatics; (2) a prolonged average residence time of 
lymphocytes in blood (thus a decrease in the lymphocytes rate of exit from the blood via 
postcapillary venules); (3) direct entry of lymphocytes into the blood vessels without passing 
through lymphatics, or in addition to lymphatics; (4) increased new cell production (Morse 
and Riester, 1967; Rai et al., 1971). Morse and Barron(1970) reported that lymphocytosis 
induced in mice by Bordetella pertussis could not be a result of cellular proliferation of 
lymphocytes, as the percentage of circulating lymphocytes with nuclear label was the same in 
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pertussis treated mice and normal untreated mice. These reports support the concept that 
lymphocytosis is a result of redistribution of lymphocytes between the circulating (blood) and 
the tissue pool (lymphoid organs) with the thoracic duct serving as the main channel for the 
lymphocytes traffic between the two pools (Gowans, 1957). The thoracic duct output of 
lymphocytes in mice during the Bordetella pertussis induced lymphocytosis is significantly 
decreased despite the high level of circulating lymphocytes compared to normal mice (Adler 
and Morse, 1973; Morse and Barron, 1970). Chigaev et al. (2008) has demonstrated that a 
possible mechanism for cell de-adhesion involves the downregulation of α4β1-integrin affinity 
by guanine nucleotide binding protein-coupled receptors (GPCR) on the peripheral blood 
leukocytes. Dimitrov et al. (2010) suggested that selective mobilisation of cytotoxic 
leukocytes by EPI involves the disruption of LFA-1 (lymphocyte function- associated 
antigen-1; equivalent to CD11a) and CX3CR1 binding to endothelium. LFA-1 (CD11a) and 
CX3CR1 are highly expressed on the cytotoxic effector function cells, γ/δ T cells, NK cells, 
and these cytotoxic cells  show highest adherence to activated endothelium in vitro and rapid 
release in response to EPI. 
1.3.6 Neuroendocrine Interaction with Immune System 
The brain and the immune system are the two major adaptive systems of the body. Although 
the immune system is regarded as autonomous, the last two to three decades have provided 
evidence that the central nervous system (CNS) receives messages from the immune system 
and vice versa messages from the brain modulate immune functions. This has led to the 
emergence of the field of psychoneuroimmunology in which the brain and the immune system 
“talk to each other” a process essential to maintaining homeostasis (Black, 1994; Elenkov, 
2008; Ziemssen et al., 2003). The two major pathways through which the immune system can 
be altered are the hypothalamic-pituarity-adrenal-axes (HPA axis) and the sympathetic-
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adrenal medullary axis (SAM axis) (Black, 1994; Padgett and Glaser, 2003). Lymphocytes, 
monocytes or macrophages are directly influenced by the HPA and SAM axis because they 
display receptors on their surface for many neuroendocrine products of these axis including 
cortisol and CAs, which are released during stress (Padgett and Glaser, 2003). 
In effect, CAs EPI and NE represent the major stress hormones and influence various aspects 
of the immune responses (Elenkov et al., 2000a). These include proliferation of B and T cells, 
production of cytokines, production of antibodies, antigen presentation, macrophage activity, 
cytotoxicity of NK and T cells, chemotaxis of monocytes and neutrophils as well as 
lymphocyte traffic and circulation (Elenkov et al., 2000a; Madden et al., 1995; Padgett and 
Glaser, 2003; Wiegers et al., 1995; Yang and Glaser, 2000). 
1.4 Effect of Catecholamines on the Immune Responses 
1.4.1 Proliferation of Lymphocytes 
Previous studies have shown that CAs or βAR agonists inhibit the proliferation of T cells in 
vitro. For example, stimulation of T cells with isoproteronol, (βAR agonist) increases cyclic 
adenosine monophosphate (cAMP) (a second messenger involved in the signal transduction) 
in lymphocytes.  Elelvated cAMP is associated with inhibition of T cell proliferation (Bartik 
et al., 1994; Elenkov, 2008; Elenkov et al., 2000a). Among the T cells populations, the 
proliferative response of CD8+ T cells is inhibited at a greater extent by cAMP than the CD4+ 
T cells. This is thought to occur as results of CD8+ T receptors having higher numbers of β-
AR expressed on their surface (Bartik et al., 1993). In addition, the elevation of the cAMP 
also inhibits IL-2 secretion (a cytokine that promotes T-cell proliferation) by T cells (Bartik et 
al., 1994; Bartik et al., 1993).  
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Another mechanism, by which CAs might inhibit T-cell proliferation, is through modulation 
of K+- channel gating. These channels represent the dominant ion channels in lymphocytes 
and are involved in the processes of lymphocyte activation and proliferation (Elenkov et al., 
2000b). NE and isoproterenol inactivate K+ channels of human CD8+ peripheral lymphocytes 
and rat thymocytes (Elenkov, 2008; Vizi et al., 1995).  
1.4.2 Catecholamines and the TH-1/TH-2 Balance 
CAs inhibit type-1/pro-inflammatory cytokine production. Both EPI and NE inhibit Th-1 
responses by suppressing the production of IL-12 (major inducer of Th-1 responses) from 
monocytes and dendritic cells through stimulation of the β2AR (Elenkov et al., 1996).  It is 
thought that the inhibition of IL-12 may re-present one of the major mechanisms by which 
CAs affect the Th-1/Th-2 balance, as IL-12 is a potent enhancer of IFN-γ synthesis by Th-1, 
and inhibitor of IL-4 synthesis by Th-2 cells (Elenkov et al., 2008; Elenkov et al., 1996; 
Panina-Bordignon et al., 1997). Moreover, EPI, NE and β2AR agonists inhibit the production 
of TNF-α by monocytes, microglial cells, as well as result in the indirect inhibition of IL-1 via 
inhibition of TNF-α and potentiation of IL-10 production (Hetier et al., 1991; Nakamura et al., 
1998; Severn et al., 1992). 
In contrast to their effects on type 1 pro-inflammatory cytokine production, CAs upregulate 
the production of regulatory cytokines by APCs including the production of IL-10, (an effect 
that is β2AR mediated and cAMP dependent) induced by lipopolysaccharides (LPS) in human 
monocytes or mouse peritoneal macrophages. Similarly, the massive release of CAs during an 
acute brain trauma, results in secretion of substantial amounts of systemic IL-10 (Elenkov, 
2008; Elenkov et al., 1996; van der Poll et al., 1996). 
 1.4.3 Effect of Catecholamines on NK-cell Activity 
 
 
32 
 
In vitro studies show that EPI and isoproterenol elevate cAMP about 2.5 fold and induce an 
inhibition of NK cell activity (Elenkov et al., 2000b; Hellstrand and Hermodsson, 1989; 
Whalen and Bankhurst, 1990). The effect is blocked by propranolol (a beta blocker) and is 
mimicked by terbutaline, (a β2AR agonist) indicating the involvement of β2AR in this 
process (Elenkov et al., 2000b; Hellstrand and Hermodsson, 1989; Whalen and Bankhurst, 
1990). In support of these findings when a β2AR agonist is administered in vivo, NK activity 
is suppressed an effect blocked by nadolol (a peripherally acting βAR antagonist) (Katafuchi 
et al., 1993a; Katafuchi et al., 1993b; Shakhar and Ben-Eliyahu, 1998). In patients with heart 
failure, (a disease characterized by chronically high levels of plasma NE), NK cells show an 
anergic cytotoxic low response to the stimulation with IL-2 and IFN-γ (Vredevoe et al., 1995). 
Thus CAs may also inhibit NK cells activity indirectly through the suppression of Th1-type 
cytokines, and particularly through the potent inhibition of IL-12 and IFN-γ production which 
are essential for promoting NK activity (Elenkov et al., 2000). NK cells are the most 
“sensitive” cells to the suppressive effect of stress.  The reason why we observe the potent 
suppressive effect of CAs on the NK cell activity might be due to the fact that NK cells 
probably possess the highest number of β2AR among lymphoid cells (Irwin, 1994). 
1.4.4 Catecholamines and T-Cytotoxic Activity 
There are only few observations on the effect of CAs on CD8+ TLs cytotoxicity. Studies have 
shown that EPI, NE and isoproterenol inhibit the in vitro generation of anti MOPC tumor (a 
murine myeloma tumour) cytotoxicity by splenic T cytotoxic lymphocytes (Cook-Mills et al., 
1995; Elenkov et al., 2000b). Furthermore, increasing cAMP with either a cAMP analogue or 
the βAR agonist metaproteronol significantly inhibits the in vitro development of memory T 
cytotoxic activity in mice (Bender et al., 1993; Elenkov et al., 2000b).  
1.4.5 Salmeterol 
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Salmeterol is a potent selective β2AR agonist that exhibits a long duration of action on 
airways smooth muscle in vitro but it is also a long acting bronchodilator in vivo (Ball et al., 
1991; Butchers et al., 1991; Johnson, 1990; Nials et al., 1993).  
 It has been reported that the sustained activity of salmeterol does not result from the 
irreversible binding to β2AR. The lipophilic N-substituent “tail” of salmeterol associates with 
an “exo-site” which holds salmeterol in a such position that allows its phenylethanolamine 
“head” to continuously associate/disassociate with, and activate/inactivate the β2AR (Ball et 
al., 1991; Nials et al., 1993). Another possible explanation for the long duration effect of 
salmeterol could result in part from the lipid solubility of the compound (Ball et al., 1991).   
A marked difference between salmeterol and other βAR agonists is the slower rates of action 
onset and offset. Whilst isoprenaline (a non-selective βAR agonist) and salbutamol (a β2AR 
agonist) have a rapid action onset (Ot50 < 3 minutes) salmeterol has an onset of action of Ot50 
< 27.6 minutes) (Ot50 refers to the time of onset of action and is defined as the time from 
starting the administration of the test agonist to achievement of 50% of response maximum). 
Moreover, whereas both isoprenaline and salbutamol are short acting (Rt50 < 7 minutes), the 
effect of salmeterol can last in excess of 8 hours (Nials et al., 1993). (Rt refers to the time for 
offset of action and is defined as the time from stopping the administration of the test agonist 
to achievement of 50% of the response maximum). Furthermore, clinical preliminary data has 
also indicated salmeterol to exhibit long lasting bronchodilator activity (lasting up to 12 
hours) following aerosol administration to both normal and asthmatic subjects (Ball et al., 
1991). However, similarly to isoprenaline, the rate of reversal of salmeterol response by β-
antagonists propranolol, pindolol, ICI118, 551 and atenolol was rapid, requiring ~11 minutes 
or less to reach 50% reversal of agonist activity (Nials et al., 1993). 
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Figure 1.5. Structure of salmeterol (A), salbutamol (B) and formoterol (C). β-
Agonists have an asymmetric centre due to the presence of β-OH group. The 
asymmetric centre leads to the molecule existing as a pair of optical isomers known as 
R and S enantiomers in a racemic mixture. The enantiomers are stereospecific. 
Salmeterol (A) has an aryl alkyl group with a chain length of 11-atoms from the amine. 
This bulkiness renders the compound more lipophilic and it also makes it more β2- 
receptor selective. Salbutamol (B) is also more selective for β2-receptors with the 
tertiary butyl group in salbutamol being responsible for its selectivity. Fenoterol (C), is 
a short acting β2-AR agonist and moderately lipophilic. It has two asymmetric centres, 
producing four enantiomers. Figure was taken from (Shan et al., 2012). 
 
 
 
A) 
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Figure 1.6. A representative model for the interaction of salmeterol, salbutamol, 
and formoterol with the β2-AR. Salmeterol is >10 000 times more lipophilic than 
salbutamol. Salmeterol partitions rapidly (<1 min) into the cell membrane. It then 
diffuses laterally in order to approach the active site of the β2-AR in the membrane. 
This process is slow (>30 min). The nature of salbutamol is hydrophilic. It enters the 
active site of the β2-AR directly from the extracellular aqueous compartment. 
Salbutamol has a limited residency time at the receptor active site resulting in a short 
duration of action (4-6 h). Formoterol is moderately lipophilic. It is taken into the cell 
membrane in the form of a depot, in a way that it progressively leaches out from the 
depot to interact with the active site of the β2-AR. The size of the depot is directly 
proportional to the concentration or dose of formoterol applied. Figure was taken from 
(Johnson, 2001). 
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1.5 Cell Migration 
1.5.1 Leukocyte Extravasation during Inflammation 
Due their migratory properties, white blood cells are recruited rapidly at sites of injury and 
infection to allow efficient surveillance of tissues for infectious pathogens. The recruitment 
process initiates in postcapillary venules which display a high intravascular shear force of up 
to ~30 dynes/cm2 (Butcher and Picker, 1996). This process is responsible for allowing 
leukocytes to exit the blood, migrate across the vascular endothelial cells, and enter the 
surrounding tissue (Fig.1.7.). The recruitment process is a “multistep paradigm” split into five 
successive steps. Initially, flowing leukocytes are marginated to the vessel wall. It is 
important to note that this process will only occur if the endothelium has been activated by 
chemical mediators of inflammation such as TNF-α, IFN-γ, and IL-1β. These mediators alter 
the receptor repertoire on the endothelium, e.g., upregulation of some selectins and members 
of the immunoglobulin superfamily (IgSF) (Fabbri et al., 1999; Francischetti et al., 2010; 
Springer, 1995). It is these molecular signals or “area codes” which are displayed on 
endothelium that will control the immigration of lymphocytes to inflamed tissues (Alon et al., 
1995; Middleton et al., 2002; Springer, 1995). 
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Figure 1.7. Schematic representation of stages involved in leukocyte recruitment and migration into tissue. 
Adapted from (Ley et al., 2007). 
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1.5.2 The Multi-Step Paradigm - Capture and Rolling 
In simple terms, margination is referred to as the transport of leukocytes to the endothelium 
wall. The flowing of blood in the body, applies a shear stress (blood velocity) to the 
endothelium and the leukocytes in the circulation. Under inflammatory conditions when the 
endothelium is activated, the blood stream facilitates the contact of leukocytes with the vessel. 
An in vitro study that involved perfusing whole blood through a verticular glass capillary 
(microslide) showed margination to be regulated by increasing the haematocrit and by 
erythrocytes aggregation, as both of these augmented the number of rolling leukocytes (Abbitt 
and Nash, 2003).  
Once in close contact with the vessel, selectins expressed upon the activated endothelium 
lining the vessel will capture the leukocytes. The selectins are membrane glycoproteins with 
an amino terminal C-type lectin domain which bind specific carbohydrate with terminal 
components that include α2,3-linkedsialic acid and α1,3 linked fructose groups symbolized by 
the sialyl Lewis x (sLex ) determinant on their respective ligands (see appendix; Table A.2) 
(McEver, 2002). These glycoproteins are expressed exclusively by bone-marrow derived cells 
and endothelial cells (Marelli-Berg et al., 2008). The selectin family consists of three closely 
related cell surface molecules. These include L-selectin (CD62L) which is expressed on 
leukocytes; P-selectin (CD62P) expressed on platelets, and E-selectin (CD62E) expressed on 
vascular endothelium. L-selectin is expressed on all circulating leukocytes such as neutrophils 
and T cells and plays an important role in mediating the binding of lymphocytes to the 
endothelium present in post capillary venules of lymph nodes and leukocyte rolling on 
vascular endothelium at sites of tissue, injury or inflammation (Lawrence et al., 1994; Ley et 
al., 1995; Rosen, 2006; Tedder et al., 1995). Upon leukocyte activation, L-selectin is shed 
(Jung and Dailey, 1990). E selectin is induced on the vascular endothelial cells by cytokines, 
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therefore its expression is limited to inflamed tissues (Springer, 1994). P-selectin is 
constitutively stored in Weibel-Palade bodies of endothelial cells and in alpha granules of 
platelets. Once it is activated by the thrombogenic and inflammatory mediators, P-selectin is 
mobilized to the cell surface and mediates adhesion of neutrophils and monocytes at sites of 
injury (Gibson et al., 1995; Lawrence et al., 1994; Lawrence and Springer, 1991; Tedder et 
al., 1995).  
In addition to in vivo studies, in vitro studies have also provided insights on selectin functions.  
It has been shown that purified CD62P and CD62E selectins support neutrophil capture from 
flow (Abbitt and Nash, 2001; Lawrence and Springer, 1991, 1993). This mainly occurs as a 
result of interactions of selectins with P-selectin glycoprotein ligand-1(PSGL-1) expressed on 
the surface of all blood neutrophils, monocytes and lymphocytes (Alon et al., 1994; Asa et al., 
1995; McEver, 2002; Tedder et al., 1995).  
Rolling follows the capture or contact of the circulating leukocytes with the luminal aspect of 
inflamed endothelium lining vessel wall. This involves separable contact formation 
“tethering” which allows the lymphocytes to roll on the surface of vessel wall in the direction 
of the blood flow (Springer, 1994).  CD62P but not CD62E selectin supports T cell rolling in 
activated endothelium (Luscinskas et al., 1995). Interestingly, leukocyte rolling has been 
challenged by findings that some integrins, can support leukocyte rolling under reduced 
psychological shear rates. In fact, α4β1 integrin (also denoted as VLA-4; very late antigen-4) 
can support T cell rolling on purified vascular cell adhesion molecule-1 (VCAM-1), purified 
mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and activated endothelium in vitro 
(Alon et al., 1995; Berlin et al., 1995; Johnston et al., 1996; Ley and Tedder, 1995; 
Luscinskas et al., 1995; Tedder et al., 1995). 
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Furthermore, α4β7 integrin (also known as LPAM-1; Lymphocyte Peyer’s patch adhesion 
molecule-1) supports T cell rolling on purified MAdCAM-1 and lamina propria in situ (Berlin 
et al., 1995). In contrast to selectin mediated rolling that occurs in high shear rates, integrin-
dependent rolling is less efficient and is limited to lower shear rates (Ley and Tedder, 1995). 
The importance of selectins is highlighted in leukocyte adhesion deficiency syndrome  type 2 
(LAD II) (Moser et al., 2009). In this syndrome defects in the glycosylation of the selectin 
ligands impairs neutrophil capture, resulting in immunodeficiency and re-current infections. 
1.5.3 Activation and Firm Adhesion 
Initial capture of lymphocytes is followed by activation of the lymphocytes by surface 
presented chemokines. Chemokines are chemotactic cytokines,  produced during endothelial 
cell activation, that bind to their respective receptors expressed on the rolling leukocytes 
activating integrin adhesiveness and directing leukocyte migration (Chigaev et al., 2008; 
McGettrick et al., 2009; Springer, 1994). Integrins are a large family of cell surface receptors 
that mediate cell-cell interaction and cell matrix interactions in diverse biological settings 
(Chen et al., 1999). Their structure consists of a transmembrane molecule that contain a non-
covalently associated α and β subunit with characteristic structural motifs (Fig.1.8.). Several 
integrins are important in the interaction of leukocytes with endothelial cells. Their primary 
ligands include matrix proteins and members of the IgSF as described in Table A.3. (see 
appendix). Since integrins exist in three different affinity states: low, intermediate and high 
(Mould and Humphries, 2004), one of the ways in which chemokines are understood to 
trigger integrin activation includes conformational changes of the heterodimer in the integrin 
ligand binding site. This causes the integrin to shift from the low affinity state to a high 
affinity state (Laudanna et al., 2002). 
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Figure 1.8. Integrin structure. Integrins are heterodimeric cell surface receptors.  Each 
integrin is formed by the non covalent association of α and β subunits with 
characteristic structural motifs. Both α and β subunits consist of large extracellular 
domains, small transmembrane domains, and short cytoplasmic domains. The 
extracellular domains serve to bind extracellular ligands, such as fibronectin (FN); 
whereas the short cytoplasmic domains, bind intracellular anchor proteins providing a 
link between the extracellular environment and the cytoskeleton. The α and β subunits 
of integrins differ in the number of extracellular domain binding sites. The extracellular 
domain of the α subunit contains four divalent-cation binding sites, whereas the 
extracellular domain of the β subunit contains a single divalent-cation-binding site and a 
cysteine-rich region (Alberts et al., 2002). 
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1.5.4 Transmigration 
The final step in the leukocyte recruitment pathway is transmigration. Transmigration plays a 
crucial role in maintaining immune surveillance and mounting rapid inflammatory responses 
to invading pathogens (Adams and Nash, 1996). It is thus considered to be a key event in host 
defense (Nourshargh and Marelli-Berg, 2005). Migration is dependent on two factors, 
regulation of integrin adhesivity and actin polymerization (Adams and Nash, 1996; Sheikh et 
al., 1997). Leukocyte endothelium migration also involves a group of proteins such as 
platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31) CD99, VE-cadherin and 
junctional adhesion molecule-1 (JAM-1) (Luscinskas et al., 2002a, b; Nourshargh and 
Marelli-Berg, 2005).  
Leukocytes migration occurs through junctions between adjacent endothelial cells 
(paracellular route) or through the body of the endothelial cells (transcellular route). During 
this process of migration the flow forces act upon the cells continuously, allowing the cells to 
release and rebind as they move. The cells first migrate into the subendothelial space, where 
they must penetrate the underlying basement membrane to be able to move through 
underlying stromal cells and structures towards the site of infection. A chemotactic gradient 
guides the migration of leukocytes.  
Considering the importance and complexity of migration, it is unlikely that a single type of 
receptor-ligand interaction could have the required physical characteristics to support all 
stages of this process in a controlled manner (Adams and Nash, 1996). Instead, a number of 
adhesion molecules and chemokines are involved in this process. It is important to note that 
there are variations in adhesion receptors and chemokines utilised by different cell types, such 
as neutrophils, and T cells. Despite this, the leukocyte recruitment pathway is similar for all 
leukocytes.  
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1.5.5 Transmigration of T cells 
Lymphocyte extravasation is a highly regulated process. Subpopulations of lymphocytes 
emigrate at specific sites according to their characteristic leukocyte repertoire. Studies in both 
mice and humans indicate that memory CD4+ T cells bearing α4β7 but lacking CD62L would 
potentially be capable of entering the gut mucosal tissues (mesenteric lymph nodes, Peyer’s 
patches, and lamina propria) which express MAdCAM-1 (Bradley and Watson, 1996). On the 
other hand, a subset of memory T cells expressing high levels of α4β1 migrate preferentially to 
nongastrointestinal, extralymphoid, inflammatory sites, in which VCAM-1 is expressed (Rose 
et al., 2001).  
It has been shown that memory T cells have increased levels of αL/β2 (LFA-1; lymphocyte 
function-associated antigen-1) and α4β1 integrins compared with naïve cells (Johnston et al., 
1996; Nakajima et al., 1994). Therefore in addition to induction of VCAM-1 and intercellular 
adhesion molecule (ICAM-1) on endothelium, the increased expression of αL/β2 and α4β1 
integrins on memory T cells might also contribute to the T cell infiltration into the airways.  
Indeed, memory T cells show stronger adhesion to cytokine stimulated cultured endothelial 
cells than naïve cells (Nakajima et al., 1994).  
Regulation of leukocyte trafficking is controlled by the interaction of cell surface adhesion 
molecules between leukocytes (i.e. integrin abundance) and vascular endothelial cells 
(counter ligand density) (Nakajima et al., 1994; Rose et al., 2001). Recent studies have 
suggested that α4β1 alone can initiate the lymphocyte endothelial cell interactions as well as 
mediate cell adhesion (Bradley and Watson, 1996). For example, leukocyte rolling and 
adhesion within mesenteric postcapillary venules in chronic vasculitis (model of 
inflammation) is dependent on α4β1 integrin (Johnston et al., 2000). Moreover, other in vivo 
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studies have shown that the interaction of α4β1 ligand (VCAM-1) with α4β1 integrin (VLA-4) 
plays a predominant role in controlling antigen induced T cell recruitment into the tissue and 
that induction of VCAM-1 expression on the endothelium at the allergic inflammatory sites, 
regulates this T cell recruitment. This is because the in vivo blocking of VCAM-1 and α4β1 
integrin (VLA-4) inhibits the antigen induced CD4+ and CD8+ T cell infiltration into the 
mouse trachea more potent than that of ICAM-1 and αL/β2 (LFA-1) (Nakajima et al., 1994).  
The crucial role of integrins in T cell migration can also be observed in and experimental 
model of arthritis in rats. These studies show that monoclonal antibodies (mAb) which block 
α4 (CD49d) and β2 (CD18) integrins, inhibit T cell tissue-migration and hereby reduce the 
severity of arthritis (Issekutz et al., 1996).   
It is important to note that the functions of integrins are dependent on integrin activation.  
This is because when integrins activate, they undergo a conformational change within a few 
minutes that increases integrins adhesiveness to ligand without affecting the quantity of 
surface-expressed receptors. However, increased integrin affinity is also a result of altered 
interaction with cytoskeleton.   
1.6 Aims of this Thesis: 
1. Previous studies have shown that central nervous system activation, (e.g., during 
psychological stress) affect CTL function. One of the hallmarks of such activity is the 
release of the catecholamines epinephrine and norepinephrine, which act on β2-adrenergic 
receptors expressed on lymphocytes. The first aim of this project is to determine the 
effects of β2-adrenergic stimulation on the production of IFN-γ by CTLs.  These analyses 
focus on CD8+ T and CD4+ T cells.  
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2. The effect of stress on the cytotoxic ability of CD8+ T and NK cells remains not well-
understood. The second aim was therefore to investigate the effect of epinephrine and 
salmeterol (a β2-adrenergic agonist), on the cytotoxic capacity of CD8+ T and NK cells in 
vitro. This was studied using a novel assay that measures cytotoxic degranulation.   
3.  Studies have documented that the selective recruitment of the leukocytes to inflamed 
tissues is determined by a specific match of adhesion molecules expressed on the cells and 
on endothelial cell surface (e.g.,VCAM-1, ICAM-1, E- or P-selectin). The final aim was 
to investigate the effect of different concentrations of salmeterol (β2 agonist) and EPI on 
lymphocytes recruitment to isolated vascular cell adhesion molecule (VCAM-1) coated 
microslides and onto endothelial cells. PBL Adhesion, Migration, Rolling Velocity, 
Transmigration and Migration velocity to the substrates were examined. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Cytokine Stimulation Assay 
2.1.1 Study Subjects 
Healthy participants were recruited from community volunteers and staff and students 
attending the University of Birmingham (UoB), UK. Each participant gave informed consent 
for participation in the study and study protocols were approved by the appropriate 
institutional review board (UoB). 
2.1.2 Isolation of Peripheral Blood Mononuclear Cells (PBMCs) 
Whole blood from healthy CMV seropositive individuals (CMV status of donors was 
determined using tetramer staining tested by the Moss group) was collected in tubes coated 
with Lithium Heparin (anti-coagulant; 1.6 mg/ml; from BD Biosciences, UK).  All blood 
samples from seated individuals were taken in standardized method between 9 am and 11 am. 
None of the individuals were on any therapy. The whole blood was gently layered onto a 
Histopaque gradient (2.5 ml Histopaque 1077; from Sigma-Aldrich, UK) and centrifuged for 
40 minutes at 1200 x g, at room temperature. Peripheral blood mononuclear cells (PBMCs) 
sedimented above the diluted blood at the Histopaque interface. The PBMCs layer was 
collected and transferred into 50 ml Falcon tubes (BD Biosciences,UK). PBMCs were washed 
twice in Roswell Park Memorial Institute Medium (RPMI 1640, from Sigma-Aldrich, UK) + 
human serum (HS) (1%) (which was heat inactivated and pooled; a gift from Dr. Oliver 
Goodyear, Cancer Studies Department, University of Birmingham, UK) for 8 minutes by 
centrifugation at 500 x g at room temperature.  Following washing, PBMCs were re-
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suspended in RPMI+HS (10%) and were cultured overnight in an incubator set at 37ºC, 5 % 
CO2 in air. 
2.1.3 Stimulation Assay 
The next morning, PBMCs were removed from the incubator and were centrifuged at 500 x g, 
4 ºC, for 5 minutes. Subsequently, PBMCs were washed with MACS Buffer (containing 
Phosphate Buffer Saline (PBS); Bovine Serum Albumin (0.5% BSA) and 
Ethylenediaminetetraacetic acid (2mM EDTA); from Miltenyi Biotec, UK). Following 
washing, cells were counted and transferred into 4 ml FACS tubes (BD, Bioscience, UK) with 
each FACS tubes containing 10 x 106 PBMCs. Cells were washed again and the purified 
peripheral blood lymphocytes (PBL) pellet was re-suspended in 60 ul of MACS Buffer at a 
final concentration of 10x106 cells. To separate CD4+ T and CD8+ T cells,  anti-human CD4 
antibody directly labelled microbeads and anti-human CD8 antibody directly labelled 
microbeads (Miltenyi-Biotec, UK) were added to 10x106 PBMCs, mixed well and incubated 
for 15 minutes in the refrigerator (2-8 ºC). A fraction (~5x104) of PBMCs were not labelled 
with CD4 or CD8 microbeads and were used as control (prior to sorting). Following 
incubation of PBMCs with microbeads, cells were washed by adding 2 ml of MACS Buffer 
per 106 cells and centrifuged at 500 x g for 5 minutes at 4ºC. The supernatant was very 
carefully decanted and the pellet was gently dislodged by tickling the tube without causing air 
bubbles. Cells were subsequently resuspended in 500 µl of MACS Buffer, ready for 
separation.  
Magnetic separation was carried with autoMACSTM Separator (Miltenyi Biotec, UK). 
AutoMACS is an automated magnetic separation machine that can be programmed to enrich 
or deplete the desired cells. Prior to separation, the instrument was prepared and primed 
(according to the autoMACS™ instructions). The FACS tube containing the sample was 
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applied and placed at the uptake port. Other FACS tubes for collecting the unlabelled and 
labelled (CD4+ and CD8+ T) cell fractions were also provided and placed at port neg 1 and 
port pos 1 respectively. Using the autoMACS cell sorter, separation Deplete05 programme 
was chosen, which allows the collection of negative fraction from outlet port neg1. (In the 
initial experiments different separation programs, like Deplete and Posseld, were also tested 
on the autoMACSTM Separator; Deplete05 proved to give both a high yield and purity). 
 Following separation, the sorted cells were collected. The labelled CD4+ and CD8+ T cells 
(positive fraction) were collected into one tube and the non-labelled non-T cells (i.e. PBMCs-
T cells; negative fraction) into another. Cells were topped up with MACS Buffer and 
centrifuged at 500 x g, 4ºC for 5 minutes. The supernatant was carefully decanted and the 
sorted fractions were re-suspended in the appropriate media. Depending on the experiment, 
the fraction of cells not to be treated with salmeterol (long-acting β2 agonist; Sigma-Aldrich, 
UK; catalogue number: S5068) were resuspended in 500 µl of RPMI 1640 + HS (10%). The 
fraction of cells to be treated with salmeterol were resuspended in 500 µl of RPMI 1640 to 
make a final concentration of 50 µM salmeterol. (This is because salmeterol is a lipophilic β2- 
AR agonist and the binding of salmeterol to serum proteins present in the incubation medium, 
may strongly diminish the free drug concentration; (Borger et al., 1998)). Cells in both 
positive and negative fraction were counted with trypan blue dye (from Sigma-Aldrich, UK). 
2.1.4 Antigen Stimulation of the Negative (PBMCs-T cells) Fraction 
 
The -ve fraction (PBMCs-T cells) were resuspended to 1 x 106 cells in 100 µl of RPMI 1640 
+ HS (10%). 100 µl of the negative fraction were added to corresponding sterile-FACS tubes. 
1 x 106 PBMCs-T cells were stimulated with either: 20 µl of Staphylococcal Enterotoxin 
B/500 µl RPMI (SEB, final concentration 500 ng/ml; from Cancer Studies, University of 
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Birmingham, UK) and 5 µl (final concentration 1 µg/ml) of anti-CD28/CD49d monoclonal 
antibody (from BD Biosciences, UK) ; or 30 µl of CMV lysate (strain AD169) per 500 µl of 
RPMI (a gift from Dr. Annette Pachnio, Cancer Studies, University of Birmingham, UK) and 
5 µl (1 µg/ml) of anti-CD28/CD49d monoclonal antibody; or 10 µl of CMV pp65 (65 kDa 
lower matrix phosphoproteins; referred to as pp65) recombinant protein / 500 µl RPMI (final 
concentration at 1 µg/ml per individual peptide; from Miltenyi Biotec, UK) and 5 µl (1ug/ml) 
of anti-CD28/CD49d monoclonal antibody. In addition each experiment had a negative 
control, where one tube was left unstimulated. Following addition of the SEB or CMV lysate 
or pp65 respectively, tubes were vortexed and cells were incubated at 37 ºC, 5 % CO2 for 1 
hour and 30 minutes.  
2.1.5 Salmeterol Treatment of the Positive Fraction (CD4+ and CD8+ T cells) 
Following counting, T cells were split equally among tubes to be stimulated with salmeterol 
and tubes to not. The volume in each tube containing the positive fraction was made to 500 µl 
of RPMI without HS. 25 µl of salmeterol (stock concentration of 1mM) or 2.5 µl of 
salmeterol (1mM) was added to T cell tubes to be treated with salmeterol, (depending on the 
experiment) to make a final concentration of 50 µM and 5 µM salmeterol respectively. 
Following addition of salmeterol, cells were mixed and both treated and untreated T cells 
were incubated at 37ºC, 5 % CO2 for 30 minutes. After incubation, T cells were washed twice 
with MACS Buffer. Following the second wash, T cells were re-suspended in RPMI + HS 
(10%) and counted for a second time. Equal number of T cells were added to corresponding 
antigen stimulated PBMC tubes (containing PBMCs without (-) T cells; i.e. mostly APCs like 
B cells and monocytes). T cells were incubated with PBMCs-T cells (for ease from here on 
denoted as APCs) at 37ºC, 5% CO2 for 1 hour before adding 1 µl of monensin (final 
concentration at 5 µg/ml; from Sigma-Aldrich, UK). Following the addition of monensin cells 
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were incubated for an additional 5 hours at 37ºC, 5 % CO2. The same principle was carried 
out when APCs were treated with salmeterol. Salmeterol treatment of the APCs was carried as 
described in section 2.1.5 when positive fractions were treated with salmeterol. Similarly to 
APCs, described in section 2.4, T cells were not treated with salmeterol. However in contrast 
to the above procedure, since CMV lysate and pp65 require antigen presentation to T cells by 
APCs; CMV lysate or pp65 or SEB were only added following incubation of APCs with T 
cells. Cells were left to incubate for 1 hour 30 minutes, after which monensin (5 µg/ml) was 
added and cells were incubated  for an additional 5 hours at 37ºC, 5 % CO2.  
2.1.6 Salmeterol Treatment of Total PBMCs 
PBMCs were counted and re-suspended into 50 ml Falcon tube to ~2 x 106 cells per 200 µl of 
RPMI without HS. Subsequently, this suspension was transferred into sterile FACS tubes to 
be stimulated or not with salmeterol. The volume in each tube containing PBMCs was 
increased to 500 µl of RPMI without HS. 25 µl of salmeterol (1 mM) or 2.5 µl of salmeterol 
(1 mM) were added to PBMCs to make a final concentration of 25 and 50 µM of salmeterol 
respectively. No salmeterol was added in the control condition. Subsequently, cells were 
mixed and both treated and untreated tubes containing PBMCs, were incubated at 37ºC, 5% 
CO2 for 30 minutes. After this incubation, PBMCs were washed twice with MACS Buffer. 
The volume in each FACS tube was made to 500 µl with RPMI + HS 10%. Subsequently, 
PBMCs were stimulated with either 500 ng/ml SEB and 1 µg/ml of anti-CD28/CD49d 
monoclonal antibody; or 30 µl of CMV lysate/500 µl RPMI and 1 ug/ml of anti-CD28-CD49d 
monoclonal antibody; or 10 µl of pp65/500 µl RPMI (1 µg/ml per individual peptide) and (1 
µg/ml) of anti-CD28-CD49d monoclonal antibody, depending on the appropriate 
corresponding labelled FACS tube. In addition each experiment had a negative control, where 
one tube was left unstimulated to control for spontaneous production of IFN-γ cytokines. 
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Following stimulation, PBMCs were incubated for 1 hour and 30 minutes at 37ºC, 5% CO2, 
after which (5 µg/ml) of monensin was added to inhibit extracellular secretion of cytokines, 
and the antigen stimulated PBMCs were incubated for an additional 5 hours at 37ºC, 5% CO2. 
The cells were then washed twice with MACS Buffer and stained with a cocktail of 
fluorescent-labelled monoclonal antibodies: CD3-PerCP, CD4-APC, CD8-APC-Cy7 (Becton-
Dickinson, UK) for 30 minutes at 4°C in the dark. At this stage, cells were washed with 
MACS Buffer and centrifuged to remove unbound antibodies and fixed with 1.5 ml FACS 
lysing solution (BD, Biosciences, UK) diluted to a 2x with same volume of double distilled 
(dd) H2O as per manufacturer’s instructions. Samples were vigorously stirred for 10 seconds 
then incubated at room temperature for 10 minutes. Following incubation, cells were washed 
as above and centrifuged at 500 x g for 5 minutes at 4ºC. The supernatant was carefully 
decanted and cells were then permeabilized by resuspending in 0.5 ml FACS permeabilizing 
solution (BD, Biosciences, UK) diluted to a 2x concentration with d.d.H2O. Samples were 
vigorously vortexed for at least 10 seconds then incubated at room temperature for 10 
minutes. Cells were washed as above and  stained with 10 µl of intracellular IFN-γ-PE 
antibody (from Becton-Dickinson, UK) incubated for 30 minutes at room temperature, in 
dark. Following staining, cells were checked for viability by haemocytometer and 
subsequently were washed with MACS Buffer (as described above) and centrifuged to 
remove unspecific binding of the antibodies to PBMCs. The remaining cell pellet was re-
suspended in 100 μl 2% paraformaldehyde (Sigma-Aldrich, UK), and stored in the dark at 
4°C until analyses.  Gated lymphocytes were acquired from each preparation. A total of 
~2x105-7x105 events were acquired using a flow cytometer (FACS-Canto II, Becton 
Dickinson, UK) and analysed using FlowJo software (Treestar Inc, Ashland, OR, USA). Cells 
that fell within the lymphocyte population were gated and analysed.  The CD3+/CD4+ (CD4+ 
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T), and CD3+/CD8+ (CD8+ T) cell population was also gated (within the lymphocyte 
population). The percentage of IFN-γ from the T cells was noted and compared to the 
unstimulated control and between different samples. 
 
2.1.7 The Purity of Positive (CD4+ and CD8+ T cell) and Negative (PBMCs minus T 
cells) Fraction 
 
To check for the purity of the positive (CD4+ and CD8+ T cells) and the negative fraction 
(PBMCs-T cells), 5 µl of (each of the fluorochrome-conjugated antibody, CD3-PERCP, CD4-
APC, CD8-APC-CY7 were added to 20 µl (~5x104) of PBMCs, as well as to the positive and 
negative fraction cells respectively. Cells were incubated for 30 minutes on ice and were 
subsequently washed twice with RPMI 1640 + BSA (1%). The purity of the negative and 
positive fraction cells was evaluated by flow-cytometry. A total of ~2 x 104-5 x 104 events 
were acquired and analysed using FlowJo software. The CD4+ T and CD8+ T population was 
gated (within the gated lymphocyte population) and the percentage of purity of the positive 
and negative fraction cells was determined. The purity of sorted populations was always 
higher than 90%.  
2.1.8 Multi-colour Flow Cytometry 
Principles and Compensation 
Flow Cytometry uses a beam of laser light to analyse the physical and chemical 
characteristics of cells, or other biological particles. The flow cytometry use is based on the 
principle that the beam of laser light is scattered and the fluorochromes (i.e. fluorescent dyes) 
become excited as each cell intercept the laser. The emitted light is collected and depending 
on its wavelength prisms and filters act to direct it to different photon multiplier tubes (PMT). 
PMT then converts the collected light into electrical signals. Scattered light is represented as 
the forward scatter (which measures the size of the cells) and the side scatter (which measures 
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the granularity of the cells). Based on forward and side scatter, gates were drawn (see chapter 
3, Figure 3.4.A.). The voltages were set so that the negative controls were displayed within 
the first decade. Anything above the first decade was considered positive. This calibration is 
only sufficient for single-colour flow cytometry and not for the multi-colour flow cytometry. 
In contrast, when using multi-colour flow cytometry, compensation is extremely important. 
This is because in multi-colour flow cytometry, there is an inherent overlap in the emission 
spectra of different dyes.  This overlap in the emission spectra of different dyes must be 
compensated. For compensation, samples stained with individual fluorochromes are run. One 
example to indicate importance of compensation is observed in fluorochromes FITC and PE. 
There is spectral overlap between the fluorochromes FITC and PE. This means that light 
detected by FL1 (FITC detector) and FL2 (PE detector) contains light from the other dye. The 
intensity of FITC emission detected by FL2 can be regarded as “excess fluorescence”. This 
“excess fluorescence” gives a false positive PE signal. To correct for such overlap, and thus 
false positive signals, a percentage of the total FITC signal generated in FL1 (FITC 
interference) is subtracted from the total PE signal generated in FL2. In the same way, to 
compensate for PE leakage into FL1, a percentage of the total PE signal generated in FL2 (PE  
interference) is subtracted from the total FITC signal generated in FL1 (Rahman et al., 2006). 
Here, the flow cytometer (FACS-Canto II, Becton Dickinson, UK) was used from Medical 
School, (UoB).  
2.1.9 Cell Counts Using a Haemocytometer 
2.1.10 Preparing Haemocytometer 
The dry Neubauer haemocytometer (Fisher, UK) was cleaned using 70% (v/v) ethanol/dH2O 
ethanol. The cover slip was carefully affixed on top of the counting chamber, making sure that 
both sides were resting on the raised area. The haemocytometer was then placed on the stage 
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of the Leica CME (compound microscope education) light microscope (Leica Microsystems, 
UK).  
 
Figure 2.1. Preparing haemocytometer. Figure was taken from (Mishell and Shigii, 1980). 
 
2.1.11 Preparing Cell Suspension 
PBMCs were re-suspended in a volume of 10 ml into a 15 ml Falcon tubes. Cell suspension to 
be counted was well mixed using a serological pipette (Appleton Woods, UK). Subsequently 
1 ml of cell suspension was drawn using a serological pipette and placed in a 2 ml Eppendorf 
tube. Using a 100 µl pipette, the cells in this sample were again gently mixed. 100 µl of cell 
suspension was drawn out and placed into a new Eppendorf tube. Subsequently 100 µl of 
trypan blue dye was added and mixed gently with this cell suspension.  
2.1.12 Counting 
 
10 µl of cell suspension containing trypan blue were drawn up using the 10 µl Gilson pipette 
(Anachem, UK).The haemocytometer was carefully filled by resting the end of the   
Gilson tip at the edge of the chambers (filling notch) taking care not to overfill. The liquid 
was drawn out of the pipette and into the chamber. 
 
 
55 
 
 
Figure 2.2. Counting. Figure was taken from (Mishell and Shigii, 1980).
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The Haemocytometer was placed under a microscope and the 40X objective lense of the 
microscope was focused on the grid area of the counting chamber. Under the microscope, the 
central area of the grid was observed to be made up of triple ruled lines that in the centre form 
a 5x5 grid of 25 squares with a total volume of 0.1 mm3 (Fig.2.3.). (Each of these 25 squares 
has an area of 0.04 mm2 and a volume of 0.004 mm3 with the depth of the chamber being 
0.1mm). Five areas inside the grid were counted. Cells falling on the bordering triple lines 
were only counted if they were on either the top or on the left lines only. 
 
Figure 2.3. The Haemocytometer grid. Figure was taken from (Mishell and Shigii, 1980). 
 
2.1.13 Calculating the Concentration of Cells 
The centre triple ruled grid (consisting of 25 squares) has a volume of 0.1 mm3. Cells were 
counted in only 5 out of the 25 squares of this grid representing a grid volume of 0.02 mm3.  
To convert to the number of cells in 0.1 mm3, the total number of cells in 5 squares were first 
divided by 5 (to give the total number of cells in 0.004 mm3) and then were multiplied by 25 
(to give the total number of cells in 0.1 mm3). The haemocytometer is designed so that the 
number of cells in one set of 25 corner squares is equivalent to the number of cells x 104/ml. 
Thus to convert this answer from cell/0.1 mm3 to cells/ml, cells were multiplied by 104                          
(0.1 mm3 * 104 =1000 mm3= 1 mm3).  
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For example:  
Let the number (no.) of cells counted in 5 squares = X. 
no. of cells/ ml suspension  =  X x 5 x 104 
Finally the total cell number/ml was multiplied by 2 to adjust for the 1:2 dilution in trypan 
blue. 
2.2 In Vitro Flow Assay 
2.2.1 Microslides 
Important components of the flow assay are the microslides. These are glass capillaries with 
rectangular cross-section (0.3mm x 0.3mm; length 50 mm) (Vitro Dynamics Inc., USA; 
available through Camlab Ltd., UK) and in this study were coated with purified adhesion 
molecules. Prior to being used for coating, microslides were pre-treated with 
Aminopropyltriethoxysilane (APES) 4% in acetone (Sigma-Aldrich, UK) with molecular 
sieve (BDH Laboratory Supplies, UK) to ensure anhydrous. Recombinant human vascular 
cell adhesion molecule (VCAM-1) (R&D systems, UK) was used in all experiments.  
2.2.2 Microslides Pre-treatment with APES 
Microslides were immersed in nitric acid (50% v/v) (Fisher, UK) in distilled water for 24 
hours to ensure they are chemically clean. The next day, they were washed for 3-4 hours 
thoroughly in beaker using running tap water and finally with deionised distilled water. They 
were then dried as thoroughly as possible at 37ºC or by sucking air through using a vacuum 
pump. Subsequently, microslides were placed in 50 ml polystyrene tubes and rinsed twice 
with anhydrous acetone (acetone with molecular sieve added to absorb any water) by gently 
inverting the tubes over 30 seconds. Using the same procedure as above, microslides were 
immersed in a freshly prepared solution of APES (4% v/v in anhydrous acetone) ensuring all 
capillaries were filled. They were subsequently removed from the APES and blotted out onto 
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tissue, ensuring that all capillaries were emptied. The procedure was repeated and the 
microslides were left in second change of APES overnight in the dark. The following day, the 
microslides were washed with two changes of anhydrous acetone followed by three washes 
with deionised distilled water by sucking a few ml through using a vacuum pump. Between 
each change care was taken to remove all the liquid from the microslides. Finally, the 
microslides were autoclaved at 121 ºC for 11 minutes and were stored aseptically indefinitely. 
2.2.3 Coating of Microslides with VCAM-1 
Recombinant human VCAM-1 was diluted to 10ug/ml in Dulbecco’s PBS (Phosphate 
Buffered Saline with MgCl2 and CaCl2; from Sigma-Aldrich). In some initial experiments, 
desired serial dilutions were made to 5 µg/ml and 20 µg/ml. A short length of 2mm ID silicon 
rubber tubing (Fisher Scientific, UK) was attached to APES coated microslide and 50 µl of 
recombinant human VCAM-1 at final desired concentration was aspirated into a microslide 
using a pipettor inserted in the silicon tubing adapter. The recombinant human VCAM-1 
coated microslide was incubated for two hours at 37ºC. Subsequently 500 µl of PBS with 1% 
(w/v) BSA (dilute from 7.5% culture-tested solution; Sigma-Aldrich) was aspirated as above 
and incubated at 37ºC for 2 hours to block non-specific binding sites.  
2.2.4 Isolation of Peripheral Blood Lymphocytes (PBLs) 
Whole blood from healthy individuals was collected in tubes coated with EDTA (anti-
coagulant) (1.6 mg/ml) (Sarstedt, UK). Whole blood was gently layered onto a Histopaque 
gradient (2.5 ml Histopaque 1077 layered onto 2.5 ml of Histopaque 1119 (Sigma-Aldrich, 
UK) and centrifuged for 40 minutes at 1200 x g at room temperature. The PBMCs sedimented 
above the blood at the Histopaque interface. The PBMCs layer was collected and transferred 
into 15 ml Falcon tubes (Scientific  Laboratory Supplies, UK). PBMCs were washed twice in 
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PBS + BSA (0.15%) 5 minutes by centrifugation at 500 x g then 320 x g at room temperature. 
PBLs were prepared by re-suspending PBMCs pellet in PBS + BSA (1%) and by panning 
PBMCs on culture plastic T25 flask (FalconTM, BD, Bioscience, UK) pre-coated with heat 
inactivated human serum. PBMCs were incubated at 37 ºC for 45 minutes to remove 
monocytes.  Following incubation of PBMCs, the non-adherent cells were collected from the 
flask and transferred into 15 ml Falcon tubes. The volume of PBLs was made to10 ml with 
PBS + BSA (1%) and PBLs were centrifuged for 5 minutes at 320 x g at room temperature. 
The purified PBLs pellet was re-suspended in PBS + BSA (0.15%) at a final concentration of 
1x10 6cells/ml. For the static assay (section 2.3.2), the purified PBLs pellet was re-suspended 
in RPMI only at a final concentration of 1x10 6cells/ml.  
2.2.5 Assay Design 
The microslide coated with VCAM-1 (10 µg/ml) was placed on a 75 x 25-mm coverslip 
(Fisher Scientific, UK).The coverslip and the microslide were incorporated into a parallel 
plate flow chamber and attached to a perfusion system mounted on the stage of phase contrast 
video microscope (Olympus IX70 with JVC TK8350 video camera attached) enclosed in a 
Perspex  chamber at 37 ºC (Fig.2.4.), (previously described by Nash et al., 1992; Cooke et al., 
1993; Rainger et al., 2001). At one end they were connected by flexible silicon to a Harvard 
withdrawal syringe pump, which was set to deliver flow at a rate equivalent to a wall shear 
stress of 0.05 Pa. At the other end they were connected to an electronic switching valve (Lee 
Products, Gerards Cross, UK). This valve selected flow from three reservoirs containing 
PBLs (PBMCs-minus plastic adherence cells) in PBS + BSA (0.15%), or cell-free wash 
buffer consisting of PBS + BSA (0.15%), or cell-free PBS + salmeterol/epinephrine at various 
concentrations. A suspension of either PBLs (1x106 cells/ml) or cell free wash buffer, or cell-
free PBS + salmeterol/epinephrine (Sigma-Aldrich, UK) at various concentrations of 0.05 µM 
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-50 µM, was perfused through the chamber at a constant wall shear stress (τw) set at 0.05 Pa 
based on the formula: Τw = (6ηQ)/wh2 
whereby: η = viscosity of perfusing medium (=7 x 10 -3 Poise for aqueous buffer at 37 ºC);  
Q = flow rate (yielding a flow rate of 0.05 Pa). 
w= the width (4mm for the chamber); h= height (133μm for the chamber). 
The microslide was perfused for 2 minutes with PBS + BSA (0.1%) to acclimatise cells. 
Subsequently a 4-minute bolus of PBLs was perfused over the VCAM-1 coated microslide 
followed by 2 minutes of cell-free wash buffer.  
Video recordings were made of a series of microscope fields along the centreline of the flow 
channel after 2 minutes of wash-out. Following on from the video recordings of five different 
microscope fields, the microslide was perfused for 2 minutes with PBS + salmeterol at 
concentrations of either 0.5 µM, or 5 µM, or 50 µM, or epinephrine at a concentration of 0.05 
µM. Cell-free wash buffer was perfused again over VCAM-1 microslide and video recordings 
of 5 different microscopic fields were made again at 2 minutes and 5 minutes following the 
PBS + salmeterol/epinephrine perfusion in order to observe the effect of 
salmeterol/epinephrine on the PBLs. 
After video recordings, the flow was stopped and the manometer tubing was cut from the 
microslide. PBLs were detached from the microslide by carefully pipetting up and down the 
microslide volumes of EDTA (stock concentration 0.02%) (BD Vacutainer, UK). Cells were 
collected in 2 ml eppendorf tubes (BD Biosciences, UK).When all cells had detached from the 
microslide (as determined from visual observations using phase contrast microscopy) PBLs 
were centrifuged at 500 x g for 3 minutes. Following on from centrifugation, the supernatant 
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was removed and the adherent lymphocytes were labelled with a cocktail of fluorescent-
labelled monoclonal antibodies: CD3-PerCP, CD4-APC, CD8-APC-Cy7, CD28-PE-CY7 
(Becton-Dickinson, UK) for 30 minutes at 4°C in the dark. At this stage, cells were washed 
with PBS + BSA (1%) and centrifuged for 5 minutes at 500 x g to remove unspecific binding 
of the antibodies to lymphocytes. The remaining cell pellet was re-suspended in100 μl PBS 
containing 2% paraformaldehyde, and stored in the dark at 4°C until analyses. Preparations 
were read within 18 hours. Gated lymphocytes (10x103-15 x 104) were acquired from each 
preparation using a flow cytometer (FACS-Canto II, Becton Dickinson, UK). Data were 
analysed using  Flowjo 7.6.1 (Treestar Inc, Ashland, OR, USA). In this way, we determined 
the percentages of each lymphocyte phenotype adhered to VCAM-1 under different 
conditions.  
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Figure 2.4. The flow assay design. The microslide coated with VCAM-1 was placed 
on a 75 x 25-mm coverslip and incorporated into a parallel plate flow chamber attached 
to a perfusion system mounted on the stage of phase contrast video microscope 
(enclosed in a Perspex chamber at 37 ºC). At one end, the microslide was connected to a 
Harvard withdrawal syringe pump and at the other end it was connected to an electronic 
switching valve. This valve selected flow from three reservoirs containing PBLs in PBS 
+ BSA (0.15%), or cell-free wash buffer consisting of PBS + BSA (0.15%), or cell-free 
PBS + salmeterol at various concentrations. A suspension of either PBLs (1x106  
cells/ml), or cell free wash buffer, or cell-free PBS + salmeterol / epinephrine at various 
concentrations of 0.05 µM -50 µM, was perfused through the chamber at a constant wall 
shear stress (τw) set at 0.05 Pa. 
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2.2.6 Analysis of Video Recordings under Flow Conditions 
The adhesion and rolling behaviour of leukocytes were recorded and analysed offline using 
Image-Pro Plus software package. The total number of adherent leukocytes were counted and 
converted to cells/mm2/106 perfused. In addition, leukocyte behaviour (rolling, firmly 
adherent) was analysed and expressed as percentage of total adherent cells. Rolling adherent 
cells were spherical and moved slowly over the VCAM-1 coated microslide. Stably adherent, 
otherwise referred to as the “activated “cells were stationary over the VCAM-1 coated 
microslide as previously described (Cooke et al., 1993). The rolling velocities of ten random 
cells were measured over ten seconds and were expressed as average rolling velocity per 
second (µm/sec).  
2.3 Static Assay 
2.3.1 Cell Culture Media 
Endothelial cells were cultured in human microvascular endothelial cells (HMEC-1)/Medium 
199 containing Earle’s salts and L-Glutamine (M199-Gibco Invitrogen Compounds, UK) 
supplemented with 20% heat inactivated fetal calf serum (FCS), 10 ng/ml epidermal growth 
factor, 35 µg/ml gentamycin,1 µg/ml hydrocortisone, 2 mM L-glutamine (all from Sigma-
Aldrich), and 2.5 µg/ml amphotericin B (Gibco Invitrogen Compounds). 
2.3.2 Treatment of PBLs with Salmeterol or Epinephrine 
PBLs were treated with salmeterol or epinephrine in the following way: 4 ml of PBLs     
(4x10 6) resuspended in serum free medium (RPMI-1640) was treated with either salmeterol 
(to make a final concentration of 5 and 50 µM respectively), or epinephrine (to make a final 
concentration of 0.05 µM epinephrine). This dose of epinephrine proved maximal efficacy 
(Dimitrov et al., 2010). Following treatment with salmeterol or epinephrine, PBLs were 
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incubated for 30 minutes at 37°C, 5% CO2. Subsequently, cells were washed twice with 
RPMI and counted. Following counting, PBLs were diluted to a cell density of 2 x 106 
cells/ml in M199 + BSA (0.15%).To maintain consistency the same procedure was carried out 
with the untreated PBLs which served as a negative control as compared to the 
salmeterol/epinephrine treated PBLs samples.   
2.3.3 Culture of Human Microvascular Endothelial Cell Line-1 (HMEC-1) 
Endothelial cells (obtained from Prof. Gerard Nash, University of Birmingham) were 
retrieved from liquid nitrogen. The pellet was defrosted and re-suspended in 5 ml of cold 
HMEC-1/culture medium. Subsequently, HMEC-1 were plated onto 1% gelatin-coated T75 
culture flasks (FalconTM, BD, Bioscience, UK) and cultured until confluent (approx. one to 
two days). To maintain a constant pH, the medium was replaced every day until the cells were 
fully confluent. 
Upon confluency, the medium was removed and 2 mls EDTA (0.02%) (Sigma-Aldrich, UK) 
was added to HMEC-1 and left for 60 seconds. The supernatant was aspirated off and HMEC-
1 were subsequently trypsinised (2.5 mg/ml) (Sigma-Aldrich, UK) in a 2:1 ratio with EDTA. 
When all the cultured HMEC-1 had detached, (as determined from visual observations using 
phase contrast microscopy) 5 ml of culture medium was added to stop the reaction. The 
contents of the T75 flask was transferred to a 15 ml Falcon tube and centrifuged at 500 x g for 
5 minutes. The HMEC-1 were re-suspended in culture medium, plated out into 9 cm petri 
dishes (Appleton woods, UK) and incubated at 37 ºC. Confluent monolayers were yielded 
within 24 hours. Depending on the experimental protocol, TNF-α (100 U/ml, Sigma-Aldrich, 
UK) and/or IFN-γ (10 ng/ml, Peprotech Inc., UK) was added to confluent monolayers for 4 
hours or 24 hours before the assay with lymphocytes or NK cells, respectively. 
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2.3.4 Natural Killer Cell (NK) Isolation 
PBMCs from peripheral blood were isolated by density gradient centrifugation, as described 
above. The PBMCs layer was collected and transferred into 50 ml Falcon tubes. Cell 
suspension was centrifuged at 500 x g for 8 minutes. The supernatant was completely 
aspirated and the cell number was determined. PBMCs were then washed twice in MACS 
Buffer and centrifuged for 10 minutes at 4°C.The supernatant was again completely aspirated 
and the cell pellet was resuspended in 40 µl of MACS Buffer per 107 total cells.  
Subsequently, 10 µl of NK cell biotin-antibody cocktail (Miltenyi Biotec, UK) was added per 
107 total cells.  The cells were mixed well with the antibody and the sample was refrigerated 
for 15 minutes (4−8 °C). Following incubation, an additional 30 µl of MACS Buffer was 
added to 10⁷ total cells. This was followed by the addition of 20 µl of NK cell microbead 
cocktail (Miltenyi Biotec, UK). The sample was mixed well and refrigerated for an additional 
15 minutes (4−8 °C), with occasional mixing. Following incubation, cells were washed by 
adding 2 ml of MACS Buffer per 10⁷ total cells and were centrifuged at 300 x g for 10 
minutes. The supernatant was aspirated completely and up to 108 cells were resuspended in 
500 µl of MACS Buffer. The sample was ready to proceed for magnetic separation. 
2.3.5 Magnetic Separation of NK cells 
Magnetic separation was carried using LS MACS Column (Miltenyi Biotec, UK). The LS 
column was placed in the magnetic field of the MACS Separator (type-Miltenyi Biotec) and 
was prepared by rinsing with 3 ml of MACS Buffer. The eluent was collected and removed.  
The cell suspension (500 µl) was applied onto the column. The unlabelled NK cells that 
passed through were collected, and the column was washed three times with 3 ml of MACS 
Buffer to remove remaining NK cells. The new buffer was added only when the column 
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reservoir was empty. For the isolation of magnetically labelled non-NK cells, the column was 
removed from the separator and placed on a suitable collection tube. 5ml of MACS Buffer 
was pipetted onto the column and the magnetically labelled cells were immediately flushed 
out by firmly pushing the plunger into the column. Following collection, the volume of NK 
cells was made to 10 ml with MACS Buffer and NK cells were centrifuged at 300 x g for 10 
minutes at 4 °C. The purified NK cell pellet was re-suspended in RPMI only at a final 
concentration of 1x10 6 cells/ml.  
 Depending on the static assay experiment, NK cells were treated with salmeterol (to make a 
final concentration of 0.05 – 50 µM) or epinephrine (to make a final concentration of 0.05 
µM) or not (which served as a negative control) and were incubated for 30 minutes at 37°C, 
5% CO2. Following incubation, cells were washed twice with RPMI Medium and were 
subsequently diluted to a cell density of 2x106 cells/ml in M199 + BSA (0.15 %).  
2.3.6 Static Assay Design-Migration Through Endothelial Cells (EC) 
Whole blood was collected into EDTA tubes (BD Vacutainer, UK), maintained at room 
temperature and processed within 30 minutes after collection. PBLs/NK cells were isolated 
and treated with epinephrine or salmeterol or not (as described in section 2.3.2 and 2.3.5 
respectively) and re-suspended in M199 + BSA (0.15%) at a final concentration of 2x106 
cells/ml.  
HMEC-1 in individual 9 cm petri dishes were washed twice with M199 + BSA (0.15%) to 
remove residual cytokines, and 1ml of purified PBLs was added onto HMECs monolayer. It is 
important to note that in these experiments, salmeterol or epinephrine was added directly to 
PBLs (for 30 minutes at 37 ºC, 5% CO2), and only following two washes of PBLs with RPMI 
(that would allow removal of salmeterol), were PBLs added to HMEC-1. Following adhesion 
of PBLs, to HMEC-1 monolayer, the lymphocytes were allowed to settle and adhere for 30 
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minutes at 37 ºC, 5% CO2. Non adherent cells were carefully removed from the HMEC-1 by 
gentle washing with M199 + BSA (0.15%) and were subsequently transferred into labelled 15 
ml Falcon tubes.  Immediately after washing, video recordings of the endothelial surface were 
made using phase-contrast video microscopy. Five fields were briefly recorded to analyse the 
number of adherent cells above the monolayer; a single field was recorded for 5 minutes to 
follow lymphocyte behaviour. Manipulations and microscopy were carried out inside a 
Perspex box held at 37 ºC.  
Following on from the video recordings, the medium containing non-adherent lymphocytes 
was aspirated from the HMEC-1 monolayer and collected into 15 ml Falcon tube. 
Subsequently, HMEC-1 were bathed in 2 ml of Accutase (Sigma-Aldrich, UK) for 5 minutes 
to detach HMEC-1 and lymphocytes. When all cells had detached, as determined from visual 
observations using phase contrast microscopy, 2 ml of culture medium was added to stop the 
reaction.  
The contents of the petri-dish were transferred to a correctly labelled 15 ml Falcon tube and 
centrifuged at 500 x g for 5 minutes.  At the same time, the non-adherent cells were also 
centrifuged at 500 x g for 5 minutes. Subsequently the non-adherent lymphocytes were 
transferred to their respectively labelled FACS tubes and the HMEC-1 with the adherent cells 
were transferred into their specifically labelled FACS tubes. FACS tubes containing cells 
were centrifuged again at 500 x g for 5 minutes. Following on from centrifugation, non-
adherent and adherent lymphocytes were labelled with a cocktail of fluorescent-labelled 
monoclonal antibodies: CD3-PerCP, CD4-APC, CD8-APC-Cy7, CD56-PE for 30 minutes at 
4°C in the dark. At this stage, cells were washed with PBS + BSA (1%) and centrifuged to 
remove unspecific binding of the antibodies to lymphocytes. The remaining cell pellet was re-
suspended in100 μl PBS containing 2% paraformaldehyde, and stored in the dark at 4°C until 
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analyses. Preparations were read within 18 hours. Gated lymphocytes were acquired from 
each preparation using a flow cytometer (FACS-Canto II, Becton Dickinson, UK). Data were 
analysed using Flowjo 7.6.1 (Treestar Inc, Ashland, OR, USA). In this way, we calculated the 
percentage of lymphocytes adhered to HMEC-1 and the percentage of lymphocytes not 
adhered to HMEC-1 under different conditions. 
2.3.7 Analysis of the Video Recordings under Static Conditions 
The video recordings were analysed off-line using Image-Pro plus softaware (DataCell Ltd., 
Finchampstead, UK). In each video field, the total number of adherent cells were counted, 
averaged and then converted to cells per mm2 using the calibrated microscope field 
dimensions. Each lymphocyte was classified as phase bright with distorted shape and 
adherent to the surface of HMEC-1 or phase dark if it had spread and migrated below the 
HMEC-1. Therefore the total number of phase bright lymphocytes and the total number of 
phase dark lymphocytes was also counted, averaged, and converted to cells per mm2 using the 
calibrated microscope field dimensions. To determine the percentage of phase dark 
lymphocytes the total number of phase dark lymphocytes was divided by the total number of 
the adherent lymphocytes. Additional data are presented as total adhesion/mm2/1x106 
lymphocytes. The migration velocities of at least ten phase dark lymphocytes underneath the 
HMEC-1 were measured by digitizing a sequence of images 1 minute apart for 6 minutes. In 
each digitized image, at least ten cells were outlined using a pointer, and the position of their 
centroid was determined. Migration velocity (µm/min) was the averaged distance moved by 
the centroid per minute.  
2.4 NK Degranulation Assay 
2.4.1 K562 (Human Erythromyeloblastoid Leukemia Cell Line) 
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The K562 cell line is a highly undifferentiated human erythroleukemic cell line which does 
not express MHC Class 1 molecules on its surface. The K562 cell line was provided by John 
Hazeldine (Centre for Translational Inflammation Research, University of Birmingham) and 
maintained in RPMI 1640 containing 10% FBS, 2 mM L-glutamine, 50 IU/ml penicillin (all 
from Sigma-Aldrich, UK) at 2x106 cells/ml. 
2.4.2 Stable MICA*009 Transfected Chinese Hamster Ovary Cells (T-CHO) 
MICA-transfected CHO (MHC class I related antigen) cells were a gift from (Seema Shafi 
Department of Immunology, King’s College, London). Transfected CHO-cells were grown in 
RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine, 1% penicillin and 1% 
streptomycin, 400 µg/ml hygromycin (all from Sigma-Aldrich) at a final concentration of 
2x106 cells/ml.  
2.4.3 Chinese Hamster Ovary (CHO) Cells Culture Media 
CHO cells, were a gift from (Seema Shafi Department of Immunology, King’s College, 
London). CHO cells were grown in RPMI 1640 supplemented with 10% FBS , 2 mM L-
glutamine , 1% penicillin and 1% streptomycin at a final concentration of 2x106 cells/ml. 
2.4.4 Culture of CHO Cells 
CHO cells were plated onto 1% gelatin-coated T75 culture flasks, and cultured until confluent 
(approx. one to two days). To maintain a constant pH, the medium was replaced every day 
until the cells were fully confluent. Upon confluency, the medium was removed and 6 ml PBS 
was added to CHO cells and left for 60 seconds. The supernatant was aspirated off and 2 ml 
of trypsin (x2) was added to CHO cells. Cells were subsequently incubated for 5-10 minutes 
at 37 ºC, 5% CO2. When all the cultured CHO cells had detached, (as determined from visual 
observations using phase contrast microscopy) 5 ml of the respective culture medium was 
added to stop the reaction. The contents of the T75 flask was transferred to a 15 ml Falcon 
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tube and centrifuged at 500 x g, at 21 ºC for 6 minutes. The CHO / or CHO-transfected cells 
were re-suspended in their respective culture medium, plated onto 1% gelatin-coated T75 
culture flasks and incubated at 37 ºC, 5% CO2. Confluent monolayers were yielded within 24 
hours.  
2.4.5 Treatment of PBMCs with Salmeterol or Epinephrine 
PBMCs freshly isolated from blood of healthy controls were treated with salmeterol or 
epinephrine in the following way: PBMCs were first pelleted by centrifuging at 500 x g for 6 
minutes and resuspended in 3 ml serum free medium (RPMI 1640) with either 0.05 µM 
epinephrine, or 5 µM salmeterol or 50 µM salmeterol and then incubated for 30 minutes at 
37°C, 5% CO2. Following incubation, cells were washed twice with RPMI and counted. 
Subsequently PBMCs were diluted to a cell density of 2x106 cells/ml in complete medium 
consisting of RPMI 1640 supplemented with 10% Fetal Bovine Serum (FBS), 2 mM L-
glutamine, 50 IU/ml penicillin ( all from Sigma-Aldrich). To maintain consistency the same 
procedure was carried out with the untreated PBMCs which served as a negative control as 
compared to the salmeterol/epinephrine treated PBMCs samples.  
2.4.6 NK Cell Killing Assay 
Untreated or salmeterol/epinephrine treated PBMCs were re-suspended at 2x106 cells/ml in 
RPMI 1640 (Sigma-Aldrich) containing 10 % FBS 2 mM L-glutamine, 50 IU/ml penicillin 
(all from Sigma-Aldrich).  Like PBMCs, the K562 cell line was also re-suspended at 2x106 
cells/ml in RPMI 1640 containing 10 % FBS 2 mM L-glutamine, 50 IU/ml penicillin (all from 
Sigma-Aldrich). Following re-suspension of both of the types of cells, PBMCs were 
stimulated with MHC devoid, K562 cells at an effector to target ratio of 1:1.Medium alone 
was used as a negative control. CD107-a-PeCy5 antibody (eBioscience, UK) was added 
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directly to the cells (5 µl of antibody/0.1 ml of cell suspension). FACS tubes were covered 
with paraffin and cells were incubated for 1 hour at 37°C in 5 % CO2. Following incubation, 
Monensin (Sigma-Aldrich) was added at a final concentration of 6 ug/ml and incubated for an 
additional 3 hours or 5 hours (depending on the experiment) at 37°C in 5 % CO2. 
Subsequently, samples were spun for 8 minutes at 500 x g at 4°C. PBMCs were then stained 
for surface NK markers CD56-PE-CY7 (BD Biosciences) and CD3-PERCP for 30 minutes in 
ice. Following incubation, cells were washed and were re-suspended in 1% paraformaldehyde 
(Sigma-Aldrich). Multi-parameter cytokine staining was used to quantify the frequency of 
degranulating NK cells. The flow-cytometry was performed on a FACS-Canto II. A total of 
3x104-2x105 events were acquired and analysed using FlowJo software. Cells that fell within 
the lymphocyte population were gated and analysed. The CD3-/CD56+ population was also 
gated (within the lymphocyte population). An independent expression of CD107a was noted 
within the CD3-/CD56+ population.  If the frequency of CD107a expressing CD3-/CD56+ 
cells was greater than in unstimulated control, the response was considered positive.  Medium 
alone and CHO cells incubated with PBMCs were used as negative control  
2.4.7 Gating Strategy for CD107a Positive NK and CD8+ T Cells 
As mentioned previously, cells that fell within the lymphocyte population were gated and 
analysed. Subsequently, the T cell population, the CD3+ CD8+ (CD8+ T cell) population and 
the CD3-/CD56+ (NK) population was also gated (within the lymphocyte population). As 
most of the remaining T cells (apart from CD8+ T cells) do not tend to have cytotoxic 
function, and thus would not express CD107a on their surface, the gated T cell-CD107a 
population (Fig.2.5.A) was used as a negative control for CD107a expression (Fig.2.5.B). The 
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same gate set for the negative control (Fig.2.5.B) was moved up and was also set for the 
samples in question (Fig.2.5.D,F). 
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Figure 2.5. Gating strategy for CD107a positive CD8+ T and NK cells.  
PBMCs were incubated with T-CHO, and CD8+ T CD107a and NK CD107a expression were determined.
A) 
B) 
C) 
D) 
E) 
F) 
Negative Control 
Gated CD8- T cells CD8+ T cells NK cells 
T cell-CD107a CD8+ T-CD107a NK-CD107a 
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Table 2.1 Clinical Details of All Individuals Studied 
Patient Sex Age 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9  
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
  
M 
M 
M 
F 
M 
F 
M 
M 
F 
M 
M 
M 
M 
M 
F 
M 
M 
M 
M 
M 
F 
M 
M 
F 
M 
M 
F 
M 
M 
M 
M 
F 
M 
M 
F 
50 
27 
43 
23 
43 
44 
55 
36 
26 
29 
47 
44 
28 
34 
37 
40 
42 
31 
50 
36                                     
35 
28 
27 
46 
32 
37 
26 
51 
33 
22 
24 
38 
55 
48 
25 
All individuals had a Caucasian background and were not under any medical treatment. 
Individuals 1-20 were all CMV positive and were used for cytokine stimulation assay. 
Individuals 21-30 were used for flow and static assays. Individuals 31-35 were used for 
degranulation assay. 
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2.4.8 Statistical Analysis 
The data in Chapters 3, 4 and 5 of this thesis were presented graphically as the mean ± SEM 
of n independent experiments. Variation between different (multiple) treatments was 
evaluated using paired sample t-test and were re-visited through the non- parametric 
Wilcoxon signed-rank test by SPSS programme (UOB). p (single-tailed) values <0.05 were 
considered statistically significant and were presented by a * symbol in Figures. Positive 
significant values only, are highlighted throughout the Chapters.  Both, paired sample t-test 
and Wilcoxon signed rank test produced very similar results. 
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CHAPTER 3 
EFFECT OF SALMETEROL ON IFN-γ PRODUCING CD4+ TLs AND CD8+ TLs 
3.1 Introduction 
The catecholamines Epi and NE represent the major stress hormones and are the main end 
products of SNS activation (Elenkov et al., 2000b). Indeed, previous studies have reported 
catecholamines to influence various aspects of the immune system. For example they 
influence proliferation of B and T cells, production of antibodies, the production of cytokines, 
antigen presentation by (APCs), the cytotoxicity of NK cells (Elenkov et al., 2000b; Madden 
et al., 1995; Padgett and Glaser, 2003; Wiegers et al., 1995; Yang and Glaser, 2000). 
However, relatively little is known about the effect of catecholamines on the function of the 
cytotoxic CD4+ T and CD8+ T lymphocytes. The memory CD8+ TLs subsets are also 
characterised by a higher expression of β2AR suggesting they are more responsive to β2AR 
stimulation than the naïve or central memory CD8+ TLs (Dimitrov et al., 2010).  
CD4+ TLs regulate and assist in active immune responses by releasing cytokines. Cytokines 
play a crucial role in maintaining the homeostasis within the immune system by mediating 
inflammatory and immune responses. Indeed, two main categories of CD4+ TLs are known 
with distinct cytokine secretion phenotype. These are Th-1 and Th-2. Whereas Th-2 are 
involved in promotion of humoral immunity by secreting IL-4, IL-10, and IL-13, Th-1 
promote cellular immunity and stimulate the functional activity of  CD8+ TLs by secretion of 
IFN-γ, IL-2, and TNF-β (Elenkov, 2008). 
The main aim of the study presented here was to investigate the effect of salmeterol on IFN-γ 
producing CD4+ TLs and CD8+ TLs. Subsequently, we wanted to investigate whether the 
effect of salmeterol on IFN-γ producing CD4+ TLs and CD8+ TLs was direct, i.e., affected 
the T cells, or indirect by affecting the APCs or both. For this reason, the present study 
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employed three different approaches. Initially, we examined the IFN-γ producing CD4+ T and 
CD8+ T cells in salmeterol treated PBMCs. Secondly we investigated IFN-γ producing CD4+ 
T and CD8+ T cells on incubation with salmeterol treated APCs. Thirdly, we investigated the 
effect of salmeterol on the proportion of IFN-γ producing CD4+ T and CD8+ T cells. Previous 
studies have reported that salmeterol inhibits the production of IFN-γ by human PBMCs 
(Mohede et al., 1996). Consistent with the literature, we hypothesised that β2AR stimulation 
(salmeterol) inhibits the percentage of IFN-γ producing CD4+ TLs and CD8+ TLs. Since the 
β2AR is expressed on CD4+ TLs, CD8+ TLs as well as on the surface of APCs (Borger et al., 
1998; Goyarts et al., 2008; Elenkov et al., 1996), we hypothesised that salmeterol would 
inhibit IFN-γ producing CD4+ TLs and CD8+ TLs both directly (by affecting β2AR 
expressed on CD4+ TLs and CD8+ TLs) and indirectly (by affecting β2AR expressed on 
APCs). The clinical details of individuals used in this assay are shown in Table 3.1. 
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Table 3.1 Clinical Details of Individuals Studied for Cytokine Stimulation Assay 
Patient Sex Age 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9  
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
M 
M 
M 
F 
M 
F 
M 
M 
F 
M 
M 
M 
M 
M 
F 
M 
M 
M 
M 
M 
 
50 
27 
43 
23 
43 
44 
55 
36 
26 
29 
47 
44 
28 
34 
37 
40 
42 
31 
50 
36                                     
All individuals had a Caucasian background and were not under any medical treatment. 
Individuals 1-20 were all CMV positive and were used for cytokine stimulation assay. 
3.2 Results 
3.2.1 Optimising the Assay - Initial Studies 
Initial experiments described in this paragraph served to optimise the assay. PBMCs were 
treated for 30 minutes with salmeterol (50 µM) after which they were activated by incubation 
with phorbol myristate acetate (PMA) (25 ng/ml) and ionomycin (IO) (1 µg/ml) (a stimuli 
independent on the effect of antigen presenting cells, which served as high positive control 
(Godoy-Ramirez et al., 2004) and incubated for 1 hour and 30 minutes at 37°C, 5 % CO2. 
Following incubation, monensin was added to inhibit intracellular secretion of cytokines. 
Cells were then incubated for a further period of 5 hours and stained with respective 
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antibodies. The percentage of IFN-γ producing CD4+ and CD8+ T cells was determined using 
FACS analysis. Our initial data showed that PMA and IO were potent activators of PBMCs, 
and increased the number of IFN-γ producing CD4+ and CD8+ TLs by 24 and 28 fold 
respectively, as compared to the untreated control (Fig.3.1.A-B). On the other hand, 
salmeterol proved to have a inhibitory effect on the production of IFN-γ producing CD4+ and 
CD8+ TLs, inducing a 5.7 fold and 4.1 fold decrease respectively compared to the positive 
control (Fig.3.1 .A-B). The choice of using PMA and IO in the initial trials relates to the fact 
that PMA + IO is a very potent stimulator of IFN-γ and since the number of antigen specific 
cytokine responding T cells is usually low, and difficult to detect. However one of the main 
drawbacks of PMA and IO is that it causes a dramatic decrease in CD4 expression, thus it can 
only be an activator of choice when the examination of the precise lymphocyte subpopulation 
is not important. Therefore for the next set of experiments, PMA + IO were replaced by 
Staphylococcus enterotoxin type B (SEB) superantigen, which acts as a positive control for 
IFN-γ producing T cells. As with PMA+IO, SEB stimulates T cells directly, and thus does not 
require antigen presentation by APCs. 
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Salmeterol (50 µM)        -                          -                          + 
Figure 3.1. (A-B). Effect of salmeterol on IFN-γ producing CD4+ T (A) and CD8 
+T (B) cells in whole PBMCs stimulated with PMA + IO and/ or salmeterol. 
PBMCs were isolated from blood and were incubated for 30 min at 37°C, 5% CO2 in 
the presence or absence of 50 µM salmeterol. Following incubation of PBMCs with 
salmeterol (50 µM), PBMCs were washed twice after which they were subsequently 
stimulated with PMA + IO and incubated for 1 hr 30 min at 37°C, 5 % CO2.  After 1 hr 
30 min of incubation of PBMCs with PMA + IO, monensin was added to inhibit 
intracellular secretion of cytokines. Cells were then incubated for a further period of 5 
hours and stained with respective antibodies. The percentage of IFN-γ producing CD4+ 
and CD8+ T cells was determined using FACS Analysis.  Horizontal lines represent 
mean values of 2 replicates (n=2). No statistics were carried out based on two values.
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3.2.2 Effect of Salmeterol on the Production of CD4+ T-IFN-γ+ and CD8+ T-IFN-γ+ 
cells. Stimulation of PBMCs with SEB 
  
In the experiment presented below, PBMCs were exposed to salmeterol (50 µM) before 
activation by SEB superantigen (Fig.3.2.A-B). This activation does not require specific 
antigen processing but evolves from direct binding to MHC class II molecules (Qasim et al., 
1991). The results presented in Fig.3.2.A show that stimulation of PBMCs with SEB caused a 
significant 12.4 fold increase in the percentage of IFN-γ+ CD4+ TLs (p=0.001 using paired t-
test; p=0.006 using Wilcoxon signed rank test) (Fig.3.2.A). In addition, the stimulation of 
PBMCs with SEB induced a significant 34.7 fold increase in the percentage of IFN-γ+ CD8+ 
TLs (p=0.001 using paired sample t-test; p=0.006 using Wilcoxon signed rank test) 
(Fig.3.2.B). 
Exposure of PBMCs to the β2AR agonist salmeterol before activation by SEB inhibited 
significantly the IFN-γ producing CD4+ TLs (p=0.009 using paired sample t-test; p=0.006 
using Wilcoxon signed rank test), reducing the proportion of IFN-γ+ cells by 1.2 fold 
compared to the positive control (Fig.3.2.A). Similarly salmeterol significantly inhibited the 
IFN-γ producing CD8+ TLs (p=0.003 using paired sample t-test; p=0.009 using Wilcoxon 
signed rank test) resulting in a 1.6 fold reduction compared to the stimulated sample 
(Fig.3.2.B). 
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SEB (500 ng/ml)              -                            +                             +                      
Salmeterol (50 µM)         -                             -                             +                      
Figure 3.2. (A-B).  Effect of salmeterol on IFN-γ producing CD4+ T (A) and CD8+ 
T (B) cells in whole PBMCs stimulated with SEB and/or salmeterol. PBMCs were 
isolated from blood and were incubated for 30 min at 37°C, 5% CO2 in the presence or 
absence of 50 µM Salmeterol. For specific conditions refer to legend for (Fig. 3.1.). 
Results are shown as the mean values of 8 replicates (n=8). *p<0.05 by paired sample t-
test, or Wilcoxon signed rank test for comparison to untreated control. The horizontal 
brackets indicate what is being compared. Flow cytometer data of a representative 
sample is shown in Fig. 3.5-3.6. (A-D). 
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3.2.3 The Effect of Salmeterol on the Proportion of CD4+ T-IFN-γ+ and CD8+ T-IFN-γ+ 
cells. Stimulation of PBMCs with CMV lysate (AD169) or CMV-pp65 
To be able to detect and analyse activation of CMV-specific CD4+ and CD8+ T cells, PBMCs 
were stimulated with either CMV lysate (30 µl of CMV lysate/500 µl RPMI) or CMV pp65 
(referred to as pp65 in the Figures; at a final concentration of 0.6 nM (~1 µg/ml) of peptide) 
following exposure to salmeterol (Fig 3.3.A-B). The choice of the CMV lysate was justified 
by the fact that CMV lysate induces a potent CD8+ T cell response, resulting in the secretion 
of effector cytokines such as IFN-γ. The CMV pp65 protein is a virion tegument protein and 
represents the main component of the enveloped subviral particle. Similarly to CMV lysate, 
CMV pp65 is an immunodominant target for CD4+ and CD8+ T cell responses to CMV, and 
induces secretion of IFN-γ, IL-2, and TNF-α. The production of these effector cytokines 
(IFN-γ, in our case) permits identification and analysis of CMV specific T cells. It is 
important to note that unlike the superantigen SEB, CMV lysate and CMV pp65 recombinant 
protein require antigen processing by APCs, to allow presentation to CD4+ T cells via MHC 
class II molecules on the surface of APCs and presentation to CD8+ T cells via MHC class I 
molecules on the surface of APCs (Arrode et al., 2002; Pita-Lopez et al., 2009; Reiser et al., 
2011) . 
The results, shown in Fig. 3.3-A, indicate that treatment of PBMCs with CMV lysate (30 
µl/500 µl volume) caused a significant 5.5 fold increase in the percentage of CD4+ T IFN-γ+ 
cells (p=0.028 using paired sample t-test; p=0.043 using Wilcoxon signed rank test) and that 
pre-treatment of PBMCs with salmeterol reduced the percentage of IFN-γ producing CD4+ T 
cells by 1.3 fold following stimulation with CMV lysate (30 µl CMV lysate/500 µl buffer) 
(this increase was significant when p value was analysed using Wilcoxon signed rank test 
p=0.043) (Fig. 3.3-A). Similarly to CMV, treatment of PBMCs with CMV pp65 (0.6 nM~1 
µg/ml) induced a significant 10.8 fold increase in the percentage of CD8+ T-IFN-γ+ cells 
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(p=0.017 using paired sample t-test; p=0.043 using Wilcoxon signed rank test), however a 
slightly more potent effect of salmeterol was observed on CD8+ TLs compared to the CD4+ 
TLs as salmeterol caused a significant 1.5 fold reduction in the percentage of CD8+ T-IFN-γ+ 
cells (p=0.004 using paired sample t-test; p=0.014 using Wilcoxon signed rank test) compared 
to the positive control (Fig. 3.3-B).  Whilst our results suggest that salmeterol reduces the 
IFN-γ producing T cells, it was not clear whether the effect of salmeterol on T cells was direct 
or indirect. This is because in addition to T lymphocytes, β2AR are present on other cells 
within the lymphocyte population such as B cells, as well as on other antigen presenting cells 
such dendritic cells and monocytes (Borger et al., 1998; Goyarts et al., 2008). Thus this β2 
agonist could influence the percentage of IFN-γ producing T cells, by binding to the β2AR on 
APCs (dendritic cells or B cells) and affecting the antigen processing or inhibiting the antigen 
presenting capability of these cells (APCs). In fact, several studies have reported 
catecholamines to inhibit the antigen presentation by epidermal Langerhans cells (Goyarts et 
al., 2008; Seiffert et al., 2002). To investigate whether salmeterol, affects the percentage of 
IFN-γ producing T cells directly or non-directly (i.e. as a consequence of an effect on APCs), 
or both, it was necessary to use a more direct approach of experiment. 
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CMV (1µg/ml)               -                             +                             +                      
Salmeterol (50 µM)       -                             -                              +           
 
             
    pp65 (1µg//ml)            -                             +                              +                      
    Salmeterol (50 µM)    -                              -                              + 
Figure 3.3. (A-B). Effect of salmeterol on IFN-γ producing CD4+ T (A) and CD8+ 
T (B) cells in whole PBMCs stimulated with CMV lysate (A) or CMV pp65 (B) 
and/ or salmeterol.  For specific conditions refer to legend for (Fig. 3.1.). Results are 
shown as the mean values of 9 replicates (n=9). *p<0.05 using paired sample t-test and/ 
or Wilcoxon signed rank test. The horizontal brackets indicate what is being compared. 
Flow cytometer data of a representative sample is shown in Fig. 3.7-3.8. (A-D). 
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Figure 3.4. (A-C). Representation of lymphocytes, CD4+ T and CD8+ T populations 
in Flow Jo graphs. Figures are representative scatter plots for data in Fig. 3.3. (A-
B). A total of 2 x 105-7 x 105 PBMC events were acquired using a dual-laser flow 
cytometer and analysed using FlowJo software. Cells that fell within the lymphocyte 
population were gated and analysed (A). Within the lymphocyte population, the 
CD3+/CD4+ T (B), and CD3+/CD8+ T (C) cell population was also gated.   
 
 
 
 
 
A) 
B) C) 
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Figure 3.5. (A-D). Effect of SEB on IFN-γ producing CD4+ T (A) and CD8+ T (B) 
cells. Figures are representative scatter plots for data in Fig. 3.3. (A-B). The CD4+ 
and CD8+ T subpopulations were gated within the PBMCs population. The percentage 
of IFN-γ producing CD4+ T (C) and CD8+ T cells (D) in SEB treated PBMCs was gated 
and compared to the unstimulated CD4+ T (A) and CD8+ T cells (B) in control. 
 
 
 
 
 
A) B) 
C) D) 
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Figure 3.6. (A-D). Effect of salmeterol on IFN-y producing CD4+ and CD8+ T cells 
following treatment of PBMCs with SEB.  Figures are representative scatter plots 
for data in Fig. 3.3. (A-B). The CD4+ and CD8+ T subpopulations were gated within 
the PBMCs population. The percentage of IFN-γ producing CD4+ T (A) and CD8+ T 
cells (B)  in SEB stimulated PBMCs was gated and compared to the percentage of IFN-
γ producing CD4+ T (C) and CD8+ T cells (D) in PBMCs treated with salmeterol and 
stimulated with SEB. 
 
  
B) A) 
C) D) 
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Figure 3.7. (A-D). Effect of salmeterol on IFN-γ producing CD4+ and CD8+
 
T cells 
following treatment of PBMCs with CMV lysate. Figures are representative scatter 
plots for data in Fig. 3.3. (A-B). The CD4+ and CD8+
 
T subpopulations were gated 
within the PBMCs population. The percentage of IFN-γ producing CD4+ T (A) and 
CD8+ T cells (B)  in CMV lysate stimulated PBMCs was gated and compared to the 
percentage of IFN-γ producing CD4+ T (C) and CD8+ T cells (D) in PBMCs treated with 
salmeterol and stimulated with CMV lysate. 
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C) D) 
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Figure 3.8. (A-D). Effect of salmeterol on IFN-γ producing CD4+ and CD8+
 
T cells 
following treatment of PBMCs with CMV pp65. Figures are representative scatter 
plots for data in Fig. 3.3. (A-B). The CD4+ and CD8+
 
T subpopulations were gated 
within the PBMCs population. The percentage of IFN-γ producing CD4+ T (A) and 
CD8+ T cells (B)  in CMV pp65 stimulated PBMCs was gated and compared to the 
percentage of IFN-γ producing CD4+ T (C) and CD8+ T cells (D) in PBMCs treated 
with salmeterol and stimulated with CMV pp65. 
 
A) B) 
C) D) 
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3.2.4 The Indirect Effect of Salmeterol on the Percentage of IFN-γ Producing CD4+ and 
CD8+ T cells 
In the next set of experiments, T cells were isolated from PBMCs and the remaining cells, 
which are to a large extent APCs like B cells and monocytes, (PBMCs – T cells), were treated 
with salmeterol (50 µM). Following this treatment, the APCs were added back to the isolated 
T cells and all cells were stimulated with SEB (Fig. 3.9. A-B). Our results showed that SEB 
significantly increased the percentage of CD4+ T-IFN-γ+ (3.2 fold; p=0.031 using paired 
sample t-test; although a borderline significance was not reached using Wilcoxon signed rank 
test, p=0.054) and CD8+T-IFN-γ+ cells (4.2 fold; p=0.032 using paired sample t-test, 
although p=0.054 using Wilcoxon signed rank test) (Fig. 3.9. A-B). In contrast, salmeterol 
caused a small but statistically significant reduction in the percentage of IFN-γ producing 
CD4+ T cells (1.19 fold inhibition; p=0.009 using paired sample t –test, although p=0.054 
using Wilcoxon signed rank test) and CD8+ T cells (1.53 fold inhibition; p=0.003 using 
paired sample t-test, although p=0.054 using Wilcoxon signed rank test), as compared to the 
positive control (Fig. 3.9. A-B). Stimulation of PBMCs with CMV pp65, following exposure 
of APCs to salmeterol, reduced the percentage of IFN-γ producing CD8+ T cells by 1.8 fold 
(Fig. 3.10. B). In contrast, the effect of salmeterol on IFN-γ producing CD4+ T cells was 
difficult to determine as no increase on the % of CD4+ T-IFN-γ+ was observed following 
stimulation of PBMCs with CMV lysate (Fig.3.10-A). Altogether, these results suggest that 
salmeterol inhibits the IFN-γ producing CD4+ and CD8+ TLs indirectly, by affecting the 
APCs.  
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SEB (500 ng/ml)          -                            +                          + 
Salmeterol (50 µM)     -                            -                           + 
Figure 3.9. (A-B). Effect of salmeterol on IFN-γ producing CD4+ T (A) and CD8+ T 
(B) cells following treatment of APCs and stimulation of PBMCs with SEB. T cells 
were isolated from PBMCs and the remaining APCs were incubated for 30 min at 37°C, 
5% CO2 in the presence or absence of 50 µM salmeterol. Following incubation with 
salmeterol, APCs were washed and T cells were added back to the APCs. PBMCs were 
then stimulated with SEB and incubated for 1 hr 30 min at 37°C, 5% CO2. 
Subsequently, monensin was added to inhibit the intracellular secretion of cytokines. 
Cells were incubated for a further period of 5 hours and stained with respective 
antibodies. The percentage of IFN-γ producing T cells was determined using FACS 
analysis. Results are shown as the mean values of 3 replicates (n=3). *p<0.05 using 
paired sample t-test. The horizontal brackets indicate what is being compared. Flow 
cytometry data of a representative sample is shown in Fig. 3.11-3.12. (A-D). 
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Lysate (30 µl/500ul)     -                             +                             + 
Salmeterol (50 µM)      -                             -                              + 
 
 
pp65 (1 µg/ml)              -                             +                              - 
Salmeterol (50 µM)      -                             -                               + 
Figure 3.10. (A-B).  Effect of salmeterol on IFN-γ producing CD4+ T (A) and CD8+ 
T (B) cells following treatment of APCs and stimulation of PBMCs with CMV-
lysate (A) or CMV pp65 (B).  Results are shown as the mean values of 3 replicates 
(n=3). For specific conditions refer to (Fig. 3.9.). Flow cytometer data of a 
representative sample is shown in Fig. 3.13-3.14. (A-D). 
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Figure 3.11. (A-D). Effect of SEB on IFN-γ producing CD4+
 
T (A) and CD8+
 
T (B) 
cells in SEB stimulated PBMCs.  Figures are representative scatter plots for data 
in Figures 3.9. (A-B). The CD4+ and CD8+
 
T subpopulations were gated within the 
lymphocyte population. The percentage of IFN-γ producing CD4+ T (C) and CD8+ T 
(D) cells in SEB treated PBMCs was gated and compared to the percentage of IFN-γ 
producing CD4+ T (A) and CD8+ T cells (B) in unstimulated control. 
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Figure 3.12. (A-D). Effect of salmeterol on IFN-γ producing CD4+ and CD8+
 
T 
cells following treatment of APCs with or without salmeterol and stimulation of 
PBMCs with SEB.  Figures are representative plots for data in Fig. 3.9. (A-B). The 
CD4+ and CD8+
 
T subpopulations were gated within the lymphocyte population. The 
percentage of IFN-γ producing CD4+ T (A) and CD8+ T cells (B)  in SEB stimulated 
PBMCs was gated and compared to the percentage of IFN-γ producing CD4+ T (C) and 
CD8+ T cells (D) in APCs treated with salmeterol and PBMCs stimulated with SEB.  
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Figure 3.13. (A-D). Effect of salmeterol on IFN-γ producing CD4+ and CD8+ T 
cells following treatment of APCs with or without salmeterol and stimulation of 
PBMCs with CMV lysate.  Figures are representative plots for data in Fig. 3.10. 
(A-B). The CD4+ and CD8+
 
T subpopulations were gated within the PBMCs 
population. The percentage of IFN-γ producing CD4+ T (A) and CD8+ T cells (B)  in 
CMV lysate stimulated PBMCs was gated and compared to the percentage of IFN-γ 
producing CD4+ T (C) and CD8+ T cells (D) in APCs treated with salmeterol and 
PBMCs stimulated with CMV lysate. 
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Figure 3.14. (A-D). Effect of salmeterol on IFN-γ producing CD4+ and CD8+
 
T 
cells following treatment of APCs with or without salmeterol and stimulation of 
PBMCs with CMV pp65.  Figures are representative scatter plots of data in Fig. 
3.10. (A-B). The CD4+ and CD8+
 
T subpopulations were gated within the PBMCs 
population.  The percentage of IFN-γ producing CD4+ T (A) and CD8+ T cells (B)  in 
CMV pp65 stimulated PBMCs was gated and compared to the percentage of IFN-γ 
producing CD4+ T (C) and CD8+ T cells (D) in APCs treated with salmeterol and 
PBMCs stimulated with CMV pp65. 
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3.2.5 The Direct Effect of Salmeterol on IFN-γ Producing CD4+ and CD8+ T cells 
To investigate whether salmeterol also has a direct effect on the percentage of CD4+ T-IFN-γ+ 
and CD8+ T- IFN-γ+, we isolated CD4+ and CD8+ T cells from PBMCs and incubated these 
T cells with salmeterol (50 µM). Following treatment of T cells with salmeterol, were the T 
cells added back to the remaining PBMCs (containing APCs such as monocytes and B cells) 
and incubated with SEB. The results showed that SEB significantly increased the percentage 
of CD4+ T-IFN-γ+ (5.2 fold; p=0.001 using paired sample t-test; p=0.001 using Wilcoxon 
singed rank test) and CD8+ T-IFN-γ+ (4.5 fold; p=0.003 using paired sample t-test; p=0.001 
using Wilcoxon singed rank test). Salmeterol (50 µM) induced a significant 1.8 fold inhibition 
on the percentage of IFN-γ producing CD4+ T cells (p=0.001 using paired-sample t-test; 
p=0.001 using Wilcoxon singed rank test) (Fig. 3.15. A) and a significant 2.1 fold inhibition 
on the percentage of IFN-γ producing CD8+ TLs (p=0.001 using paired sample t-test;  
p=0.001 using Wilcoxon singed rank test) compared to the positive control (Fig. 3.15. B). 
Another interesting observation is the fact that the percentage of IFN-γ producing CD4+ and 
CD8+ T cells following stimulation with SEB is ~5-9 fold lower than the positive control 
observed in the previous experiments (Fig. 3.2). These discrepancies probably reflect the large 
donor to donor variation on SEB induced IFN-γ producing T cells. One of the factors which 
appears to have an influence on the T cell response to SEB is age. As shown in Fig. 3.16. B, it 
is mostly the 40-49 and 50-59 age group that respond better to SEB, whilst the 30-39 and the 
20-29 age group stand at a lower end of the spectrum characterised by lower stimulation of 
IFN-γ production from T cells in response to SEB. This could possibly be explained as older 
people are characterised by a higher proportion of effector memory T cells, which respond to 
infections, more vigorously and faster. On the other hand, gender does not seem to influence 
T cell IFN-γ production in response to SEB. Both, females and males had a similar response, 
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and this is observed throughout the chapters of this thesis.  However, it is important to note 
that in all three studies of this thesis, the majority of participants were males, thus a more 
precise answer on whether gender influences T cell IFN-γ production in response to SEB, 
would have been achieved if equal number of male and female participants had been 
recruited.  
We next asked whether salmeterol inhibits the IFN-γ producing T cells in a dose dependent 
manner. Two concentrations of salmeterol (5 and 50 µM) were analysed (Fig. 3.17. A-B). Our 
data show that stimulation of PBMCs with SEB significantly increased the percentage of IFN-
γ producing CD4+ (p=0.014 using paired sample t-test; p=0.003 using Wilcoxon singed rank 
test) and CD8+ T cells (p=0.049 using paired sample t-test; p=0.003 using Wilcoxon singed 
rank test) compared to the unstimulated PBMCs. In addition, salmeterol at concentration of 
50 µM, significantly suppressed the percentage of IFN-γ producing CD4+ TLs (p=0.039 using 
paired sample t-test; p=0.030 using Wilcoxon singed rank test) by 1.27 fold compared to the 
positive control (Fig. 3.17. A). In contrast, at a concentration of 5 µM, salmeterol had a 
smaller suppressive effect, inhibiting the percentage of IFN-γ production by 1.1 fold. 
Similarly, a 50 µM concentration of salmeterol caused a significant inhibition on the 
percentage of IFN-γ producing CD8+ T cells (1.8 fold decrease) compared to the positive 
control (p=0.016 using paired sample t-test; p=0.003 using Wilcoxon singed rank test) (Fig. 
3.17. B). In contrast, a 5 µM concentration of salmeterol caused a 1.6 fold inhibition, relative 
to the positive control, which did not reach significance using paired sample t-test but reached 
significance using Wilcoxon singed rank test as p=0.011. These findings suggest that 
salmeterol inhibits the IFN-γ production in a dose dependent manner. 
To examine, whether the inhibitory effect of salmeterol on the percentage of IFN-γ producing 
CD4+ and CD8+ TLs, was consistent when PBMCs were stimulated with different stimuli, 
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PBMCs were stimulated with either CMV lysate or CMV pp65 (Fig. 3.18. A-B). The results 
show salmeterol to cause a 1.2 fold inhibition on the percentage of IFN-γ producing CD4+ T 
cells, when PBMCs were stimulated with CMV lysate (significant value was reached only 
using Wilcoxon singed rank test p=0.022) (Fig. 3.18. A). More importantly, following 
stimulation of PBMCs with CMV pp65, the percentage of IFN-γ producing CD8+ T cells was 
reduced by 3.4 fold (significant value was reached only using Wilcoxon singed rank test 
p=0.022) (Fig. 3.18. B). Altogether, these results suggest that salmeterol has a suppressive 
effect on the percentage of IFN-γ producing CD4+ T and CD8+ T cells by a direct effect on 
these cells, as opposed to indirectly via APCs. 
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SEB (500 ng/ml)             -                             +                             + 
Salmeterol (50 µM)        -                             -                              + 
Figure 3.15. (A-B). Salmeterol inhibits IFN-γ producing CD4+ T (A) and CD8+ T 
(B) cells stimulated with SEB. T cells were isolated from PBMCs and incubated for 30 
min at 37°C, 5% CO2 in the presence or absence of 50 µM salmeterol. Following 
incubation with salmeterol, T cells were washed and added to the rest of the PBMCs. 
Subsequently, PBMCs were stimulated with SEB and incubated for 1 hr 30 min at 37°C, 
5 % CO2. Following incubation of PBMCs with SEB, monensin was added to inhibit 
intracellular secretion of cytokines. Cells were incubated for a further period of 5 hours 
and stained with respective antibodies. The percentage of IFN-y producing T cells was 
determined using FACS Analysis. Results are shown as the mean values of 20 replicates 
(n=20). *p<0.05 using paired sample t-test and/or Wilcoxon singed rank test. 
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SEB (500 ng/ml) -                            +                           + 
Sal. (50 µM)        -                             -                           + 
Figure 3.16. (A-B). Salmeterol inhibits IFN-γ producing CD4+ T (A) and CD8+ T 
(B) cells stimulated with SEB in different age –groups.  For specific conditions refer 
to (Fig. 3.15). ). *p<0.05 using paired sample t-test and/ or Wilcoxon singed rank test. 
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SEB (500 ng/ml)         -                     +                     +                     + 
Salmeterol (5 µM)      -                     -                      +                      - 
Salmeterol (50 µM)    -                     -                       -                     + 
Figure 3.17. (A-B). Effect of Salmeterol on IFN-γ producing CD4+ T (A) and CD8+ 
T (B) in PBMCs stimulated with SEB. Results are shown as the mean values of 10 
replicates (n=10). For specific conditions refer to (Fig. 3.15). *p<0.05 using paired 
sample t-test and/ or Wilcoxon singed rank test. 
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Figure 3.18. (A-B). Effect of salmeterol on IFN-γ producing CD4+ T (A) and CD8+ 
T cells (B) in PBMCs stimulated with CMV lysate (A) or CMV pp65 (B) 
respectively.  Results are shown as the mean values of 5 replicates (n=5). For specific 
conditions refer to (Fig.3.15).   
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3.2.6 Salmeterol Inhibits IFN-γ Producing CD4+ and CD8+ T cells via a β2 Adrenergic-
Dependent Pathway 
To confirm that the effects of salmeterol were mediated by stimulation of β2AR, T cells were 
treated with salmeterol (50 µM) in the presence or absence of different concentrations (10, 25 
and 50 µM) of the selective β2 antagonist, ICI 118, 551 (Fig. 3.19. A-B). In the absence of ICI 
118,551, salmeterol induced a 1.5 fold suppression on the percentage of IFN-γ producing 
CD4+ TLs (Fig. 3.19. A) and 1.1 fold suppression on the IFN-γ producing CD8+  TLs (Fig. 
3.19. B). The inhibition of IFN-γ producing T cells by salmeterol was completely reversible 
by ICI118,551 when used at concentration of 25 µM in both CD4+ and CD8+ T lymphocytes. 
These findings confirm that salmeterol-induced IFN-γ inhibition is mediated by β2AR. Our 
data (Fig. 3.19. A) also show that ICI 115, 881 at a concentration of 10 µM did not 
completely reverse the inhibition of salmeterol in IFN-γ producing CD4+ TLs as compared to 
the negative control (i.e., SEB + salmeterol), whilst it did not have any effect on the 
percentage of IFN-γ producing CD8+ TLs (Fig. 3.19. B). In contrast, treatment of T cells with 
salmeterol (50 µM) and ICI118, 551 (50 µM) completely reversed the suppressive effect on 
CD8+ TLs (Fig. 3.19. B), whilst it reversed the inhibition of IFN-y producing CD4+ TLs by 
1.18 fold (Fig. 3.19. A).  
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SEB (500 ng/ml)+             +             +            +             + 
Sal. (50 µM)        -             +             +            +             + 
ICI. (10 µM)       -              -              +            -              - 
ICI. (25 µM)       -              -               -            +             -     
ICI. (50 µM)       -              -               -             -             + 
Figure 3.19. (A-B). Effect of salmeterol and ICI 115, 881  (10-50 µM) on IFN-γ 
producing CD4+ T (A) and CD8+ T (B) in PBMCs stimulated with SEB. T cells 
were isolated from PBMCs and incubated for 30 min at 37°C, 5% CO2 in the presence 
or absence of 50 µM salmeterol and/or ICI (10-50 µM). Following incubation of T cells 
with salmeterol (50 µM) and/or ICI (10-50 µM), T cells were washed and added to the 
rest of the PBMCs. Subsequently, PBMCs were stimulated with SEB and incubated for 
1 hr 30 min at 37°C, 5 % CO2. Following incubation, monensin was added to PBMCs to 
inhibit intracellular secretion of cytokines. Cells were incubated for a further period of 5 
hours and stained with respective antibodies. The percentage of IFN-γ producing T cells 
was determined using FACS Analysis. Results are shown as the mean values of at least 
3 replicates (n=3). Flow cytometer data of a representative sample (n=1) is shown in 
Fig. 3.20-3.22. (A-D). 
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Figure 3.20. (A-D). Effect of SEB on IFN-γ producing CD4+
 
T (A) and CD8+
 
T (B) 
cells in PBMCs treated with SEB. Figures are representative plots for data in Fig. 
3.18. (A-B). The CD4+ and CD8+
 
T subpopulations were gated within the PBMCs 
population. The percentage of IFN-γ producing CD4+ T (C) and CD8+ T cells (D) in 
SEB stimulated PBMC was gated and compared to the percentage of IFN-γ producing 
CD4+ T (A) and CD8+ T cells (B) in unstimulated control. 
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C) D) 
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Figure 3.21. (A-D). Effect of salmeterol (50 uM) on IFN-γ producing CD4+ and 
CD8+
 
T cells following treatment of T cells with or without salmeterol and 
stimulation of PBMCs with SEB. Figures are representative plots for data in Fig. 
3.18. (A-B).  The CD4+ and CD8+
 
T subpopulations were gated within the PBMCs 
population. The percentage of IFN-γ producing CD4+ T (A) and CD8+ T cells (B)  in 
SEB stimulated PBMCs was gated and compared to the percentage of IFN-γ producing 
CD4+ T (C) and CD8+ T cells (D) in T cells  treated with salmeterol and PBMCs 
stimulated with SEB. 
 
A) B) 
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Figure 3.22. (A-D). Effect of salmeterol (50 uM)and ICI 115, 551 (25 uM) on IFN-γ 
producing CD4+ and CD8+
 
T cells after treatment of T cells with salmeterol and 
with or without ICI 115, 551; followed by stimulation of PBMCs with SEB. Figures 
are representative plots for data in Fig. 3.18. (A-B). The CD4+ and CD8+
 
T 
subpopulations were gated within the PBMCs population. In A) and B), the CD4+ and 
CD8+T cells respectively were treated with salmeterol only. In C) and D), CD4+ and 
CD8+T cells respectively were treated with salmeterol and ICI 115, 551. 
A) B) 
C) D) 
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3.3 Discussion 
It has been reported that catecholamines and β2AR agonists have inhibitory effects on 
lymphocyte function. For example salmeterol, a potent long-acting β2AR agonist (Bail et al., 
1991; Butchers et al., 1991; Nials et al., 1993) inhibits IFN-γ production by PBMCs (Mohede 
et al., 1996; Salicru et al., 2007). However, there is a lack of information regarding the effect 
of salmeterol on CD4+ T and CD8+ T lymphocyte subsets. In this study the effect of 
salmeterol on the cytotoxic CD4+ T and CD8+ T cells, was measured in vitro by means of 
measuring the % of IFN-γ producing CD4+ and CD8+ T cells in PBMCs from CMV positive 
individuals. By in vitro testing we were able to exert substantial experimental control and 
hereby determine direct effects of salmeterol on T cells at the single cell level, and 
differentiate these from indirect effects on T cells as result of modulation via other cell types 
like APCs that may also be responsive to salmeterol. For this purpose the present study 
employed three different approaches in order to take into account all of these aspects. 
Initially, we examined the effect of salmeterol on the IFN-γ producing CD4+ T and CD8+ T 
cells in treated PBMCs stimulated with SEB and demonstrated that salmeterol (50 µM) 
diminished significantly the proportion of IFN-γ producing T cells (Fig. 3.2. A-B), as 
compared to the SEB stimulated PBMCs. Secondly we investigated the effect of salmeterol 
on IFN-γ producing CD4+ T and CD8+ T cells when not the T cells, but the APCs were 
incubated with salmeterol. Our findings suggest that salmeterol significantly inhibits IFN-γ 
producing CD4+ T and CD8+ T lymphocytes by inhibiting the function of APCs (Fig. 3.9. A-
B). The exact mechanism responsible for mediating this immune inhibitory effect remains to 
be elucidated, but it is possible that catecholamines affect several pathways including the 
expression of class II and costimulatory molecules on APCs, the efficiency of antigen 
processing, as well as changes in cytokine production and response to cytokines. For example, 
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Seiffert et al. (2002) demonstrated that catecholamines inhibit the antigen presenting 
capability of epidermal Langerhans cells from BALB/c mice. Furthermore, other studies have 
reported that the stress affected population of Langerhans cells (LC) possess a significant 
decrease in γ-interferon induced major histocompatibility class II (Ia) expression and an 
obvious alteration in LC morphology (characterised by decrease number of dendrites and cell 
size) (Hosoi et al., 1998; Kawaguchi et al., 1998). Since cytotoxic CD4+ T and CD8+ T cells 
would respond to presentation of CMV pp65 antigen via MHC II or MHC I respectively on 
APCs (Arrode et al., 2002; Pita-Lopez et al., 2009; Reiser et al., 2011) by secretion of IFN-γ, 
one of the ways by which salmeterol could inhibit IFN-γ producing T cells could be by 
affecting MHC II or MHC I expression and inhibiting antigen processing by APCs. 
Finally, we investigated whether salmeterol could also have a direct effect on the percentage 
of IFN-γ producing CD4+ and CD8+ TLs, by treating only T cells with salmeterol. Our 
results indicate that salmeterol at higher concentration (50 µM) significantly inhibits both 
IFN-γ producing CD4+ and CD8+ TLs (Fig. 3.16-3.17. A-B). One mechanism responsible for 
reducing the secretion of some cytokines (i.e., IFN-γ, TNF-α, IL-1, IL-2) by 
monocyte/macrophages or T cells is elevation of intracellular cAMP levels (Loza et al., 2006; 
Sanders et al., 1997; Sekut et al., 1995).   
Supporting our findings, Betz and Fox. (1991) demonstrated that prostaglandin E2 (PGE2), 
which similarly increases cAMP levels through activation of adenylate cyclase, inhibited the 
pigeon cytochrome c-induced IFN-γ production levels by a pigeon cytochrome c specific Th-
1 cell clone. Similarly, Snijdewint et al. (1993) and Van der Pouw-Kraan et al. (1992) have 
also shown that increased cAMP levels correspond to a decreased level of IFN-γ production 
from T cells. Importantly, β2AR selective agonist terbutaline (10-8-10-5 M) inhibited IFN-γ 
production from murine (BALB/c mice) Th-1 cells (Sanders et al., 1997), whereas the β2AR 
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selective agonist salbutamol (10-5 M) suppressed the level of IFN-γ production by T cells 
activated with PHA and PMA (Kohm and Sanders, 2001; Paul-Eugene et al., 1993).  
In line with these, both isoproterenol (a βAR non selective agonist) and fenoterol (a β2AR 
selective agonist) inhibited the Con A-induced IFN-γ production by human T cells in a dose 
dependent manner (Borger et al., 1998). These findings are consistent with our data which 
show that at concentration of 50 µM, salmeterol induced a higher inhibition of IFN-γ 
producing T cells as compared to a concentration of 5 µM. However, in contradiction to 
previous reports that have demonstrated complete inhibition of Th-1 cytokine production by 
cAMP elevating agents (Betz and Fox, 1991; Gajewski et al., 1990; Snijdewint et al., 1993), 
salmeterol never induced a complete inhibition of IFN-γ producing CD4+ T or CD8+ TLs in 
the model system presented here. One reason that might explain this discrepancy is that 
different cAMP-increasing agents have distinct cellular dynamics resulting in different T cell 
responses. For example, whereas surface receptor cAMP ligands increase cAMP mainly at the 
site of receptor stimulation, for a transient period of time, other cAMP analogues may 
increase cAMP levels for a long period of time, allowing cAMP levels to diffuse throughout 
the cell (Bauman et al., 1994). Thus, whereas the cAMP levels resulting from a non-receptor-
mediated change may be extensive and long lasting, the increased cAMP levels resulting from 
a receptor mediated change may be localised and transient inducing thus a limited change in 
cell function.  
Finally, the present study, examined the selectivity of β2AR stimulation, using ICI118, 551; a 
β2AR selective antagonist. Our results demonstrated that salmeterol inhibits IFN-γ producing 
T cells. Moreover this effects seemed to act through β2AR, because incubation of T cells with 
salmeterol (50 µM) and ICI 118,551 (25 µM), completely reversed the inhibitory effect of 
salmeterol. These data are consistent with findings by Borger et al. (1998) which show that 
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only stimulation of β2AR expressed on the surface of T cells is sufficient to influence the 
production of IFN-γ. Overall our data suggest that salmeterol affects T cell subsets directly by 
stimulating β2AR expressed on the surface of T cells, and indirectly by stimulating β2AR 
expressed on antigen presenting cells. The use of specific antigens (i.e. CMV lysate and pp65) 
in these studies as opposed to SEB was important to dissect these responses (see section 
3.2.3).  
Another important observation from our data is that the inhibitory effect of salmeterol on 
IFN-γ is stronger for CD8+ T as compared to CD4+ T cells. One reason that could explain 
these findings is the fact that the number of β2AR on CD8+ T cells is higher (2434-5967 
binding sites/cell) than the number of β2AR on the surface of CD4+ T lymphocytes (619-
1237 binding sites per cell) (Wahle et al., 2001). It has been reported that lymphocytes 
exhibiting reduced β2AR densities, also exhibited a reduced catecholamine response 
(Baerwald et al., 1999). Throughout our experiments the stimulatory effect of SEB, CMV 
lysate and CMV pp65 on T cells showed large variation. These differences are probably the 
result of the PBMCs populations in different individuals, which may vary, and thus may 
reflect a diverse starting population of T cells and the measurement of function at the 
population versus single cell level (Loza et al., 2006). This would be particularly relevant for 
the CMV studies as different individuals would have different numbers of memory cells, due 
to age for example (Ben-Smith et al., 2008) (as was confirmed in Fig. 3.16. B, whereby the 
41-49 and 50-59 age group responded better to SEB) and for CMV pp65 studies where 
specific human leukocyte antigen (HLA) haplotypes may influence the response. Gender 
however, did not make any difference in T cell response to SEB, as both females and males 
responded in a very similar way. One of the issues presented in these studies is the dilution of 
salmeterol, carried out with ethanol, as salmeterol is only sparingly soluble in water.  In order 
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to eliminate the possibility that the small effect of salmeterol is not due to the solvent, we 
could have included controls. However, the fact that β2-antagonist ICI118, 551 was diluted 
with water and reversed the effect of β2 agonist salmeterol, suggest that ethanol did not add to 
the affect of salmeterol. Yet, future studies on the effect of ethanol on cells should be assessed 
to better understand how ethanol could affect the cells in short term studies. This is because, it 
is important to note that the vast majority of studies on the effects of ethanol have been done 
in vivo on long term alcoholics and not in short term studies. 
In conclusion, our data presented evidence that β2AR stimulation (salmeterol) exerts an 
inhibitory effect on IFN-γ producing CD4+ T and CD8+ T lymphocytes. The salmeterol 
induced inhibition of the IFN-γ producing T cells appears explained by direct effects on T 
cells as well as indirectly, possibly via affecting processing and/or presentation by APCs. 
While the exact mechanisms underlying these effects remain to be elucidated, studies by Loza 
et al. (2006) have reported that the inhibition of PMA-stimulated IFN-γ production by PGE2 
and β-agonist is a result of inhibition of p38 phosphorylation. P38 is a member of the mitogen 
activated protein (MAP) kinase subfamily that is involved in regulating cellular responses to 
inflammation. Significantly, IFN-γ production is dependent on p38 activation. Continuing 
studies will provide a better understanding on the role of β2AR agonist in controlling the 
development of protective cytotoxic T cell responses and thus contributing towards the 
treatment of serious diseases in which cytokines play a pathogenic role. 
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CHAPTER 4 
EFFECTS OF β2-ADRENERGIC AGONISTS ON LYMPHOCYTE ADHESION AND 
MIGRATION 
4.1 Introduction 
Migration of leukocytes from the blood, through various organs and back into the blood is 
essential to the maintenance of an effective immune defense network. In effect, the 
recruitment of white blood cells at sites of injury and infection is crucial to allowing sufficient 
surveillance of tissues for infectious pathogens. This recruitment is a process that can be split 
into five successive steps. Initially, flowing leukocytes marginate to the vessel wall and are (i) 
captured to the vascular endothelium that lines the vessel and (ii) roll along it. Subsequently 
leukocytes (iii) become rapidly activated (seconds) and arrested on the endothelium 
monolayer in a stable secondary adhesion that can be potentially reversible over minutes. The 
final step involves leukocytes (iv) spreading and migrating along and then across the 
endothelial lining of the blood vessel through (v) both the apical and basolateral basement 
membranes and finally through stroma in the underlying tissues (Ley et al., 2007; Ludwig et 
al., 2009). This migration of lymphocytes to inflamed tissues occurs as a result of the 
interactions of specific leukocytes’ cell surface receptors (e.g., selectins, integrins, chemokine 
receptors) with their ligands found on endothelial cells (Akiyama, 1996; Johnston et al., 1996; 
Ley et al., 2007). Tissue migration of lymphocytes is critically controlled by modulation of 
integrin affinity on the surface of leukocytes as well as by molecular signals (e.g. 
chemokines) which are displayed on the endothelium (Alon et al., 1995; Middleton et al., 
2002; Springer, 1995). These molecular signals cause the transcriptional upregulation and 
expression of adhesion molecules such as VCAM-1, ICAM-1, MAdCAM-1 (Fabbri et al., 
1999; Francischetti et al., 2010; Springer, 1995). Thus a number of adhesion molecules and 
chemokines are involved to support the process of tissue infiltration in a controlled manner.  
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Previous studies have documented that the process of leukocytes trafficking and subsequent 
cellular immune responses in the local tissues are modulated by stress, as best documented in 
lymphocytosis (Anane et al., 2009a; Anane et al., 2010a; Atanackovic et al., 2006; Campbell 
et al., 2009). One factor mediating this response is βAR activation.  It has been demonstrated 
that β2AR stimulation modifies the adhesive (and possibly migratory) behaviour of 
leukocytes in a subset-specific manner (Dimitrov et al., 2010). For example stress 
lymphocytosis is largely driven by a selective increase in cytotoxic lymphocytes such as NK 
cells and γδ and memory cytotoxic CD8+ T cells, with less contribution observed from other 
non-cytotoxic lymphocytes subsets such as T helper CD4+ and B (CD19+) lymphocytes 
although expressing functional β2AR (Anane et al., 2010a; Benschop et al., 1996c; Campbell 
et al., 2009). 
In this chapter we examined the effects of β2AR stimulation, induced by different 
concentrations of salmeterol (a β2-agonist) and epinephrine, on adhesive and migratory 
behaviours of leukocytes. Specifically, we tested CD8+ T cells and NK cells to VCAM-1 
coated glass capillaries (microslides) (see Fig. 4.1) in a flow based assay in vitro. The results 
of this chapter are presented in means ± SEM and all significant data are indicated by a p-
value, derived from paired sample t-tests.  The clinical details of individuals used in this assay 
are shown in Table 4.1. 
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Table 4.1 Clinical Details of Individuals Studied for Flow and Static Assays 
Patient Sex Age 
 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
  
 
F 
M 
M 
M 
M 
M 
F 
M 
M 
M 
 
                      
35 
28 
27 
46 
32 
37 
26 
31 
33 
22 
 
All individuals had a Caucasian background and were not under any medical treatment. 
Individuals 21-30 were used for flow and static assays.  
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4.2 Methods                                                                                       
A)      B) 
 
 
 
Fig 4.1. Represents: A) The microslide. This is a glass capillary with rectangular cross-
section (0.3mm x 0.3mm; length 50 mm) and in this study was used to coat with purified 
adhesion molecules. B) A short length of silicon rubber tubing attached to 
aminopropyltriethoxysilane (APES) coated microslide. This was essential before the addition 
of recombinant human VCAM-1 at final desired concentration. 
 
The decision to study VCAM-1 was based on previous findings which showed that VCAM-1 
is a receptor that supports lymphocyte capture and stable adhesion under physiological flow 
conditions (Abbitt and Nash, 2001; Alon et al., 1995; Berlin et al., 1995; Johnston et al., 
2000; Johnston et al., 1996; Miles et al., 2008). This is in contrast to ICAM-1 which is unable 
to support lymphocyte capture in vitro under physiological shear, but is functional in static 
assays (Berlin et al., 1995; Johnston et al., 2000). All flow experiments were carried in a 
Perspex  chamber at 37 ºC (previously described by Nash et al.,1992; Cooke et al.,1993; 
Rainger et al., 2001) in the presence of flow at a rate equivalent to a wall shear stress of 0.05 
Pa, in order to mimic in vivo conditions (in post-capillary venules). In all experiments, the 
microslide was perfused for 2 minutes with PBS + BSA (0.15%) to acclimatise the cells. 
Subsequently a 4-minutes bolus of PBLs (peripheral blood lymphocytes without monocytes) 
was perfused over the VCAM-1 coated microslide followed by 2 minutes of cell-free wash 
buffer. Video recordings were made of a series of microscope fields along the centreline of 
the flow channel after 2 minutes of wash-out or otherwise dependent on the specific 
experiment.  
 microslide silicon rubber tubing   microslide 
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Figure 4.2. The flow assay design. The microslide coated with VCAM-1 was placed on a 75 
x 25-mm coverslip and incorporated into a parallel plate flow chamber attached to a perfusion 
system mounted on the stage of phase contrast video microscope (enclosed in a Perspex 
chamber at 37 ºC). At one end, the microslide was connected to a Harvard withdrawal syringe 
pump and at the other end it was connected to an electronic switching valve. This valve 
selected flow from three reservoirs containing PBLs in PBS + BSA (0.15%), or cell-free wash 
buffer consisting of PBS + BSA (0.15%), or cell-free PBS + salmeterol / epinephrine at 
various concentrations. A suspension of either PBLs (1x106  cells/ml), or cell free wash 
buffer, or cell-free PBS + salmeterol / epinephrine at various concentrations of 0.05 µM -50 
µM, was perfused through the chamber at a constant wall shear stress (τw) set at 0.05 Pa. 
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4.3 Results 
4.3.1 Optimising the Flow Assay 
The overall aim of this flow assay was to determine the effects of the β2AR (salmeterol) 
stimulation on adhesive and migratory behaviour of leukocytes. Previous data have shown 
that stress/ epinephrine induces a rapid release of effector memory T and NK cells into the 
peripheral blood and that this effect occurs within 1-2 minutes (Anane et al., 2009; Anane et 
al., 2010; Atanackovic et al., 2006; Benschop et al., 1996b; Campbell et al., 2009; Dhabhar et 
al., 1995; Dimitrov et al., 2010; Silberman et al., 2003; Simpson et al., 2007; Viswanathan 
and Dhabhar, 2005). 
Whilst taking into account previous findings and addressing the aim of this flow assay, it was 
important to design a protocol that could answer the question of how these cells were induced 
to move. A series of assay variables to investigate the effect of salmeterol on PBLs binding to 
adhesion molecules needed to be considered. These included: 
(a) The concentration of the adhesion molecule used to coat the microslides. 
(b) The duration of salmeterol perfusion and  
(c) the timing of the recordings following the salmeterol perfusion. 
4.3.2 Determining Which VCAM-1 Concentration Best Captures PBLs In Vitro 
In the initial experiments a 4 minutes bolus of PBLs (1x106 cells/ml)  was perfused over 
different concentrations of purified VCAM-1 coated microslides (5-20 µg/ml) through the 
chamber at a constant wall shear stress (τw) set at 0.05 Pa under flow. Initially, behaviour and 
adhesion of PBLs was evaluated at 2 and 9 minutes after wash-out (Fig. 4.3. A-B). The data 
show that when VCAM-1 was used at a concentration of 5 µg/ml, ~80% of cells could be 
clearly seen to roll, whereas ~ 20% of cells were stationary, adhered onto the VCAM-1 coated 
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microslide (Fig. 4.3. A-B). In contrast, at 10 µg/ml VCAM-1, ~42% of cells rolled and 58% 
of cells were firmly adherent, while at 20 µg/ml VCAM-1 ~21% of PBLs were rolling and 
~79% firmly adherent (Fig .4.3. A-B). Moreover, increasing VCAM-1 concentration from 5 
µg/ml – 10 µg/ml significantly increased the number of rolling PBL at 2 minutes (p=0.046 
using paired sample t-test; p=0.034 using Wilcoxon signed rank test) and 9 minutes following 
wash-out (p=0.028 using paired sample t-test; p=0.034 using Wilcoxon signed rank test). In 
addition increasing VCAM-1 concentration from 5 µg/ml to 20 µg/ml significantly increased 
the number of stationary adherent PBLs at both 2 minutes (p=0.013 using paired sample t-
test; p=0.034 using Wilcoxon signed rank test) and 9 minutes after wash-out perfusion 
(p=0.036 using paired sample t-test; p=0.034 using Wilcoxon signed rank test).  In contrast no 
significant change was observed in the total number of rolling and stationary adherent PBLs 
(i.e. total adhesion) at any VCAM-1 concentration used (i.e. between 5 and 10 µg/ml, or 5 and 
20 µg/ml, or 10 and 20 µg/ml). Similarly, no change was observed in the number of rolling 
and stationary adherent PBLs between 2 and 9 minutes after wash out, indicating that the 
number of lymphocytes adherent to VCAM-1 remained stable (Fig. 4.3. A-B). This was an 
important concept in the next set of experiments, whereby we aimed  to investigate the effect 
of epinephrine or salmeterol at 0, 2 and 9 minutes following lymphocytes perfusion, allowing 
confirmation that any change in the percentage or the number of adherent PBLs to VCAM-1 
coated microslide is due to the effect of treatment. As we wanted to investigate whether 
salmeterol had any effect on lymphocyte recruitment from flow, we initially decided to coat 
the mircroslides with 10 µg/ml VCAM-1 assuming that the effect of salmeterol would be 
strong enough to detach the rolling PBLs. (These data showed that 10 µg/ml VCAM-1 caused 
42% of cells to roll). 
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Fig.4.3. Effect of increasing VCAM-1 concentration on PBLs captured from flow. 
Microslides were coated with increasing concentrations of purified human VCAM-1. A 
4-min bolus of lymphocytes was perfused over the VCAM-1 and adhesion was assessed 
2 min (A) and 9 min (B) after wash out. Data are mean ± SEM from four independent 
experiments. *p<0.05 indicates that the effect of increasing VCAM-1 concentration on 
PBLs capture from flow was significant (using paired sample t-test and/or Wilcoxon 
singed rank test) compared to 5 µg/ml VCAM-1. 
* 
* 
* 
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4.3.3 Determining Epinephrine/Salmeterol Perfusion and Timing of Recordings 
 
A second potentially important factor was the duration of epinephrine / salmeterol perfusion 
and the timing of the analysis following the epinephrine / salmeterol perfusion. Since the 
release of effector memory T and NK cells into the peripheral blood occurs within 2 minutes 
following stress or epinephrine (Benschop et al., 1996c), we hypothesised that epinephrine or 
salmeterol would cause a rapid (within 2 to 5 minutes) detachment of lymphocytes under 
conditions of flow.  For this reason we decided to perfuse epinephrine or salmeterol over 
adhered lymphocytes for a period of 2 minutes, and measure its effect at 0, 2, and 8 minutes 
following perfusion (Fig. 4.4). 
 
 
 
 
Figure 4.4. Epinephrine/Salmeterol Perfusion and Timing of Recordings. 
In addition to video recordings, which allowed analyses of the adhesion and rolling behaviour 
of leukocytes, we were also interested to determine the phenotype of the PBLs adhered to 
VCAM-1, and had to design a method that would allow us to collect enough PBLs from the 
microslides, to perform flow cytometry and represent an overall picture of the results.  
4.3.4 Different Options of Retrieving PBLs from Microslide 
Four different options were tested to retrieve PBLs from microslides (Fig. 4.5. A-D).  In all 
retrieval options manometer tubing was connected at both sides of the microslides and the 
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options differed only on the number of clamps used and the position of where the manometer 
tubing was first cut following the stoppage of the flow. In option 1, no clamps were used.  To 
collect PBLs, left side tubing was cut and the right side tubing was carefully removed from 
the microslide. Volumes of 200 µl of EDTA were pipetted up and down in the microslide to 
collect as many adherent cells as possible in 2 ml eppendorf tubes. This was the same for all 
options. In option 2, the right tubing was clamped and the left tubing was cut after the 
stoppage of the flow, followed by the right side of tubing. In option 3, the right tubing was 
clamped and cut, followed by the left side of tubing. In option 4, both the left and the right 
side tubing was clamped and cut when the flow was stopped.  
The results showed that retrieval options 2, 3, 4 resulted in higher percentages of lymphocytes 
(CD4+ T, CD8+ T, and NK cells) collected from the microslide. In contrast, retrieval option 1 
was excluded, as it only collected ~45% of adherent lymphocytes. Although almost no 
difference in results between retrieval options 2, 3, and 4 were observed (Fig. 4.6. A-B), we 
decided to choose option 4 and clamp both, the left and the right side tubing as a precaution to 
minimise PBLs loss. 
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A) Option 1 
 
 
 
 
 
B) Option 2 
 
 
 
 
 
C) Option 3 
 
 
 
 
 
D) Option 4 
 
 
 
 
 
 
 
 
Figure  4.5. Different Options of Retrieving PBLs from Microslide. 
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Figure 4.6. Comparison of lymphocyte retrieval options for collecting CD4+ T, 
CD8+ T and NK cells.  Cells were collected, labelled and analysed by flow cytometry 
to assess the percentage of CD4+ T, CD8+ T (A) and NK cells (B) attached to the 
VCAM-1.  The data are the mean from at least two independent experiments. No 
statistics were carried out based on two independent experiments. 
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4.3.5 Effect of Epinephrine and Salmeterol on PBLs Rolling and Adhesion 
In the next set of experiments, the effect of epinephrine or salmeterol treatment on 
lymphocytes behaviour and rolling velocity was investigated. A 4-minutes bolus of 
lymphocytes was perfused over 10 µg/ml VCAM-1 coated microslide at a wall shear stress of 
0.05 Pa. Salmeterol or epinephrine was added at time 0 following wash-out and their effect on 
PBLs behaviour was measured following 2 and 8-minutes of wash out respectively. The 
results show that the percentage of rolling PBLs was slightly increased on treatment with 
salmeterol or epinephrine as compared to the untreated control (from ~9% in the control 
condition to ~12 and 16 % rolling PBLs upon treatment with salmeterol and epinephrine 
respectively), whereas the percentage of the stationary adherent PBLs was decreased at a low 
degree (from ~91% to ~88% upon treatment with salmeterol and to ~84% following treatment 
with epinephrine) (Fig. 4.7. A-B). Perfusion of salmeterol (5 µM) resulted in a ~2% increase 
in the rolling of PBLs at 0 minute following washout compared to the control condition (as 
compensated by a ~2% decrease in the percentage of adherent PBLs). This change remained 
persistent at 2 minutes but was increased ~1% following 8 minutes after wash out (Fig. 4.7. 
A). By comparison, epinephrine (0.05 µM) resulted in a ~3% increase at 0 minute compared 
to untreated control and rose to a ~7% increase in the rolling of PBLs following 8 minutes of 
washout (as compensated by a ~7% decrease in stationary adherent PBLs).  The number of 
adherent PBLs was reduced non-significantly when 5 uM salmeterol (by an average of ~15%) 
or 0.05 µM epinephrine (by an average of~19%) was perfused when compared to the 
untreated control following 0 to 8 minutes of wash-out. (These discrepancies might reflect 
different donor PBLs) (Fig. 4.8.). In addition, neither epinephrine nor salmeterol affected total 
lymphocyte recruitment to a 10 µg/ml VCAM-1 coated microslide, over time (0-8 minutes). 
Next the effect of salmeterol or epinephrine on the average rolling velocity of PBLs was 
 
 
128 
 
investigated (Fig. 4.9.). A salmeterol concentration of 5 µM increased the rolling velocity by 
~ 0.5 µm/sec compared to the control following 0 minute of wash-out (i.e. from ~2.8 µm/sec 
to ~3.3 µm/sec) or by~0.7 µm/sec following 8 minutes of washout (i.e. from 2.8 µm/sec to 3.5 
µm/sec). Similarly to salmeterol, epinephrine (0.05 µM) increased the rolling velocity by ~ 
0.4 µm/sec compared to the control (i.e. from ~2.8 µm/sec to ~3.1 µm/sec) following 2 
minutes of washout, and by a ~2.6 µm/sec increase (i.e. from ~2.8 µm/sec-~5.4 µm/sec) 
following 8 minutes of washout, although this difference was not significant possibly due to 
PBLs donor variation. The results were analysed using paired sample t-test and Wilcoxon 
signed rank test and no significant difference was found in both cases as described above. 
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Figure 4.7. Effect of salmeterol and epinephrine on lymphocytes recruitment to 
VCAM-1 coated microslide in a flow based assay. A 4-min bolus of lymphocytes was 
perfused over 10 µg/ml VCAM-1 coated microslide at a wall shear stress of 0.05 Pa. 
Salmeterol or epinephrine was added at time 0 and their effect on PBLs behaviour ((A) 
rolling-(B) stationary) was measured following 2 and 8-min of wash out respectively. 
The data are the mean ± SEM from five independent experiments. 
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Figure 4.8. Effect of salmeterol and epinephrine on lymphocytes adhesion to 
VCAM-1 coated microslides from flow. The data are the mean ± SEM from five 
independent experiments. For conditions see Figure legend 4.7.  
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Figure 4.9. Effect of salmeterol or epinephrine on the rolling velocity of lymphocytes 
recruited to VCAM-1 coated microslides from flow. The data are the mean ± SEM      
from five independent experiments.  For conditions see Figure legend 4.7.
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4.3.6 Effect of Different Concentrations of Salmeterol on PBLs Adhesion and Rolling 
As epinephrine at concentration of 0.05 µM and salmeterol at concentration of 5 µM did not 
significantly affect the recruitment, behaviour, or the average rolling velocities of PBLs to 10 
µg/ml of VCAM-1 coated microslide, it was considered whether a wider range of salmeterol 
concentrations would have any affect. Therefore, in the next set of experiments, we measured 
the effects of various salmeterol concentrations (0; 0.5; 5; 50 µM) on the lymphocytes 
recruitment, behaviour and rolling velocities (Fig. 4.10-4.12). As above, a 4-minutes bolus of 
lymphocytes was perfused over 10 µg/ml VCAM-1 coated microslide at a wall shear stress of 
0.05 Pa. A specific concentration of salmeterol was added at time 0 and its effect on PBLs 
behaviour was measured following 2 and 8-minutes of wash out respectively (Fig. 4.10. A-B). 
The data indicates that over time 0.5 µM salmeterol moderately increased the percentage of 
rolling cells and decreased adherent PBLs (Fig. 4.10. A-B). In contrast salmeterol at a 
concentration of 50 µM, caused a significant increase in the percentage of rolling PBLs 
(p=0.007 using paired sample t-test; p=0.014 using Wilcoxon signed rank test) and a 
significant decrease in the percentage of adherent PBLs (p=0.009 using paired sample t-test; 
p=0.014 using Wilcoxon signed rank test) over time from 0 to 8 minutes after wash-out (Fig. 
4.10. A-B). Similarly salmeterol 50 µM, significantly decreased the percentage of rolling 
PBLs at 8 minutes following wash-out as compared to the untreated control (p=0.032 using 
paired sample t-test; p=0.033 using Wilcoxon signed rank test). Surprisingly at salmeterol 
concentration of 5 µM there was no effect on PBLs behaviour. 
The overall data indicate that salmeterol at concentrations of 0.5 and 50 µM, increased the 
rolling and decreased adhesion of PBLs (in consistency with what is observed in an individual 
during exercise or when stressed). In contrast a salmeterol concentration of 5 µM had almost 
no effect on lymphocytes behaviour as demonstrated by the percentage of rolling and adherent 
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PBLs to 10 µg/ml VCAM-1 coated microslides.  
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Figure 4.10. Effect of different concentrations of salmeterol on lymphocytes 
recruitment to VCAM-1 coated microslide in a flow based assay. A 4-min bolus of 
lymphocytes was perfused over 10 µg/ml VCAM-1 coated microslide at a wall shear 
stress of 0.05 Pa. Salmeterol was added at time 0 and its effect on PBL behaviour was 
measured following 2 and 8-min of wash out. The data are the mean ± SEM from five-
six independent experiments.         
 
 
134 
 
We next examined the effect of various concentrations of salmeterol on the total number of 
PBLs recruited to 10 µg/ml of VCAM-1 coated microslide. As observed previously the 
number of recruited PBLs only slightly differed in between different salmeterol 
concentrations (0 to 5 µM) (Fig. 4.11.). At baseline (0 minute) following washout, 0.5 and 5 
µM salmeterol induced ~20% and a ~14% decrease respectively. In contrast, at a 
concentration of 50 µM, a ~45 % decrease in the number of PBLs recruited to 10 µg/ml 
VCAM-1 coated microslide was observed compared to the untreated control. Interestingly 
salmeterol at 50 µM significantly decreased the percentage of total PBLs as compared to 0.5 
µM (p=0.050 using paired sample t-test; p=0.058 using Wilcoxon signed rank test) and 5 µM 
(p=0.019 using paired sample t-test; p=0.023 using Wilcoxon signed rank test) respectively at 
baseline (0 minute) following washout.  This significant decrease persisted at 5 µM following 
8 minutes of washout (p=0.010 using paired sample t-test; p=0.014 using Wilcoxon signed 
rank test). Over time (from 0 to 8 minutes) adhesion moderately decreased in untreated PBLs, 
slightly increased in 0.5 µM salmeterol treated PBLs, and significantly increased in 5 µM 
salmeterol treated PBLs (p=0.0043 using paired sample t-test; p=0.014 using Wilcoxon 
signed rank test). In contrast total adhesion remained almost unchanged between 0-8 minutes 
after wash-out following treatment of cells with 50 µM salmeterol. 
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Figure 4.11. Effect of different concentrations of salmeterol on lymphocytes 
adhesion to VCAM-1 coated microslide in a flow based assay. The data are the mean 
± from five-six independent experiments. For specific conditions see Figure legend 
4.10. 
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We next investigated the effect of different concentrations of salmeterol on the average rolling 
velocity of PBLs (Fig. 4.12). Our data show that 50 µM salmeterol, significantly increased 
rolling velocity with time from 0 to 8 minutes following wash-out (from an average of 2.5 
µm/sec to an average of 3.6 µm/sec respectively; p=0.023 using paired sample t-test; p=0.023 
using Wilcoxon signed rank test). At 0 minute following 50 µM salmeterol perfusion, the 
PBLs average rolling velocity was increased by ~0.1 µm/sec as compared to the untreated 
control. This increase was slightly more pronounced at 2 minutes of washout (~0.2 µm/sec) 
and significantly more pronounced following 8 minutes of washout (~1.3 µm/sec increase; 
p=0.024 using paired sample t-test; p=0.023 using Wilcoxon signed rank test) compared to 
the untreated control. In addition, perfusion of 50 µM salmeterol significantly increased the 
PBLs rolling velocity compared to 0.5 µM (p=0.009 using paired sample t-test; p=0.023 using 
Wilcoxon signed rank test) and 5 µM salmeterol (p=0.040 using paired sample t-test; p=0.038 
using Wilcoxon signed rank test) after 8 minutes of wash-out. By comparison, there was 
almost no effect of 0.5 µM salmeterol on rolling velocity and a small increase (~0.6 µm/sec at 
2 minutes and ~0.3 µm/sec at 8 minutes) following 5 µM salmeterol perfusion (Fig. 4.12).  
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Figure 4.12. Effect of different concentrations of salmeterol on the rolling velocity 
of lymphocytes recruited to VCAM-1 coated microslide from flow. The data are the 
mean ± from five-six independent experiments. For specific conditions see Figure 
legend 4.10. 
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4.3.7 Effect of Epinephrine and Salmeterol on PBLs Adhesion and Rolling to 20 µg/ml 
VCAM-1 
Although the changes seen support a role for increased rolling and decreased stationary cells 
in response to salmeterol, at different concentrations of salmeterol the changes remained 
relatively small. To address this, a higher concentration of VCAM-1 coated microslide (20 
µg/ml) was used. In the next set of experiments we measured the effects of various salmeterol 
concentrations on the lymphocytes behaviour on 20 µg/ml VCAM-1 coated microslides.  
We examined the effect of different concentrations of salmeterol (0-50 µM) on lymphocytes 
recruitment, behaviour and rolling velocity. A 4-minutes bolus of lymphocytes was perfused 
over 20 µg/ml VCAM-1 coated microslide at a wall shear stress of 0.05 Pa. Salmeterol at a 
specific concentrations was added at time 0 and their effect on PBLs behaviour was measured 
following 2 and 8-minutes of wash out respectively. As previously, our data show that the 
biggest increase in rolling and subsequently the biggest decrease in stationary PBLs occurred 
at the highest concentration of salmeterol (although in contrast to the previous data this 
increase was relatively small) (Fig. 4.13. A-B). Interestingly, at 0.5 µM salmeterol 
significantly decreased the percentage of PBLs rolling (~9.4% decrease; p=0.041 using paired 
sample t-test, p=0.069 using Wilcoxon signed rank test) and it subsequently increased the 
percentage of stationary PBLs. Overall, the changes in the percentage of rolling PBLs (Fig. 
4.13. A) correspond to changes in the percentage of stationary adherent PBLs (Fig. 4.13. B), 
however increasing VCAM-1 concentration did not significantly improve the results.
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Figure 4.13. Effect of different concentrations of salmeterol on lymphocytes 
recruitment to 20 µg/ml VCAM-1 coated microslide in a flow based assay. A 4-min 
bolus of lymphocytes was perfused over 20 µg/ml VCAM-1 coated microslide at a wall 
shear stress of 0.05 Pa. Salmeterol was added at time 0 and their effect on PBLs 
behaviour ((A) rolling-(B) stationary) was measured following 2 and 8-min of wash out 
respectively. The data are the mean ± SEM from five-six independent experiments.  
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The number of PBLs recruited following perfusion of 50 µM salmeterol showed a significant 
~33% decrease (p=0.027 using paired sample t-test; p=0.034 using Wilcoxon signed rank test) 
compared to the number of PBLs recruited to untreated control (Fig. 4.14.). This change 
remained at 2 minutes (p=0.040 using paired sample t-test; p=0.023 using Wilcoxon signed 
rank test) and 8 minutes (~35% decrease) of washout compared to the control, although 
borderline significance was observed at 8 minutes (p=0.056 using paired sample t-test; 
p=0.038 using Wilcoxon signed rank test). In addition, at baseline (0 minute) following 
washout salmeterol at 50 µM significantly decreased the number of total PBLs as compared to 
0.5 µM (p=0.002 using paired sample t-test; p=0.014 using Wilcoxon signed rank test) and 5 
µM salmeterol (p=0.007 using paired sample t-test; p=0.022 using Wilcoxon signed rank test) 
(Fig. 4.14.). Similarly at 8 minutes following washout, salmeterol at 50 µM, significantly 
decreased the number of total PBLs as compared to 0.5 µM  (p=0.037 using paired sample t-
test; p=0.022 using Wilcoxon signed rank test) and 5 µM salmeterol (p=0.009 using paired 
sample t-test; p=0.014 using Wilcoxon signed rank test). Over time (from 0 to 8 minutes) 
adhesion moderately increased in untreated and 0.5 µM salmeterol treated PBLs, and 
significantly increased in 5 µM salmeterol treated PBL (p=0.023 using paired sample t-test; 
p=0.022 using Wilcoxon signed rank test). In contrast total adhesion remained almost 
unchanged between 0-8 minutes after wash-out following treatment of cells with 50 µM 
salmeterol (Fig. 4.14.). Overall, these data are in agreement with our previous data whereby a 
50 µM concentration of salmeterol decreased the recruitment of PBL to 10 µg/ml VCAM-1 
coated microslide by ~45% (see Fig. 4.11.). 
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Figure 4.14. Effect of different concentrations of salmeterol on lymphocytes 
adhesion to 20 µg/ml VCAM-1 coated microslide in a flow based assay. The data are 
the mean ± from at least five independent experiments. For conditions see Figure legend 
4.13. 
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The final factor to be investigated was the effect of different concentrations of salmeterol on 
the PBLs rolling velocity (Fig. 4.15.). As shown in this Figure, a salmeterol concentration of 
50 µM, immediately increased (at 0 minute of washout) the PBLs rolling velocity by ~2.1 
µm/sec compared to the untreated control (i.e. from ~2.2 µm/sec to ~4.0 µm/sec). However 
the rolling velocity decreased by 1.0 µm/sec (i.e. from ~4.0 µm/sec to ~3.0 µm/sec) following 
2 and 8 minutes of washout as compared to the average PBLs rolling velocity immediately 
after salmeterol perfusion (at 0 minute) but increased by 1.0 µm/sec compared to the 
untreated control. Taken together these data indicate that salmeterol at concentrations of 50 
µM moderately increased the PBLs averaged rolling velocity to 20 µg/ml coated VCAM-1 
microslide. Almost no change in PBLs rolling velocity was observed at smaller concentrations 
of salmeterol. 
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Figure 4.15. Effect of different concentrations of salmeterol on the rolling velocity 
of lymphocytes recruited to 20 µg/ml VCAM-1 coated microslide from flow. The 
data are the mean ± from five-six independent experiments. For conditions see Figure 
legend 4.13. 
 
 
 
144 
 
4.3.8 Effect of Different Concentrations of Salmeterol (0.5-50 µM) on the Detachment of 
CD8(+)CD28(-) T cells and NK cells from the 10ug/ml VCAM-1 Coated Microslide 
Although the changes in total PBLs were generally small, we next wanted to determine 
whether salmeterol had any effects on the percentage of specific central memory/naive 
CD8(+)CD28(+) T cells (Arosa, 2002; Sallusto et al., 2004; Schirmer et al., 2002; Werwitzke 
et al., 2003), effector memory CD8(+)CD28(-) T cells (Arosa, 2002; Sallusto et al., 2004; 
Schirmer et al., 2002; Werwitzke et al., 2003) and NK cells (from adherence to 10 µg/ml 
VCAM-1 coated microslide) that have been shown to efflux in response to catecholamines 
(Dopp et al., 2000; Schedlowski et al., 1993a; Schedlowski et al., 1993b). These specific 
lymphocytes subpopulations were chosen to be assessed due to their expression of high levels 
of β2AR (Dimitrov et al., 2010). Immediately following the flow assay, PBLs were collected 
from the 10 µg/ml VCAM-1 coated microslides and cells were labelled with the respective 
antibodies. Flow cytometry analysis was used to determine the percentage of CD8(+)CD28(-), 
CD8(+)CD28(-) and NK cells (defined as CD3- and CD56+).  
The data show that at concentration of 0.05 µM, 0.5 µM and 50 µM, salmeterol did not have 
any effect on the percentage of CD8(+)CD28(+) naive/central memory T cells and 
CD8(+)CD28(-) effector-memory T cells adherence to 10 µg/ml VCAM-1 coated microslide 
(Fig. 4.16. A). In contrast, at 5 µM concentration, more CD8(+)CD28(+) central 
memory/naive cells adhered (i.e. from ~73% to 89%) while more CD8(+)CD28(-) effector 
memory cells detached (i.e. from ~27% to 11%) compared to the control. This is in line with 
previous studies which show that stress mainly induces an increase in the effector memory 
cells (Anane et al., 2010; Benschop et al., 1996b; Dimitrov et al., 2010). 
Salmeterol at concentration of 50 µM, significantly decreased the percentage of NK cells 
adherence to 10 µg/ml VCAM-1 compared to the control (p=0.013 using paired sample t-test; 
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p=0.054 using Wilcoxon signed rank test). In contrast, salmeterol at different concentrations 
(0.05-5 µM) used in this assay, did not have any significant effect on the percentage of NK 
cells adherent to 10 µg/ml VCAM-1 coated microslides (Fig. 4.16. B).
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Figure 4.16. Effect of salmeterol on the percentage of T cells and NK cells adherent 
to 10 µg/ml VCAM-1. Cells were collected, labelled and analysed by flow cytometry to 
assess the percentage of CD8+ T (A) and NK cells (B) attached to the VCAM-1. In A, 
the CD8+ T cell population was subdivided into CD28 high expressing cells and CD28 
low expressing cells. The data are the mean ± SEM from at least three independent 
experiments. Paired sample t test showed a significant difference *p<0.05 between 
salmeterol 50 µM and untreated (0) control regarding the percentage of adherent NK 
cells. 
* 
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4.3.9 The Static Assay  
Since neither salmeterol nor epinephrine had clear significant effects on lymphocytes 
recruitment, behaviour (stationary adherence) or lymphocytes rolling velocity over VCAM-1 
in a flow based assay, we considered the possibility that salmeterol or epinephrine would 
affect lymphocytes behaviour by affecting other adhesion molecules in combination with 
VCAM-1 in a “non-flow” static assay model. 
For our static assay model, HMEC-1 (human microvascular endothelial cell line-1) were used 
as a binding substrate;  HMEC-1 express amongst others VCAM-1, ICAM-1 and E-selectin 
which being fast acting adhesion receptors are crucial to capturing and adhesion of 
lymphocytes to endothelial cells. These receptors are displayed on the surface of the 
endothelial cells and are upregulated in response to cytokines such as TNF-α, IFN-γ and IL-1 
(McGettrick et al., 2009; Weinkopff and Lammie, 2011). In addition they are easily available, 
and grow easily.  
4.3.10 Effect of Pre-treating PBLs with Epinephrine and Salmeterol on their Ability to 
Adhere and Migrate to Unstimulated HMEC-1 
 
To determine whether epinephrine or salmeterol have any effect on the PBLs adhesion, 
migration or migration velocity to unstimulated HMEC-1, PBLs were incubated with 
salmeterol (0 µM-50 µM) or epinephrine (5 x 10-3 µM) for 30 minutes, washed and allowed to 
adhere to unstimulated HMEC-1 for 30 minutes. Non adherent cells were removed and 
adhesion (Fig. 4.17. A), transmigration (Fig. 4.17. B) and migration velocity (Fig. 4.17. C) 
were analysed by phase contrast microscopy. The results show that epinephrine (0.005 µM) 
and salmeterol at all concentrations used (0.05 µM-50 µM) caused a ~10.5 % increase in the 
percentage of adherent PBLs to unstimulated HMEC-1. This increase was significant for 
epinephrine 0.005 µM (p=0.006 using paired sample t-test; p=0.022 using Wilcoxon signed 
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rank test) and salmeterol at all concentrations, viz., 0.05 µM (p=0.006 using paired sample t-
test; p=0.022 using Wilcoxon signed rank test), 0.5 µM (p=0.007 using paired sample t-test; 
p=0.022 using Wilcoxon signed rank test), 5 µM (p=0.028 using paired sample t-test; p=0.022 
using Wilcoxon signed rank test) and 50 µM (p=0.018 using paired sample t-test; p=0.022 
using Wilcoxon signed rank test). The highest increase in PBLs adhesion was observed at 
smaller concentrations of salmeterol (0.05-0.5 µM) suggesting that the optimal effect of 
salmeterol is observed at lower concentrations used in this assay. In contrast to PBLs 
adhesion, salmeterol at all concentrations (0.05-50 µM) and epinephrine (0.05 µM) did not 
affect the lymphocyte transmigration to unstimulated HMEC-1 compared with the untreated 
PBLs (Fig. 4.17. B). This lack of effect may be due to the high proportion (~88%) of 
untreated PBLs that had transmigrated following 30 minutes of incubation with HMEC-1. 
Furthermore, no difference in the lymphocytes transmigration was also observed between the 
different salmeterol concentrations. Salmeterol increased the migration velocity of PBLs at 
the lowest concentration of salmeterol 0.05 µM (~0.5 µm/sec) but not at the higher 
concentrations.  
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Figure 4.17 Effect of pre-treating PBLs with β2AR agonists on their ability to 
adhere and migrate. PBLs were incubated with salmeterol (0 µM-50 µM) or 
epinephrine (0.5 µM) for 30 min, washed and allowed to adhere to unstimulated 
HMEC-1 for 30 min. Non adherent cells were removed and adhesion (A), 
transmigration (B) and migration velocity were analysed at between 35 min – 42 min by 
phase contrast microscopy. The data are the mean ± SEM from five independent 
experiments. *p<0.05 using paired t-test and/or Wilcoxon signed rank test using 
untreated control as a reference.  
* * * * * 
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4.3.11 Effect of Pre-incubating PBLs with Epinephrine or Salmeterol on the Percentage 
of CD4+, CD8+ T and NK Adhered to Unstimulated HMEC-1 
 
To determine whether salmeterol has any effects on the percentage of adherent CD4+ T, 
CD8+ T and NK cells to HMEC-1 monolayer, following video recordings, adherent PBLs and 
HMEC-1 cells were detached from the culture plate with accutase. Adherent lymphocytes 
were labelled with a cocktail of fluorescent-labelled monoclonal antibodies, and results were 
analysed by flow cytometry to assess the percentage of T cells (Fig. 4.18. A) and NK cells 
(Fig. 4.18. B) adherent to HMEC-1 monolayer. Our data show that salmeterol at 
concentrations of (0.05-50 µM) and epinephrine (0.05 µM) caused a ~5% increase in the 
percentage of CD4+ T and a ~2.5% increase in the percentage of CD8+ T cells respectively. 
Similarly, the percentage of NK cells increased (by ~1.3%) upon different concentrations of 
salmeterol treatment or epinephrine. These results suggest that salmeterol and epinephrine 
increase the percentage of specific lymphocytes subpopulations; CD4+, CD8+ T and NK cells 
to unstimulated HMEC-1 monolayer, although these results were not significant (all p values 
from the paired t-test  and Wilcoxon signed rank test were >0.05).  
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Figure 4.18. Effect of β2AR agonists on the percentage of T cells and NK cells 
adherent to HMEC-1. PBLs were incubated with salmeterol (0 µM-50 µM) or 
epinephrine (0.05 µM) for 30 min, washed and allowed to adhere to unstimulated 
HMEC-1 for 30 min.  Cells were collected, labelled and analysed by flow cytometry to 
assess the percentage of T cells (A) and NK cells (B) adherent to HMEC-1 monolayer. 
The data are the mean ± SEM from three independent experiments. 
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We next wondered whether pre-incubation of PBLs with salmeterol or epinephrine would 
affect the PBLs adhesion, migration and migration velocity to cytokine treated HMEC-1 
expressing ICAM-1, VCAM-1 and E-selectin. These receptors displayed on the surface of 
endothelial cells, are upregulated in response to cytokines such as TNF-α, IFN-γ and IL-1 
(McGettrick et al., 2009; Weinkopff and Lammie, 2011). Therefore in our next experiments, 
it was important to set up an in vitro inflamed model, which would allow the upregulation of 
ICAM-1, VCAM-1 and E-selectin on the surface of endothelium and thus enable us to 
measure the effect of salmeterol on PBLs adhesion, migration and migration velocity.  
Various cytokines and cytokine combinations were tested to set up an in vitro inflamed model 
that would result in a high percentage of PBLs adhesion and migration to HMEC-1. 
4.3.12 Determining Which Cytokine Combination Causes the Highest Adhesion and 
Migration of PBLs to HMEC-1 
Initial experiments served to optimise the assay condition for using untreated HMEC-1 cells 
as a substrate. To further investigate the process in inflammatory conditions it was necessary 
to determine the optimal cytokine stimulation for HMEC-1 which would result in the highest 
adhesion of PBLs. Previous studies had indicated that the stimulation of endothelial cells 
(HUVEC) with a range of cytokines (IL-1, TNF-α, IFN-γ, or TNF-α and IFN-γ), caused 
modest increases in T cell adhesion and migration (McGettrick et al., 2009). 
A cytokine stimulation period of 24 hours was required for optimal expression of VCAM-1 
and ICAM-1 (through which the PBLs capture is possible), whereas E-selectin optimal 
expression was reached following 4 hours of endothelial cells stimulation with cytokines 
(Chen et al., 2002b; Ley and Tedder, 1995; Lindsey et al., 2000; Wong and Dorovini-Zis, 
1995). For this reason in our initial experiments, HMEC-1 were stimulated with TNF-α (100 
 
 
153 
 
U/ml) or IFN-γ (10ng/ml) for 4 or 24 hours, alone or in combination. Following stimulation of 
HMEC-1 with cytokines, PBLs were allowed to adhere to HMEC-1 for 30 minutes, non 
adherent cells were washed off and the percentage of adhesion (Fig. 4.19. A) transmigration 
(Fig. 4.19. B) and the number of total PBLs adherent (Fig. 4.20.) were analysed immediately 
by phase contrast microscopy.   
Results show that there was a significant ~11% increase (p=0.012 using paired sample t-test; 
p=0.034 using Wilcoxon signed rank test) in lymphocyte adhesion on TNF-α-24h and a 
significant ~12 % increase (p=0.031 using paired sample t-test; p=0.034 using Wilcoxon 
signed rank test) in lymphocyte adhesion to IFN-γ+TNF-α-24h-stimulated HMEC-1 
compared to untreated control (Fig. 4.19. A). In contrast, when HMEC-1 were stimulated with 
TNF-α-4h or IFN-γ-24h alone, only a ~2.5% increase in the lymphocyte adhesion to HMEC-1 
was observed compared to the unstimulated HMEC-1. Furthermore, stimulation of HMEC-1 
with any cytokine combination only moderately increased the percentage (by an average of 
~8%) of adherent lymphocytes that migrated through HMEC-1 compared to the unstimulated 
control (Fig. 4.19. B), and likewise, a small difference in lymphocyte migration was observed 
between different cytokine combination treatments. These results suggest that the percentage 
of adherent PBLs that migrated was not affected by cytokine treatments. From looking at the 
total number of adherent PBLs per mm2, we observed that the proportion of PBLs adherent to 
HMEC-1 stimulated with IFN-γ+TNF-α-24h was ~86% significantly higher (p=0.035 using 
paired sample t-test; p=0.034 using Wilcoxon signed rank test) compared with unstimulated 
HMEC-1 (Fig. 4.20.). Treatment with TNFα-24h also significantly increased the proportion of 
PBLs adherent to HMEC-1 (p=0.014 using paired sample t-test; p=0.034 using Wilcoxon 
signed rank test), but since  treatment with IFN-γ+TNF-α-24h  cytokine combination 
supported the highest number of PBLs adherent to HMEC-1 than any other cytokine 
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treatment, it was decided to stimulate HMEC-1 with IFN-γ (10ng/ml) and TNF-α (100U/ml) 
for 24 hours. 
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Figure 4.19. Effect of cytokine treatment on HMEC-1 on PBLs adhesion and 
migration. HMEC-1 were stimulated with TNF-a (100 U/ml) or IFN-γ (10ng/ml) for 4 
or 24h, alone or in combination. At desired time, PBLs were allowed to adhere to 
HMEC-1 for 30 min, non adherent cells were washed off and adhesion (A) and 
transmigration (B) was analysed immediately by phase contrast microscopy. Data are 
the mean ± SEM from four independent experiments. *p<0.05 using paired t-test and/or 
Wilcoxon signed rank test using untreated control (None) as a reference.  
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Figure 4.20. Effect of cytokine treatment of HMEC-1 on total number of adherent 
PBLs. Data are the mean ± SEM from four independent experiments. *p<0.05 using 
paired t-test and/or Wilcoxon signed rank test using untreated control (None) as a 
reference. For conditions see Figure legend 4.19. 
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4.3.13 Effect of Pre-incubating PBLs with Different Concentrations of Salmeterol on 
PBLs Adhesion, Migration and Migration Velocity to Cytokine Stimulated HMEC-1 
 
To determine whether salmeterol has any effects on the PBLs adhesion, migration or 
migration velocity to IFNγ + TNF-α cytokine treated HMEC-1, PBLs were incubated with 
salmeterol (0 µM-5-50 µM) for 30 minutes, washed and allowed to adhere to stimulated 
HMEC-1 for 30 minutes. Non adherent cells were removed and adhesion (Fig. 4.21. A), 
transmigration (Fig. 4.21. B) and migration velocity (Fig. 4.21. C) were analysed by phase 
contrast microscopy. Our results show that salmeterol at concentration of 50 µM, increased 
(by~3.6%) the PBLs adhesion to cytokine treated HMEC-1 (Fig.4.21.A), whilst decreasing 
(by~6.2%) the migration of PBLs to cytokine stimulated HMEC-1 compared to the untreated 
control (Fig.4.21.B). Furthermore, the migration velocity was decreased in a dose dependent 
manner. A salmeterol concentration of 5 µM decreased the rolling velocity by ~0.4 µm/min 
whereas at 50 µM, salmeterol decreased the rolling velocity by ~1.9 µm/min (Fig. 4.21. C). 
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Figure 4.21. Effect of pre-treating PBLs with salmeterol on their ability to adhere 
and migrate on cytokine treated HMEC-1. PBLs were incubated with salmeterol (0 
µM-50 µM) for 30 min, washed and allowed to adhere to IFN-γ + TNF-α treated 
HMEC-1 for 30 min. Non adherent cells were removed and adhesion (A), 
transmigration (B) and migration velocity were analysed at between 35 min-42 min by 
phase contrast microscopy. The data are the mean ± SEM from at least four independent 
experiments.   
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4.3.14 Effect of Pre-incubating PBLs with Different Concentrations of Salmeterol on the 
Percentage of CD4+, CD8+ T and NK Adhered to Cytokine Treated HMEC-1 
  
To determine whether salmeterol has any effects on the percentage of adherent CD4+ T, 
CD8+ T and NK cells to cytokine treated HMEC-1 monolayer, following on from video 
recordings, adherent PBLs and HMEC-1 cells were detached from the culture plate with 
accutase. Adherent lymphocytes were labelled with a cocktail of fluorescent-labelled 
monoclonal antibodies, and results were analysed by flow cytometry to assess the percentage 
of T cells (Fig. 4.22. A) and NK cells (Fig. 4.22. B) adherent to HMEC-1 monolayer. The data 
shown in these Figures indicate that salmeterol at concentrations of (5-50 µM) increased the 
percentage of CD4+ T cells in a salmeterol dose dependent manner. At a concentration of 5 
µM salmeterol the percentage of CD4+ T cells increased by ~2.4%, whereas at 50 µM a 
significant increase by ~7.9% (p=0.049 using paired sample t-test; p=0.072 using Wilcoxon 
signed rank test) was observed compared to the untreated control (see Fig. 4.22. A). Similarly, 
at 50 µM salmeterol increased (by~2.7%) the percentage of adherent CD8+ T cells, however a 
~3.6% decrease in the percentage of CD8+ T cells adherent to HMEC-1 monolayer was 
observed at 5 µM, as compared to the untreated control. (This decrease was significant using 
using Wilcoxon signed rank test; p=0.034). Furthermore, salmeterol at 5 µM decreased the 
percentage of NK cells adherent by ~3.6% compared to the untreated control, but it further 
decreased (total average mean ~4.2%) the percentage of NK cells at a concentration of 50 µM 
(see Fig. 4.22. B). Similarly to the case above, this decrease proved to be significant when 
using Wilcoxon signed rank test whereby p=0.034 for both 5 uM and 50 uM salmeterol.
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Figure 4.22. Effect of salmeterol on the percentage of T and NK cells adherent to 
cytokine treated HMEC-1. PBLs were incubated with salmeterol (0 µM-50 µM), 
washed and allowed to adhere to IFN-γ +TNF-α treated HMEC-1 for 30 min. Cells 
were collected, labelled and analysed by flow cytometry to assess the percentage of T 
(A) and NK cells (B) adherent to HMEC-1 monolayer. The data are the mean ± SEM 
from four independent experiments. *p<0.05 using paired t-test using untreated control 
(0) as a reference. 
* 
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4.4 Discussion 
The results in this chapter demonstrate for both the VCAM-1 flow assay and HMEC-1 static 
assay that catecholamines acting via the β2AR induce an increase in rolling behaviour and a 
decrease in stationary behaviour of PBLs. Moreover, the specific effect on memory CD8+ T 
cells and NK cells supports the previous findings that stress lymphocytosis leads to a selective 
increase in such cells (Anane et al., 2010; Benschop et al., 1996b; Campbell et al., 2009).  
There are, however, caveats; most importantly the changes generally were small and typically 
did not reach statistical significance. This may have been due to the wide range of response in 
some experiments which may be indicative of the response of different donors. Most of the 
blood donors in this study were males, so gender may have not had any influence on the 
response to salmeterol. In addition, most of blood donors were among the mid-twenties and 
mid-thirties age group, which could explain why the effects are very small. It may also be that 
the most optimal conditions for analysing the effects of catecholamines on adhesion were not 
reached in these studies. VCAM-1 was selected as a target molecule based on previous studies 
with lymphocytes (Ley et al., 2007; McGettrick et al., 2009). However, VCAM-1 and its 
ligand α4β1 (VLA-4) are particularly relevant to activated lymphocyte responses, (Hernandez-
Caselles et al., 1996; Kurokawa et al., 1995) and while the cells released into the blood are 
memory cells they may utilise other receptors.  
The initial aim was to study the effects of β2AR stimulation on migratory behaviour of  
CMV-specific T cells (see Chapter 3) and confirm the effect of salmeterol by using β2-
antagonists; however, in light of the current effects showing the changes were small, studying 
such low-frequency cells and further extending the experiment by using β2-antagonists  was 
deemed unrealistic.  
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 Regardless, it may be that certain populations of memory T cells and NK cells will be 
affected more than others. It has been suggested that exercise demarginates older cells that are 
awaiting destruction in the spleen (Shephard, 2003). This could potentially now be addressed 
as memory T cells constitute a diverse phenotype that is just now being understood (Younes 
et al., 2011). Similarly, NK cells can be separated in to distinct populations based on 
licensing, i.e., whether they have been primed by HLA ligands (Yokoyama, 1998). Perhaps 
surprisingly, recent data has shown that it is unlicensed NK cells that control CMV infection 
(Orr et al., 2010). As licensing is determined by HLA genotype of each individual this could 
explain the differences seen in the current studies of NK migration. Regardless of these 
mechanisms, the results presented in this chapter consistently showed a pattern that would 
support the efflux of cells from the tissues to the blood due to catecholamine stimulation. 
The association between catecholamines and adhesion molecule expression and function is 
complex. As stated, the numbers and phenotypes of circulating leukocyte subsets can change 
dramatically during and immediately following exercise or stress (Shephard, 2003). NK cell 
influx in humans in response to catecholamines did not associate with either increased 
adhesion molecules on NK cells or soluble adhesion molecules (Schedlowski et al 1996). In 
contrast however, Nagao et al. (2000) found a decrease in CD44 and CD18 on NK cells 
during exercise or administration of catecholamines. CD44 may be due to release from the 
endothelium via hyaluronic acid (Nagao et al., 2000). Therefore we need to look more closely 
at other adhesion molecules and migration.  
The surface expression of adhesion molecules makes an important contribution to 
mobilisation  responses by changing patterns of cell trafficking (Shephard, 2003). NK cells 
that are mobilised during exercise have been reported to express high levels of macrophage-1 
antigen (Mac-1; CD11b), a marker associated with cellular activation (Huntington et al., 
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2007; Shephard, 2003). Analogous changes can be induced by other forms of stress that 
release catecholamines or by catecholamine infusion, and responses are blocked by β2-
blocking agents. Catecholamines also modify adherence and expression of other adhesion 
molecules in vitro (Shephard, 2003). 
It is suggested that norepinephrine may play an endogenous neuroprotective role in the CNS 
in disorders where inflammatory events contribute to pathology (Feinstein et al., 2002; 
Marien et al., 2004; O'Sullivan et al., 2009; O'Sullivan et al., 2010; Zarow et al., 2003). 
Infiltration of peripheral immune cells into the brain via increased chemokines and cell 
adhesion molecules (CAMs) expression is known to exacerbate neuroinflammation and 
contribute in a number of neurodegenerative disease states (Ballestas and Benveniste, 1997; 
Brochard et al., 2009; Constantin, 2008; Lee and Benveniste, 1999; O'Sullivan et al., 2010; 
Weiner, 2009). In rats treated with the norepinephrine reuptake inhibitors (NRIs) desipramine 
and atomoxetine (agents that increase extracellular norepinephrine in the CNS), a suppression 
of interferon-inducible protein-10 (IP-10, CXCL-10) and regulated upon activation normal T-
cell expressed and secreted (RANTES, CCL-5), and the CAMs,  VCAM-1 and ICAM-1 is 
observed in cortex and hippocampus, following a systemic challenge with bacterial 
lipopolysaccharide (LPS) (O'Sullivan et al., 2010). The inhibitory action of NRIs on 
chemokines and CAMs expression was mimicked by in vitro exposure of cultured glial cells 
to norepinephrine, but not to the NRIs themselves (O'Sullivan et al., 2010) supporting the 
theory that norepinephrine has anti-inflammatory properties. In agreement with this finding, 
previous in vitro studies have demonstrated reduced RANTES release from lung epithelium 
and ICAM-1 expression in airway smooth muscles following administration of βAR agonists 
(Hallsworth et al., 2001; Kaur et al., 2008). 
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Adhesion of circulating monocytes to the vascular endothelium is one of the earliest steps in 
the development of atherosclerosis, mediated in part by β2-integrins (Gahmberg et al., 1998; 
Greeson et al., 2009; Luster et al., 2005; Merched et al., 2010; Ross, 1999). In a study on the 
effects of stress,   the Anger Recall Interview (ARI) was utilised and the expression of LFA-1 
(CD11a), Mac-1 (CD11b) and p150/95 (CD11c) on circulating monocytes (CD14+) were 
monitored in 173 healthy, nonsmoking men and women (Greeson et al., 2009). The results 
showed that those individuals who showed the largest increases in norepinephrine during the 
ARI showed an increase in monocyte β2-integrin expression (Greeson et al., 2009). Thus, 
heightened psychological and physiological stress responses induced phenotypic changes in 
monocytic expression of β2-integrins that are consistent with the role of 
monocytes/macrophages in vascular inflammation (Luster et al., 2005; Merched et al., 2010; 
Ross, 1999; Takala et al., 1996).  
Catecholamines can also influence on cytokine production and expression of adhesion 
molecules by human neutrophils (Chen et al., 2005; Kurokawa et al., 1995; Mills et al., 2002; 
Shephard, 2003; Wahle et al., 2005). Resting and LPS-activated neutrophils from healthy 
volunteers challenged with epinephrine showed decreased expression of ICAM-1 on activated 
neutrophils upon co-incubation with 1 mM EPI for 6 hrs (Wahle et al., 2005). Conversely, 1 
mM EPI for 12 and 18 hrs decreased the spontaneous loss of ICAM-1 on resting neutrophils 
(Wahle et al., 2005). This data suggests that β2AR are functionally coupled to signalling 
cascades in human neutrophils, however the response may alter with time of incubation 
(Wahle et al., 2005).  
Finally it is not just leukocytes that are influenced by catecholamines. Dermal fibroblasts 
migrate into a wound bed, proliferate, synthesize extracellular matrix proteins and contract the 
wound (Gabbiani et al., 1972; Grinnell, 1994; Pullar and Isseroff, 2006). Fibroblasts express 
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β2AR and cutaneous keratinocytes can synthesize catecholamines (Pullar et al., 2003; Pullar 
et al., 2006; Sivamani et al., 2009). Activation of β2AR on keratinocytes leads to a reduction 
in migration, while in dermal fibroblasts show increased migration, but inhibited collagen gel 
contraction (Chen et al., 2002a; Pullar et al., 2003; Pullar and Isseroff, 2006). Surgical stress 
can lead to increased catecholamine release and impair wound healing (Pullar et al., 2003; 
Pullar et al., 2006; Pullar and Isseroff, 2006).  
In conclusion, we found that catecholamines induce a modest change in the adhesion of PBLs 
or substrate that supports the release of these cells from tissues into blood at times of stress as 
indicated by both, paired sample t- test and Wilcoxon signed ranked test. The efflux of 
specific populations of cells has been related to the high level of expression of β2AR, 
however the small size of changes suggest that other factors (specific cell types) have still to 
be identified or simply that the mechanisms studied here do not play a relevant role in stress-
induced lymphocytosis. To confirm the involvement of the β2AR in this process, it was 
important to include β2AR–antagonist control as in the cytokie stimulation study (chapter 3), 
however due to the time in which salmeterol was passed over cells (2 minutes),  the small 
responses of T cells to salmeterol, and the complexity of the assay itself, it wasn’t possible to 
use an antagonist at this stage. As in the previous studies, one of the issues to address in 
chapter 4,  is the dilution of salmeterol with ethanol which could have possibly influenced 
onto the effect of salmeterol on T cells. However, the fact that similar results were observed 
when epinephrine (diluted with water),  was used as a control, provides confidence that the 
results are real and the data can be trusted. Yet, to eliminate any possibilities on the effect of 
ethanol on NK and T cells,  the effect of ethanol on NK and T cells should be investigated in 
future short term studies. 
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CHAPTER 5 
EFFECT OF ADRENERGIC STIMULATION ON THE CYTOTOXIC FUNCTION 
OF CD8+ T AND NK CELLS 
 
5.1 Introduction 
NK cells were discovered in the mid-1970s as large granular lymphocytes that had natural 
cytotoxicity against tumour cells, viruses, bacteria and parasites (Cooper et al., 2001; Evans et 
al., 2011; Loza et al., 2002; Paust and von Andrian, 2011; Tonnesen et al., 1989; Vivier et al., 
2008). For this reason, they are considered potentially important for the immunosurveillance 
against cancer and virus infections (Hellstrand et al., 1985). NK cells also represent a bridge 
between the innate and the adaptive immune response due to their ability to secrete large 
amounts of cytokines that shape and drive adaptive immune response (Alter et al., 2004).  
One of the major effector lymphocytes of the adaptive immune response includes CD8+ T 
cells.  Similarly to the NK cells, CD8+ T cells are involved in the recognition and lysis of 
infected and transformed cells. Both CD8+ T and NK cells express a high number of βAR, 
particularly of epinephrine-sensitive β2 subtype (Anane et al., 2009; Anane et al., 2010; 
Benschop et al., 1996b; Hellstrand et al., 1985). Previous studies have demonstrated that CNS 
activities can broadly influence both CD8+ T and NK cells function (Elenkov et al., 2000; 
Padgett and Glaser, 2003; Schedlowski et al., 1996; Snijdewint et al., 1993; Van der Pouw-
Kraan et al., 1992; Yang and Glaser, 2000). In effect, activation of the sympathetic nervous 
system under various stresses such as exercise, mental stress or loss of blood and surgery, are 
often associated with altered NK cell activity (Gan et al., 2002; Klokker et al., 1998). These 
effects may have clinical significance. It has, for example, been demonstrated that 
administration of β2 agonists in vivo increases tumour cell metastasis rates through reduction 
of NK cell activity (Shakhar and Ben-Eliyahu, 1998).   
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In this chapter we investigated the effect of β2 agonists (i.e. epinephrine and salmeterol) on 
the cytotoxic functions of both CD8+ T and NK cells in vitro. To address this aim, PBMCs 
were treated with epinephrine (0.05 µM) or salmeterol (5-50 µM) and were stimulated with 
either untransfected Chinese hamster ovary cells (CHO) or, MHC class I chain-related gene A 
(MICA*009) transfected Chinese hamster ovary cells (T-CHO). These transfected cells lack 
expression of MHC class I molecules, which mimics the conditions of some tumours and 
infected cells. The subsequent NK response is, in theory, amplified by the simultaneous 
expression of MICA on these cells. MICA are “stress-induced” ligands that are found on 
many tumour cells and are upregulated upon infection (Endt et al., 2007). This upregulation 
represents one of the signals by which CD8+ T cells and NK cells detect, and respond to by 
killing the target. MICA is recognized by the activating cell surface receptor NKG2D on NK 
cells and some cytolytic CD8+ T cells (Endt et al., 2007; Saito et al., 2011). This activation, 
which often combines signals from other activating receptors, (Lanier, 2008; Vivier et al., 
2004) induces target cell death through the release of the cytotoxic granule contents, perforin 
and granzymes.  
Lining the membrane of cytolytic granules is the lysosomal-associated membrane protein-1 
(LAMP-1), otherwise referred to as CD107a (Alter et al., 2004). It has recently been 
demonstrated that CD107a is upregulated on the surface of CD8+ T and NK cells following 
stimulation together with a loss of perforin expression. CD107a is thus considered a marker of 
CD8+ T and NK cell activation and cytolytic function (Betts et al., 2003). For this reason the 
cytolytic activity of CD8+ T and NK cells in this study was assessed by measuring the 
percentage of CD107a positive cells by translocation to the surface of CD8+ T and NK cells, 
as assessed by flow cytometry.  
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To confirm the effect of epinephrine and salmeterol on the cytotoxic functions of CD8+ T 
cells and NK cells, PBMCs were treated (or not), with epinephrine (0.05 µM) or salmeterol 
(5-50 µM). Subsequently the cells were incubated with the K562 cell line (a highly 
undifferentiated human erythroleukemic cell line) and CD107a expression was determined.  
Similarly to T-CHO cells, K562 cell line lack the expression of MHC class I molecules and 
express MICA (which provides NK cells with the activatory signals they need by ligating 
NKG2D) (Gong et al., 2010). This model allowed us to mimic a condition of viral infection 
and transformation that occurs in vivo, which is also associated with the upregulation of 
MICA and the loss of the expression of MHC class I molecules. Both cell lines were tested 
because although K562 are readily killed by cytotoxic cells they are a human line and 
therefore other elements (in addition or apart from MICA) of NK and CTLs activation may be 
involved. By comparison, T-CHO are not human and only express human MICA through 
which they are readily killed. The clinical details of individuals used in this study are shown 
in Table 5.1. 
Table 5.1. Clinical Details of Individuals Studied for Degranulation Assay 
Patient Sex Age 
31 
32 
33 
34 
35 
  
M 
M 
M 
M 
F 
24 
38 
55 
48 
25 
All individuals had a Caucasian background and were not under any medical treatment. 
Individuals 31-35 were used for degranulation assay.  
 
5.2 RESULTS 
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5.2.1 The Effect of β2 Agonists on the Cytolytic Potential of CD8+ T and NK Cells 
Following Exposure of PBMCs with MICA*009 Transfected Chinese Hamster Ovary 
Cells (T-CHO) for Six Hours 
We investigated the effect of epinephrine (0.05 µM) and salmeterol (5-50 µM) on the 
cytolytic potential of CD8+ T and NK cells following exposure of PBMCs with T-CHO, by 
measuring CD107a upregulation, following flow cytometry analysis.  
PBMCs were incubated with T-CHO cells at an effector to target ratio of 1:1. CD107-a-
PeCy5 antibody was added directly to the cells at 5 µl of antibody/0.1ml of cell suspension. 
The cells were subsequently incubated for six hours at 37°C in 5 % CO2 based on standard 
killing assays (Alter et al., 2004; Betts et al., 2003).  Incubation of PBMCs with CHO served 
as a negative control. Following the above procedures, PBMCs were stained for surface 
CD8+ T and NK markers (see chapter 2, materials and methods) and cells were analysed by 
flow cytometry to assess the CD107a upregulation as a marker of degranulation of CD8+ T 
cells. The results represent the mean ±SEM data and positive p values from the paired sample 
t-test are highlighted. Our data show that surface expression of CD107a was low (~1%) on 
CD8+ T cells from unstimulated PBMCs (Fig. 5.1. A) and increased (2.3 fold) following 
incubation with CHO cells that served as a negative control. Stimulation of PBMCs with T-
CHO did not increase the expression of CD107a on the surface of CD8+ T cells compared to 
negative control condition following stimulation of PBMCs with CHO cells (0.96 fold) (Fig. 
5.1. A). Following incubation of PBMCs with CHO cells, Epinephrine (0.05 µM) decreased 
CD107a CD8+ TLs surface expression by 1.7 fold (Fig. 5.1. A-Fig. 5.2. A-C). However, 
neither epinephrine (0.05 µM) or salmeterol (5 µM) had an effect on the CD8+ T cells 
CD107a surface expression following stimulation of PBMCs with T-CHO (Fig. 5.1. A), 
although higher concentrations of salmeterol (50 µM) showed a significant 1.45 fold increase 
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(p=0.030 using paired sample t-test; p=0.022 using Wilcoxon signed rank test) following 6 
hours incubation. Taken together these data indicate that at low concentration, salmeterol had 
no effect on the surface expression of CD107a on CD8+ T cells but it significantly increased 
the expression of CD107 on the surface of CD8+ T cells at 50 µM concentration.  
Similarly to the CD8+ T cells, NK cells from freshly isolated PBMCs in this experiment, 
possessed a low expression of CD107a (~3.5%) that is moderately increased (1.4 fold) upon 
NK cell activation after incubation of PBMCs with T-CHO cells (Fig. 5.1. B).  Incubation of 
PBMCs with CHO cells increased the NK cells CD107a surface expression by 2 fold 
compared to that observed in freshly isolated PBMCs, however there was no increase on NK 
cells CD107a surface expression following stimulation of PBMCs with T-CHO cells 
compared to stimulation with CHO cells. As observed in the case of CD8+ T cells, 
epinephrine decreased the NK cells surface expression of CD107a (by 1.4 fold), following 
incubation with CHO cells, however neither epinephrine nor salmeterol had any effect on the 
NK cell surface expression of CD107a upon stimulation of PBMCs with T-CHO cells.  
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Figure 5.1. The effect of β2 agonists on the CD107a surface upregulation on CD8+ 
T (A) and NK cells (B) as a functional marker of CD8+ T and NK cell cytotoxicity. 
PBMCs were isolated from fresh blood and incubated with epinephrine (0.05 µM) or 
salmeterol (5-50 µM) for 30 minutes at 37°C in 5 % CO2.  Following incubation, 
PBMCs were washed, and mixed with CHO (served as negative control) or MICA*009 
transfected CHO (T-CHO) cells at an effector to target ratio of 1:1. To measure the 
percentage of CD107a upregulation on the surface of CD8+ T and NK cells, following 
mixing, cells were immediately labelled with CD107-a-PeCy5 antibody and incubated 
for 5 hours at 37°C in 5 % CO2.  Subsequently, PBMCs were stained for surface CD8+ 
T and NK markers and cells were analysed by flow cytometry to assess the percentage 
of CD107a upregulation. The data are the mean ± SEM from five independent 
experiments. Paired sample t test and/or Wilcoxon signed ranked test showed a 
significant effect of salmeterol (50 µM) on the cytotoxicity of the CD8+ T cells; 
*p<0.05 compared with positive control (PBMCs+T-CHO). Flow cytometry data of a 
representative sample (n=1) is shown in Fig. 5.2-5.5. 
                            Epi 0.05 µM   -             -           +             -           +             -            -                                                                            
-                             Sal. 5 µM        -             -           -              -           -             +            -          
                            Sal. 50 µM       -                -             -               -              -              -              +                              
 * 
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Figure 5.2. (A-D). Effect of epinephrine (0.05 µM) on CD107a expression on 
surface of CD8+ T and NK cells following treatment of PBMCs with or without 
epinephrine and subsequent incubation with CHO cells for 6 hours.  The CD107a-
CD8+ T and CD107a-NK cell surface expression were gated within the CD8+ T and 
NK population respectively. The percentage of CD107a-CD8+ T (A) and  CD107a-NK  
cells (B) in CHO stimulated PBMCs were compared to the percentage of CD107a-
CD8+ T (C) and CD107a-NK cells (D) in PBMCs treated with epinephrine and 
incubated with CHO cells. N=1. 
 
CD8+ T 
NK 
B) 
C) D) CD8+ T  NK 
A) NK 
 
 
173 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. (A-D). Effect of epinephrine (0.05 µM) on CD107a expression on 
surface of CD8+ T and NK cells following treatment of PBMCs with or without 
epinephrine and subsequent stimulation with T-CHO cells for 6 hours. The 
CD107a-CD8+ T and CD107a-NK cell surface expression were gated within the CD8+ 
T and NK population respectively. The percentage of CD107a-CD8+ T (A) and  
CD107a-NK  cells (B)  in T-CHO stimulated PBMCs were compared to the percentage 
of CD107a-CD8+ T (C) and CD107a-NK cells (D) in PBMCs treated with epinephrine 
and stimulated with T- CHO. N=1. 
  
C) D) 
CD8+ T 
NK 
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CD8+ T  
 
 
174 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. (A-D). Effect of salmeterol (5 µM) on CD107a expression on surface of 
CD8+ T and NK cells following treatment of PBMCs with or without salmeterol (5 
µM) and subsequent stimulation with T-CHO cells for 6 hours.  The CD107a-CD8+ 
T and CD107a-NK cell surface expression were gated within the CD8+ T and NK 
population respectively. The percentage of CD107a-CD8+ T (A) and  CD107a-NK  
cells (B)  in T-CHO stimulated PBMCs were compared to the percentage of CD107a-
CD8+ T (C) and CD107a-NK cells (D) in PBMCs treated with salmeterol (5 µM) and 
stimulated with T-CHO. N=1. 
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Figure 5.5. (A-D). Effect of salmeterol (50 µM) on CD107a expression on surface of 
CD8+ T and NK cells following treatment of PBMCs with or without salmeterol 
(50 µM) and subsequent stimulation with T-CHO cells for 6 hours.  The CD107a-
CD8+ T and CD107a-NK cell surface expression were gated within the CD8+ T and 
NK population respectively. The percentage of CD107a-CD8+ T (A) and  CD107a-NK  
cells (B) in T-CHO stimulated PBMCs were compared to the percentage of CD107a-
CD8+ T (C) and CD107a-NK cells (D) in PBMCs treated with salmeterol (50 µM) and 
stimulated with T-CHO. N=1. 
A) B) 
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5.2.2 The Effect of β2 Agonists on the Cytolytic Potential of CD8+ T and NK cells 
Following Exposure of PBMCs with T-CHO for Three Hours 
Since stimulation of PBMCs with T-CHO cells did not upregulate the expression of 
CD107a on the surface of CD8+ T and NK cells, there was the possibility that we had 
missed the time point at which the CD107a was optimally expressed. For this reason, in 
the next experiments, PBMCs were stimulated with T-CHO for a shorter period (3 
hours). We again investigated the effect of epinephrine (0.05 µM) and salmeterol (5-50 
µM) on the cytolytic potential of CD8+ T, and NK cells following stimulation of 
PBMCs with T-CHO.  
Surprisingly, our results indicated that expression of CD107a on the surface of CD8+ T 
cells was high (~11%) in unstimulated PBMCs alone (Fig. 5.6. A) and comparable 
(~10%) following incubation of PBMCs with T-CHO cells, which served as a positive 
control. Incubation of PBMCs with T-CHO increased CD8+ T cells surface expression 
of CD107a (1.16 fold) comparable to that of PBMCs incubation with CHO cells (Fig. 
5.6. A). Both epinephrine (0.05 µM) and salmeterol at concentration of 5 µM caused a 
significant decrease ((1.46 fold; p=0.010 using paired sample t-test; p=0.014 using 
Wilcoxon signed rank test) and (1.53 fold; p=0.049 using paired sample t-test; p=0.028 
using Wilcoxon signed rank test) respectively)), in the CD107a expression on CD8+ T 
cells incubated with T-CHO, thereby suggesting that epinephrine and salmeterol 
decrease the CD8+ T cell cytotoxicity (Fig. 5.6. A). Furthermore, at 50 µM salmeterol 
also decreased the expression of CD107a on CD8+ T cells incubated with T-CHO (by 
1.3 fold), although this change was not significant. 
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Fig. 5.6. B shows that, similarly to the CD8+ T cells, the CD107a expression on the 
surface of NK cells in unstimulated freshly isolated PBMCs (represented by None in the 
graph) was high (~13%) and incubation of PBMCs with CHO cells did not upregulate 
the CD107a expression. However, there was 1.4 fold increase on the CD107a NK cells 
surface expression following stimulation of PBMCs with T-CHO (Fig. 5.6. B).  
Fig. 5.6. B shows that the effect of salmeterol and epinephrine on the CD107a NK cell 
surface expression was comparable to that observed in CD8+ T cells. Both epinephrine 
(0.05 uM) and salmeterol at concentrations of 5 µM and 50 µM reduced the CD107a 
NK cell surface expression by an average of 2 fold (Fig. 5.6. B). Wilcoxon signed rank 
test only, showed that epinephrine (0.05 uM) and salmeterol (50 µM) significantly 
reduced the CD107a NK cell surface expression as in both cases p=0.014. 
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Figure 5.6.The effect of β2 agonists on the CD107a surface upregulation on CD8+ T 
(A) and NK cells (B) as a functional marker of CD8+ T and NK cell cytotoxicity. 
PBMCs were isolated from fresh blood and incubated with epinephrine (0.05 µM) or 
salmeterol (5-50 µM) for 30 minutes at 37°C in 5 % CO2. Following incubation, 
PBMCs were washed, and mixed with CHO (served as negative control) or T-CHO cells 
at an effector to target ratio of 1:1. To measure the percentage of CD107a upregulation 
on the surface of CD8+ T and NK cells, following mixing, cells were immediately 
labelled with CD107-a-PeCy5 antibody and incubated for 3 hours at 37°C in 5 % CO2.  
Subsequently, PBMCs were stained for surface CD8+ T and NK markers and cells were 
analysed by flow cytometry to assess the percentage of CD107a upregulation. 
Horizontal lines represent mean ± SEM from five independent experiments. Paired 
sample t test and/or Wilcoxon signed rank test showed a significant effect of 
epinephrine (0.05 µM) and salmeterol (5 µM) on the cytotoxicity of the CD8+T cells; 
*p<0.05 compared with positive (PBMCs+T-CHO) control. Flow cytometry data of a 
representative sample (n=1) is shown in Fig. 5.7-5.10. 
                             Epi 0.05 µM    -         -          +          -         +          -           -                                                                            
-                              Sal. 5µM          -         -          -           -         -          +           -          
                             Sal. 50µM        -         -          -           -         -           -           +                              
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Figure 5.7. (A-D). Effect of epinephrine on CD107a expression on surface of CD8+ 
T and NK cells following treatment of PBMCs with or without epinephrine (0.05 
µM) and subsequent incubation with CHO cells for 3 hours.  The CD107a-CD8+ T 
and CD107a-NK cell surface expression were gated within the CD8+ T and NK 
population respectively. The percentage of CD107a-CD8+ T (A) and  CD107a-NK  
cells (B) in CHO stimulated PBMCs were compared to the percentage of CD107a-
CD8+ T (C) and CD107a-NK cells (D) in PBMCs treated with epinephrine and 
incubation with CHO. N=1. 
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Figure 5.8. (A-D). Effect of epinephrine on CD107a expression on surface of CD8+ 
T and NK cells following treatment of PBMCs with or without epinephrine (0.05 
µM) and subsequent stimulation with T-CHO cells for 3 hours. The CD107a-CD8+ 
T and CD107a-NK cell surface expression were gated within the CD8+ T and NK 
population respectively. The percentage of CD107a-CD8+ T (A) and  CD107a-NK  
cells (B)  in T-CHO stimulated PBMCs were compared to the percentage of CD107a-
CD8+ T (C) and CD107a-NK cells (D) in PBMCs treated with epinephrine and 
stimulated with T-CHO. N=1. 
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Figure 5.9. (A-D). Effect of salmeterol on CD107a expression on surface of CD8+  
and NK cells following treatment of PBMCs with or without salmeterol (5 µM) and 
subsequent stimulation with T-CHO cells for 3 hours. The CD107a-CD8+ T and 
CD107a-NK cell surface expression were gated within the CD8+ T and NK population 
respectively. The percentage of CD107a-CD8+ T (A) and  CD107a-NK  cells (B)  in T-
CHO stimulated PBMCs were compared to the percentage of CD107a-CD8+ T (C) and 
CD107a-NK cells (D) in PBMCs treated with salmeterol and stimulated with T-CHO. 
N=1. 
 
 
A) B) 
C) D) 
CD8+T  
CD8+ T  
NK  
NK  
 
 
182 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. (A-D). Effect of salmeterol on CD107a expression on surface of CD8+ 
T and NK cells following treatment of PBMCs with or without salmeterol (50 µM) 
and subsequent stimulation with T-CHO cells for 3 hours.  The CD107a-CD8+ T 
and CD107a-NK cell surface expression were gated within the CD8+ T and NK 
population respectively. The percentage of CD107a-CD8+ T (A) and  CD107a-NK  
cells (B) in T-CHO stimulated PBMCs were compared to the percentage of CD107a-
CD8+ T (C) and CD107a-NK cells (D) in PBMCs treated with salmeterol and 
stimulated with T-CHO. N=1. 
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5.2.3 The Effect of β2 Agonists on the Cytolytic Potential of CD8+ T and NK Cells 
Following Exposure of PBMCs with Human Erythroleukemic Cell Line (K562) for 
Three Hours 
To confirm the effect of epinephrine (0.05 µM) and salmeterol (5-50 µM) on the cytolytic 
potential of CD8+ T and NK cells, PBMCs were stimulated for three hours with K562 cells  
that lacked the expression of MHC class I. Similarly to the experiments with T-CHO cells, 
PBMCs were stimulated with K652 cells at an effector to target ratio of 1:1, and following 
staining with CD107a antibody, PBMCs + K562 were incubated for three hours at 37°C in 5 
% CO2. Incubation of PBMCs with medium alone, served as a negative control. Following 
incubation, PBMCs were stained for surface CD8+ T and NK markers and cells were 
analysed by flow cytometry to assess the percentage of CD107a upregulation as a marker of 
activated CD8+ T and NK cells.   
The data show that expression of CD107a on the CD8+ T cell surface was low (~4%) in 
unstimulated PBMCs (Fig. 5.11. A) and this did not increase following stimulation of PBMCs 
with K562 cells. Furthermore, in contrast to the reducing effect of salmeterol on the CD107a 
CD8+ T cells surface expression following stimulation of PBMCs with T-CHO cells for 3 
hours, neither salmeterol nor epinephrine had any effect on the CD8+ T cells surface 
expression of CD107a upon stimulation with K562 cells (Fig. 5.11. A). 
As shown in Fig. 5.11. B, CD107a expression on the surface of NK cells in unstimulated 
freshly isolated PBMCs was 7.5% (Fig. 5.11. B). In contrast to CD8+ T cells CD107a 
expression, the expression of CD107a on the surface of NK cells increased significantly 
(p=0.024 using paired sample t-test; p=0.037 using Wilcoxon signed rank test) by 1.6 fold 
following stimulation of PBMCs with K562 cells. Both epinephrine (0.05 µM) and salmeterol 
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(5 µM and 50 µM) decreased the surface expression of CD107a on NK cells by an average of 
1.4 fold (Fig. 5.11. B). This decrease was significant at 50 uM concentration of salmeterol 
(p=0.030 using paired sample t-test; p=0.037 using Wilcoxon signed rank test). 
 Overall, the data suggest that catecholamines did not affect the CD8+ T cell cytotoxicity, as 
observed following stimulation of PBMCs with K562 cells for 3 hours. However they do 
decrease the cytotoxicity of NK cells.  
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Figure 5.11.The effect of β2 agonists on the CD107a surface upregulation on CD8+ 
T (A) and NK cells (B) as a functional marker of CD8+ T and NK cell cytotoxicity. 
PBMCs were isolated from fresh blood and incubated with epinephrine (0.05 µM) or 
salmeterol (5-50 µM) for 30 minutes at 37°C in 5 % CO2.  Following incubation, 
PBMCs were washed, and mixed with K562 cells at an effector to target ratio of 1:1. To 
measure the percentage of CD107a upregulation on the surface of CD8+ T and NK 
cells, following mixing, cells were immediately labelled with CD107-a-PeCy5 antibody 
and incubated for 3 hours at 37°C in 5 % CO2. Subsequently, PBMCs were stained for 
surface CD8+ T and NK markers and cells were analysed by flow cytometry to assess 
the percentage of CD107a upregulation. Data are mean ± SEM from six independent 
experiments. *p<0.05 by paired sample t-test and/or Wilcoxon signed rank test 
compared to untreated (None) control. *p<0.05 by paired sample t-test compared to 
positive (PBMCs+ K562) control.  Flow cytometry data representative of 1 example 
(n=1) is shown in Fig. 5.12-5.14. 
Epi 0.05 µM              -                  -                  +                 -                   -      - 
Sal 5 µM                    -                  -                   -                +                   -            
Sal 50 µM                  -                  -                   -                 -                   +               
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Figure 5.12. (A-D). Effect of epinephrine (0.05 µM) on CD107a expression on 
surface of CD8+ T and NK cells following treatment of PBMCs with or without 
epinephrine (0.05 uM) and subsequent stimulation with K562 cells for 3 hours.  
The CD107a-CD8+ T and CD107a-NK cell surface expression were gated within the 
CD8+ T and NK population respectively. The percentage of CD107a-CD8+ T (A) and  
CD107a-NK cells (B)  in K562 stimulated PBMCs were compared to the percentage of 
CD107a-CD8+ T (C) and CD107a-NK cells (D) in PBMCs treated with epinephrine and 
stimulated with K562 cells. (N=1). 
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Figure 5.13 (A-D). Effect of salmeterol on CD107a expression on surface of CD8+ 
T and NK cells following treatment of PBMCs with or without salmeterol (5 µM) 
and subsequent stimulation with K562 cells for 3 hours.  The CD107a-CD8+ T and 
CD107a-NK cell surface expression were gated within the CD8+ T and NK population 
respectively. The percentage of CD107a-CD8+ T (A) and CD107a-NK  cells (B)  in 
K562 stimulated PBMCs were compared to the percentage of CD107a-CD8+ T (C) and 
CD107a-NK cells (D) in PBMCs treated with salmeterol (5 µM) and stimulated with 
K562 cells. (N=1). 
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Figure 5.14 (A-D). Effect of salmeterol on CD107a expression on surface of CD8+ 
T and NK cells following treatment of PBMCs with or without salmeterol (50 µM) 
and subsequent stimulation with K562 cells for 3 hours.  The CD107a-CD8+ T and 
CD107a-NK cell surface expression were gated within the CD8+ T and NK population 
respectively. The percentage of CD107a-CD8+ T (A) and CD107a-NK cells (B) in 
K562 stimulated PBMCs were compared to the percentage of CD107a-CD8+ T (C) and 
CD107a-NK cells (D) in PBMCs treated with salmeterol and stimulated with K562 
cells. (N=1). 
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Figure 5.15 (A-C). 50 µM concentration of salmeterol is not toxic to population of 
lymphocytes. To confirm that 50 µM salmeterol was not toxic to PBMCs, PBMCs were 
treated with either no salmeterol (A); with 50 µM salmeterol (B) or with 200 uM 
salmeterol (C). The percentage of lymphocytes in untreated PBMCs (A) were compared 
with the percentage of lymphocytes in the 50 µM salmeterol treated PBMCs (B) and 
200 µM salmeterol treated PBMCs (C). 
PBMCs treated with 50 µM Sal PBMCs treated with 200 µM Sal B) C) 
Untreated PBMCs A) 
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5.3 Discussion 
CD8+ T cells and NK cells are cytotoxic lymphocytes potentially important for the 
immunosurveillance against cancer and virus infections. Both express a high number of βAR, 
particularly of epinephrine-sensitive β2 subtype (Anane et al., 2009; Anane et al., 2010; 
Benschop et al., 1996b; Campbell et al., 2009; Hellstrand et al., 1985) and for this reason, 
they are “stress sensitive” (Gan et al., 2002). The data presented in this chapter support the 
concept that catecholamines inhibit killing of target cells by NK cells and to a lesser extent by 
CD8+ T cells.  
Previous studies have demonstrated that activities of the central nervous system can have an 
impact on both T cells and NK cells function (Elenkov et al., 2000; Madden et al., 1995; 
Padgett and Glaser, 2003; Yang and Glaser, 2000). However, the precise effect of various 
psychological or physical stresses on the cytotoxicity of CD8+ T and NK cells remains 
controversial. Some studies link stress with an increased NK cell activity and others report 
inhibition of CD8+ T and NK cell cytotoxicity. In previous studies, CD8+ T and NK cell 
cytotoxicity was measured through the standard chromium release and flow-based killing 
assays (Betts et al., 2003; Brunner et al., 1968; Liu et al., 2002; Sheehy et al., 2001; Slezak 
and Horan, 1989). For example, Brunner et al. (1968) incubated the pre-labelled radioactive 
chromium (51CR) allogeneic target cells (tumour allograft) with sensitized lymphoid cells 
(from spleen cells of mice) and measured the target cell lysis by lymphoid cells by release of 
radioactive chromium (51CR) from pre-labelled target cells. More specifically, the cytotoxic 
effect of the sensitized lymphoid cells, was expressed by the difference in chromium release 
in the presence of the immune lymphoid cells (experimental release) and chromium release in 
the presence of normal lymphoid cells (spontaneous chromium release from labelled target 
cells alone) (Brunner et al., 1968; Chahroudi et al., 2003). Thus the release of chromium from 
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direct target cells represents a direct quantitative measurement of target cell lysis and the lytic 
activity of the effector cells in the lymphocytes population. However, the Cr release assay has 
a number of disadvantages.  For example, the high non-specific spontaneous release of 
chromium might influence the effector cell population. Moreover, there are problems with 
labelling certain cell types, the low sensitivity of the assay itself, as well as health risks 
problems associated with gamma irradiation (Chahroudi et al., 2003; Sheehy et al., 2001). For 
these reasons investigators began to research other methods that could eliminate problems 
associated with chromium assay release (Sheehy et al., 2001; Slezak and Horan, 1989).   
One of the recently used methods to determine the targeted cell lysis is the fluorometric 
assessment of T lymphocyte antigen specific lysis assay (FATAL) (Sheehy et al., 2001).  This 
is a non-radioactive assay which employs two fluorescent markers to recognise and evaluate 
the target population.  The fluorescent markers utilised are: PKH-26 (a lipid associated dye) 
and 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester (CFSE). The latter is an 
uncharged fluorescein derivative which diffuses through the (target) cell membrane and 
cleaves to produce a charged form (Sheehy et al., 2001).  Following incubation of CTL 
effectors  with the PKH-26þ labelled targets, the CFSE dye is instantaneously lost from the 
target cells as the membrane of the target cells is damaged (due to the lytic activity of CTLs).  
Thus this assay measures the target cell death by means of measuring the loss of CFSE in the 
PKH-26þ targets, following incubation with CTL effectors (Chahroudi et al., 2003). It is 
important to note that this assay is totally dependent on the measurement of target cell 
membrane destruction, which is a late-consequence of the apoptotic process, and thus in 
certain circumstances whereby the CTL-mediated apoptosis may not result in actual cell 
destruction until for a long period of time, even this assay can be semi-sensitive (Chahroudi et 
al., 2003). Furthermore, it is important to note that both of these assays do not examine the 
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CD8+ T and NK cells that mediate killing directly. Instead, their examination of the CD8+ T 
and NK effector cell function is an indirect interpretation of target cell death by means of 
measuring chromium release (in the chromium assay) or the CFSE release (in the FATAL 
assay) following incubation of target cells with these effector cells (Betts et al., 2003). For 
these reasons we decided to use the CD107a assay to measure target cell killing. 
In this chapter we have investigated the effect of epinephrine and salmeterol (β2 agonist), on 
the cytotoxic functions of both CD8+ T and NK cells in vitro, using a novel assay that directly 
measures degranulation, and thus functional capacity, of the responding CD8+ T and NK cells 
per se (Alter et al., 2004; Betts et al., 2003) but does not measure killing. Since CD107a has 
been shown a marker for the cytotoxicity of both CD8+ T and NK cells (as its expression was 
associated with the loss of perforin following antigen stimulation), we quantified the CD8+ T 
lymphocyte and NK cell activity by determining the percentage of CD107a expression on the 
surface of CD8+ T and NK cells.  
The results show that pre-treatment of PBMCs with epinephrine or salmeterol does not appear 
to have a general effect on CD8+ T, or the NK cell activity, following stimulation of PBMCs 
with T-CHO at six hours (although pre-treatment with 50 µM salmeterol significantly 
increased the CD107a CD8+T cell surface following stimulation of PBMCs with T-CHO). As 
CD107a  expression on the surface of CD8+ T and NK cells was only slightly upregulated 
following stimulation of untreated PBMCs with T-CHO for 6 hours comparable with 
unstimulated PBMCs alone, and did not upregulate in comparison with stimulation of PBMCs 
with CHO, this may have missed the appropriate time point. By comparison, CD107a 
expression on the surface of NK cells was increased following stimulation of untreated 
PBMCs with T-CHO for 3 hours compared with untreated PBMCs alone and PBMCs treated 
with CHO. This was not observed with CD8+ TLs. Thus, our data suggest that the optimal 
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expression of CD107a occurs following 3 hours of PBMCs’ stimulation with T-CHO, and that 
after 3 hours the CD107a surface expression, might start to degrade from the surface of both 
CD8+ T and NK cells. In contrast to the findings in our study, other studies by Betts et al. 
(2003) and Alter et al. (2004) assessed the percentage of CD107a expression following 
stimulation of PBMCs with K562 cell-line for six hours. The reason for these differences is 
not clear. Both epinephrine and salmeterol decreased the cytolytic potential of CD8+ T and 
NK cells following incubation of PBMCs with T-CHO target cells for three hours. The 
decrease on the cytolytic potential of CD8+ T cells was significant following incubation of 
PBMCs with epinephrine (0.05µM) (p=0.010) or salmeterol (5µM) (p=0.049). Our findings 
are in agreement with Shakhar et al. (1998) who demonstrated that administration of β2 
agonists in vivo, increased tumour cell metastasis rates through reduction of NK cell activity. 
In addition, Oya et al. (2000) have reported that the cytotoxicity induced by NK cells was 
suppressed following exposure of mice to stress, although other stress responses such as 
cortisol may have played a role. Direct in vivo administration of epinephrine in mice 
decreased the NK cytotoxicity in liver mononuclear cells (MNC) of mice (24 hours after 
injection of epinephrine) as determined following incubation of MNC against mouse 
lymphoma (YAC-1 cell line) (Oya et al., 2000). Furthermore, addition of epinephrine (10-6 M) 
directly to lymphocytes/target cell mixtures in vitro has been shown to inhibit the NK cell 
cytotoxicity (Hellstrand et al., 1985).  
In contrast to this and our data it has been demonstrated that pre-treatment of lymphocytes, 
with low concentrations of epinephrine (10-7-10-9 M) enhanced the NK cells activity via 
lymphocyte βAR (Hellstrand et al., 1985). Tonnesen et al. (1989) showed that excessive 
release of catecholamines in a case study in a patient undergoing surgical removal of 
phaeochromocytoma (a small vascular tumour of the adrenal medulla) induces NK cell 
 
 
194 
 
cytotoxicity in vivo. In line with this, administration of epinephrine in patients (n=30) 
undergoing partial laminectomy (a surgical procedure in which the posterior arch of a vertebra 
is removed) under general anaesthesia increased the NK cell activity (Nomoto et al., 1994). In 
this study, arterial blood samples were obtained from each patient after administration of 
premedication, after induction of anaesthesia, before administration of epinephrine and 15, 30, 
60 and 120 minutes following administration of an average dose of 2µg kg-1 epinephrine 
(comparable with the epinephrine concentration found during major surgery). After the taking 
of blood samples, the NK cell activity was measured in a chromium-51 release assay 
following incubation of mononuclear cells from patients for use as effector cells against pre-
labelled 51 CR K-562 target cells (Nomoto et al., 1993; Nomoto et al., 1994). This epinephrine 
-induced increase in NK cell activity might be direct, as result of epinephrine directly 
activating the lymphoid β2AR. It is also possible that this increased NK cell activity can be 
explained by an increase in the number of circulating NK cells following the release of 
epinephrine, as opposed to the increased NK cells activity at a single NK cell level per se 
(Nomoto et al., 1994). For example, Shephard and Rhind. (1994) reported an increased in NK 
cell numbers and total NK cell activity during an acute bout of exercise. However, since the 
total increase in NK cell number was bigger than the total increase in the NK cytolytic 
activity such result could possibly reflect a suppression of NK cell activity at a single NK cell 
level. Yet, the effect of exercise on NK cytolytic activity unfortunately remains conflicting; 
with other studies showing a decreased in NK cell activity following exercise (Peters et al., 
1994; Rincon et al., 1996). 
In the second part of this chapter we showed that β2 agonists did not affect the cytolytic 
potential of CD8+ T cells, but decreased the cytolytic potential of NK cells following 
stimulation of PBMCs with K562 cells for three hours. This decrease in NK cell cytotoxicity 
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was significant at higher concentration of salmeterol (50 uM) (p=0.030). Importantly, whereas 
K562 cells have proved to be very good stimulators of NK cell cytotoxicity (p=0.024), it did 
not stimulate the CD8+ T cell cytotoxicity compared to the negative control. Thus, the effect 
of epinephrine and salmeterol on the cytotoxic function of CD8+ TLs stimulated with K562 
cells remains ambiguous.  
 If we had to consider the variation between CD8+ T and NK cells cytotoxicity responses to 
epinephrine and salmeterol, we could explain such results by variations in density of 
sensitivity of lymphocytes β2AR. More specifically, since NK cells express higher levels of 
β2AR (Wahle et al., 2001), and are more sensitive to stress response compared to CD8+ TLs, 
the stimulation of more β2AR by salmeterol and epinephrine can have a greater effect on the 
transmembrane signalling process of catecholamines. Indeed, the heterogeneity of the CD8+ 
TLs population may have stronger effects on particular subsets expressing higher levels of 
β2AR on their surface (Dimitrov et al., 2010). Our intention was to use CMV-tetramer 
positive EM cells to address this but the use of a much smaller population of cells would have 
been difficult to measure. 
Another possible explanation for such results is that CD8+ TLs require antigen recognition for 
full activation compared to NK cells and that stimulation period of 3 hours may not be 
sufficient to see the response in CD8+ T cells following stimulation of PBMCs with K562 cell 
line. Indeed, Penack et al. (2005) showed that optimal expression of CD107a occurs between 
3 and 6 hours post stimulation. Moreover, the degranulation in central memory and effector 
memory CD8+ T cells specific for the lymphocytic choriomeningitis virus (LCMV) obtained 
from mice increased up to 4 hours after stimulation with glycoprotein peptides amino acids 
33-41 (gp33–41) (Wolint et al., 2004). Similar degranulation kinetics have been shown for 
human T cell responses whereby the maximum CD107a CD8+ T cell surface expression 
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occurred following 6 hours of stimulation with anti-CD3 when nearly every perforin 
expressing cell had degranulated (Betts et al., 2003). Recent work from Shafi et al. 2011 have 
also reported that interindividual variation in lymphocyte stress surveillance in response to 
MICA could be shown in NK cells but not for CD8+ T cells using the CD107a assay, and 
such findings may impact on the data presented in this thesis.  
It is important to address that initially, it was our intention to extend the experiment by using 
a β2-antagonist in combination with salmeterol (to treat PBMCs), in order to confirm that the 
reductive effect of salmeterol on PBMCs was due to the stimulation of β2-ARs. Unfortunately 
due to time constraints of the project, this was not achieved and remains to be investigated in 
the future studies. 
One of the issues to address in this study is that in contrast to epinephrine concentration (at 
nanomole (nM) levels), which is consistent with the physiological concentration of 
epinephrine in peripheral blood (Gan et al., 2002), the concentrations of salmeterol used in 
this study are in micromole levels (uM). However, since primary and secondary lymphoid 
tissues are innervated by adrenergic and noradrenergic nerve fibres, which are in direct 
(synaptic) contact with the immune competent cells, it is assumed that the concentrations 
around the nerve terminals or between synaptic gaps should be higher than the concentration 
of epinephrine in the peripheral blood (Gan et al., 2002). Importantly, such concentrations of 
salmeterol were not cytotoxic to immune cells as compared to untreated PBMCs (Fig. 5.15. 
A-C). In contrast, PBMCs treated with concentrations of salmeterol (200 µM) (too high to be 
used in this study) proved to be cytotoxic (Fig. 5.15. A-C). Thus, although this needs to be 
confirmed by future studies, it could be that the equivalent micromole level of catecholamine 
could be physiological, in the first site where epinephrine is released (Gan et al., 2002). 
Furthermore, the dilution of salmeterol with ethanol as in previous studies, does not for 
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certain eliminate the possibility that some effect of salmeterol could also be due to small 
effect of ethanol. However, the fact that the data presented in this chapter are in strong 
agreement with what has been observed by Seema et al., 2011, provides confidence that the 
effects are due to salmeterol alone and that they are real. Yet, to eliminate any discrepancies, it 
is important that the effect of ethanol on NK, and T cells, is investigated in future studies. 
In conclusion, our data suggest that epinephrine and salmeterol inhibit the cytotoxic function 
of CD8+ T and NK cells, following stimulation of PBMCs with T-CHO for 3 hours. 
Moreover, the effect of epinephrine and salmeterol tends to be dependent upon the specific 
stimulus used to stimulate PBMCs and the timing of stimulation. No effect of epinephrine and 
salmeterol was observed in CD8+ TLs, following stimulation of PBMCs with K562 cells, 
although both decreased the cytotoxic function of NK cells following stimulation of PBMCs 
with K562 cells. Exactly how epinephrine and salmeterol inhibit the CD8+ T and NK cells 
cytotoxicity, is not investigated in this study. However one possibility could involve the down 
regulation of the NKG2D receptor by epinephrine and salmeterol. This receptor is expressed 
on all NK cells and on activated CD8+ T cells and has been implicated as a key trigger for 
some forms of NK cell mediated cytotoxicity (Billadeau et al., 2003). It has been reported that 
decreased NKG2D expression correlates with an impaired function of CD8+ T and NK cells 
(Saito et al., 2011; Wiemann et al., 2005). The inhibition of CD8+ T lymphocytes and NK 
cells cytotoxicity is thought to have clinical relevance for the ability of NK cells to fight 
infectious diseases, to survey against cancer cells and prevent tumour metastasis. 
Understanding the mechanisms by which CD8+ T and NK cells’ cytotoxicity is inhibited by 
β2 agonists could help in finding treatment for cancer and other infectious diseases.
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CHAPTER 6 
GENERAL DISCUSSION 
6.1 The Effect of β2AR Stimulation on the IFN-γ Production from CD8+ and CD4+ T 
Cells 
The data collected in Chapter 3 extended earlier findings and provided evidence that β2-
agonists inhibit the IFN-γ producing CD4+ and CD8+ T cells (Betz and Fox, 1991; Sanders et 
al., 1997; Snijdewint et al., 1993; Van der Pouw-Kraan et al., 1992). The effect of salmeterol 
on the IFN-γ producing CD4+ and CD8+ T cells was a result of salmeterol having both, a 
direct and an indirect effect on T cells. In the latter case salmeterol would affect T cells 
indirectly by firstly affecting other immune cells expressing β2AR. Indeed, it has been 
reported that both, epinephrine and norepinephrine in vitro and in vivo may downregulate 
inflammatory responses particularly by targeting monocytes/macrophages and T lymphocytes, 
decreasing the excessive synthesis of pro-inflammatory cytokines (i.e. TNF-α, IL-1B, IL-12) 
and elevating levels of anti-inflammatory cytokines (i.e. IL-10, IL-1) via a βAR dependent 
mediated pathway (Hasko et al., 1998a; Hasko et al., 1998b; Platzer et al., 2000; van der Poll 
et al., 1996; Van der Poll and Lowry, 1997). In line with these findings, immunodepression 
after brain injury, neurosurgery, major injury and trauma is thought to be associated with high 
levels of IL-10, as result of catecholamine mediated IL-10 de novo synthesis by monocytes in 
vitro (Woiciechowsky et al., 1998). Furthermore, myocardial infarction is linked with a 
temporary attenuation of the ability of monocytes to present antigen and release TNF (Platzer 
et al., 2000; Shibata et al., 1997). Grebe et al. (2009) suggest that norepinephrine released 
from the sympathetic nervous system (SNS) during infection, interacts with β2AR on 
dendritic cells, and alters them to mediate their costimulatory capacity. It should be noted that 
the modulation of immunity can also be controlled by neurotransmitters other than 
epinephrine and norepinephrine. One of these neurotransmitters is dopamine, which exerts its 
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effects by binding to dopamine receptors (DARs) found on the surface of immune cells 
including T cells, DCs and other immune cells (Besser et al., 2005; Pacheco et al., 2009; 
Sarkar et al., 2006; Watanabe et al., 2006). There are two different types of DARs. Type 1 
DARs (D1 and D5) are coupled to Gas with subsequent production of cAMP, type 2 DARs 
(D2, D3, D4) are normally coupled to Gi and subsequent inhibition of cAMP synthesis 
(Pacheco et al., 2009; Sibley et al., 1993). Studies in human and murine T cells have shown 
that the stimulation of D1 and D5 receptors impairs the function of T cells as result of 
increasing levels of cAMP. Moreover, stimulation of D1 not only impairs the function of 
cytotoxic CD8+ T cells (Saha et al., 2001)  but also diminishes the function and 
differentiation of regulatory T cells (Tregs) that play crucial roles in the control of immune 
homeostasis (Cosentino et al., 2007; Pacheco et al., 2009). Immune deficiency and 
dysregulation is also observed in older individuals (Gouin et al., 2008; Graham et al., 2006; 
Segerstrom et al., 2008). Older individuals have a high proportion of “aged” late-
differentiated CD8+ T cells, which are thought to be the most stress and adrenergic sensitive. 
Indeed, immunosenescence is characterized by an accumulation of late differentiated CD8+ T 
cells, a reduced response to recall antigens, an increased sensitivity to infections, predicting 
thereby morbidity and mortality in old individuals (Caruso et al., 2009; Pawelec et al., 2006; 
Sansoni et al., 2008).  
It should be pointed out that the data collected in this thesis shows a large variation in 
response between different donors. One possibility to explain such variations could be linked 
to inter-individual differences in unstimulated baseline hormone level involved in shaping 
individual’s response. Elenkov et al. (2008) reported a link between adrenomedullary 
epinephrine and innate cytokine profiles in humans, demonstrating that the activity of 
cytokine-secreting cells toward relatively high or low pro-inflammatory cytokine profiles in 
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rodents and humans, is conditioned by relatively low or high baseline levels of epinephrine 
respectively. 
Questions remain on how exactly catecholamines induce immunosuppression of the immune 
system. Although not directly investigated in our study, salmeterol probably reduces the 
proportion of the IFN-γ CD4+ and CD8+ T cells via mechanisms that involve increased levels 
of cAMP. Consistent with this possibility, studies by Raskovalova et al. (2007) have reported 
that cytokine production and cytolytic activity of human anti-melanoma specific CD4+ T and 
CD8+ T lymphocytes can be inhibited by Adenosine-Protein kinase A type 1 signalling. 
Adenosine is an endogenous adenine nucleoside (that is formed from ATP, ADP, and AMP) 
and mediates inhibition of the IFN-γ, IL-2, TNF-α, IL-13, macrophage inflammatory protein 
(MIP-1α) production via a process that leads to stimulation of cAMP production. Stimulation 
of cAMP leads to the activation of protein kinase A (PKA) (Lokshin et al., 2006; 
Raskovalova et al., 2007). More specifically, it has been reported that the suppressive effects 
of adenosine in human T cells are thought to be a result of the activation of PKA I regulatory 
subunit of the PKA (Raskovalova et al., 2007). In line with these findings, other studies have 
reported that the inhibitory effect of cAMP elevating agents on the functional activity of the T 
cells is the result of cAMP-mediated release of the regulatory PKA I subunit and is 
independent of the catalytic activity from of the PKA  (Lokshin et al., 2006; Raskovalova et 
al., 2007). 
Exactly how cAMP affects the downstream molecular signalling of IFN-γ production is yet to 
be elucidated. One possible mechanism could involve inhibition of the transcription factor 
signal transducer and activation of transcription (STAT-1) activity. To be able to exert its 
antiviral and immunomodulatory activities, IFN-γ needs to bind to the type II interferon 
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receptor widely expressed in peripheral blood cells and bone marrow hematopoietic 
progenitors (Platanias and Fish, 1999). The binding of cytokines to their respective receptors 
results in receptor homo- or hetero-dimerization and triggering of intracellular signals such as 
the protein tyrosine kinases, Janus kinases (Jaks) (Ihle, 1995; Pelletier et al., 2003; Platanias 
and Fish, 1999; Schindler and Darnell, 1995). In the case of IFN-γ, Jak-1 and Jak-2 are the 
two tyrosine kinases associated with the interferon-γ receptor 1 and 2 (IFNGR1) and 
(IFNGR2). Upon activation, (as result of ligand binding) these tyrosine kinases are activated 
and phosphorylate IFNGR1 providing docking sites for STAT-1 transcriptional activator 
(Greenlund et al., 1994; Greenlund et al., 1995). The ability of STAT-1 to act as a substrate 
for Jak tyrosine kinase activity, allows it to undergo tyrosine phosphorylation. Following 
tyrosine phosphorylation, STAT-1 proteins form homodimers that translocate to the nucleus 
to regulate gene transcription by binding to the IFN-γ-activation site elements (GAS) in the 
IFN-γ regulated gene promoters. Ivashkiv et al. (1996) reported inhibition of STAT-1 
expression or DNA-binding activity of STAT-1 following treatment with cAMP and 
immediate activation with phytohaemagglutinin (PHA) and IFN-γ in human mononuclear T 
cell cultures and T cells. Other studies have reported that extracellular signal-regulated kinase 
(ERK) signalling is required for maximum IFN-γ synthesis (Baumgarth et al., 1997) and that 
cAMP inhibits the activation of ERK1/2 pathways in primary human T cells (Grader-Beck et 
al., 2003). Similarly, Treg activity is reported to be correlated with activation of the ERK1/2 
signalling pathway and dopafivee suppresses Treg activity by possible inhibition of ERK1/2 
(Kipnis et al., 2004). 
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Figure 6.1. Possible mechanism by which cAMP might inhibit IFN-γ production.  MKK1/2: mitogen activated protein kinase kinase 
1/2; ERK: extracellular signal-regulated kinase; JAK: janus kinase; Stat: signal transducer and activation of transcription; GAS: IFN-γ-
activation site elements; Y-P: tyrosine phosphorylation;             : regions of Stat proteins containing SH2-phosphotyrosine. 
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6.2 Influence of Catecholamines on Lymphocytes Mobilisation 
It has been repeatedly demonstrated that acute physical exercise and mental stress increases 
immune cells in peripheral circulation, with the biggest increases observed in NK cells and 
CD8+ cytotoxic T cells (Anane et al., 2009; Anane et al., 2010; Atanackovic et al., 2006; 
Benschop et al., 1996b; Campbell et al., 2009; Dhabhar et al., 1995; Dimitrov et al., 2010; 
Silberman et al., 2003; Simpson et al., 2007; Viswanathan and Dhabhar, 2005). It is known 
that the effects of catecholamines on immune cells are caused by binding to β2AR on PBMCs 
with high levels of β2AR expressed on NK cells and intermediate levels on T cells (Anane et 
al., 2009; Anane et al., 2010; Benschop et al., 1996b; Campbell et al., 2009). The increased 
number of immune cells could be a result of reduced margination of lymphocytes to 
endothelial cells lining venules. This means that cells which would normally be adhered to 
endothelial cells prior to migration into tissues are kept in general circulation (Carlson et al., 
1996). In Chapter 4, we demonstrated that catecholamines modulate lymphocyte migration by 
altering lymphocyte-endothelium cell adhesion in static and lymphocyte-VCAM-1 cell 
adhesion in flow assays. Adhering NK and CD8+ T cells lose adherence to monolayers of 
HMEC-1 or VCAM-1 coated on microslides after the addition of catecholamines. Although 
the changes were not statistically significant and only occurred at higher concentrations of 
salmeterol, these results show a consistent trend in that catecholamine-induced rolling and 
detachment of PBLs from endothelial cells or VCAM-1 coated microslide is mediated via 
β2AR. Since both NK cells as well as endothelial cells express β2AR, the effect of 
catecholamines on the adhesion of NK and CD8+ T cells supports their influx into blood 
under conditions of stress. 
Moreover, the effect of catecholamines is linked to a specific profile of adhesion molecule 
and chemokine receptor expression. Stress mobilized cells with low expression of CD62L and 
 
 
 
204 
 
high expression of integrin LFA-1 such as effector CD8+ T cells and CD16+CD56dim 
cytotoxic NK cells, have been reported. Effector memory cells are also characterised by their 
high expression of inflammatory chemokine receptors (such as CCR5, CXCR1, CXCR3, and 
CX3CR1). In addition, epinephrine selectively mobilized cells with cytotoxic effector 
function including CCR7-CD45RA+CD8+ effector T cells (EFF), CD4-CD8- γ/δ T cells, 
CD3+CD56+ NKT-like cells, CD16+CD56dim cytotoxic NK cells, and CD14dimCD16+ 
proinflammatory monocytes all of which are characterized by high expression of  CD11a and 
CX3CR1 (Dimitrov et al., 2010). It is thought that PBMCs are attached to endothelium 
through CD11a via CX3CR1-induced signalling, and that these cells are immediately released 
into the circulation on epinephrine binding. Furthermore, the same subset of cytotoxic effector 
cells showed preferential adhesion to activated endothelium in vitro and this effect was 
blocked by epinephrine (Dimitrov et al., 2010). Thus, it could be possible that epinephrine 
mediates its effect by inhibiting CX3CR1 -CD11a binding. Whether catecholamines alter the 
affinity of adhesion molecules interactions, or downregulate the expression of adhesion 
molecules on endothelial cells, such as VCAM-1, which is reported to mediate lymphocyte 
adherence to cytokine activated culture human endothelial cells (Carlos et al., 1990), should 
be the basis of future work.   
 
6.3 Effects of Catecholamines on the Cytotoxicity of NK Cells and CD8+ T Cells 
The effect of catecholamines on the CD8+ T and NK cell cytotoxicity was tested in two 
different cell lines. Firstly T-CHO which are non-human cells transfected to express human 
MICA, and K562 a human cell line, both of which lack the expression of MHC class I. In 
both assays salmeterol inhibited killing in a dose-dependent manner, although it was clear that 
NK cells were more sensitive to catecholamine treatment. It has previously been reported that 
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one of the ways by which NK and T cell lose their cytotoxicity is through the downregulation 
of NKG2D. The release of TGF-β by tumour cells downregulates expression of NKG2D in 
CD8+ T and NK cells and diminishes MICA and ULBP2 transcript expression and surface 
protein levels on malignant glioma cells (Gonzalez et al., 2008; Lee et al., 2004; Ljunggren, 
2008). In addition, it has also been hypothesised that the suppression of cytotoxic T cell 
activity by TGF-β is also partially mediated by upregulation of inhibitory receptors, such as 
CD94/NKG2A (Lee et al., 2004). However, NKG2D downregulation can not be the only 
factor to account for the lost cytotoxicity in CD8+ T and NK cells. Guerra et al. (2008) 
demonstrated that NKG2D deficient mice developed normally and were characterized by 
normal numbers and proportions of lymphocytes. Furthermore, the expression of other 
activation and inhibitory receptors was similar to that in wild mice and these NK cells 
retained NKG2D-independent cytotoxicity against different tumour lines and responsiveness 
to direct crosslinking of activation receptors other than NKG2D (Ljunggren, 2008). 
Importantly, in the K562 human cell line other elements of NK and CTL activation may be 
involved. For example, catecholamines could inhibit/reduce the expression of (TNF)-family 
death ligand on the surface of NK cells, suppressing their interaction and engagement with 
respective receptors on target cells and thus leading to inhibition of target cells apoptosis. 
Moreover, it has been reported that a CD40-dependent pathway is involved in the induction of 
cytotoxicity of T cells and on human NK cells (Carbone et al., 1997; Sartorius et al., 2003). 
CD40, known as a member of the tumour necrosis factor receptor (TNF-R) family, is a 
surface receptor expressed on APCs such as B cells, dendritic cells, and monocytes and has 
the capacity to initiate multifaceted activation signals in normal B cells and dendritic cells 
(DCs). CD40 interacts with CD40 ligand (CD40L) expressed on activated T cells and NK 
cells. It is this CD40L-CD40 interaction which is important for induction of T and NK cell 
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cytotoxicity (Carbone et al., 1997; Sartorius et al., 2003; Schoenberger et al., 1998). Thus, 
another possibility by which catecholamines could inhibit the cytotoxicity of T cells and NK 
cells would be by inhibiting this interaction i.e. through downregulation of CD40 receptor on 
the surface of APCs or downregulation of the CD40L in activated T or NK cells. Consistent 
with this suggestion, Tamura et al. (2004) reported that adrenergic agonists, norepinephrine, 
epinephrine, isoproterenol and the β2 agonists terbutaline and salbutamol inhibited the 
expression of CD40 on monocytes in mixed lymphocyte reaction (MLR). Interestingly 
ligation of the CD40 triggers a complex signalling cascade that also results in the 
phosphorylation of p38 mitogen activated protein kinase which in turn leads to downstream 
NFƘβ upregulation and cytokine production (Chakrabarti et al., 2007; Vogel et al., 2004). 
Thus as mentioned in Chapter 3 one of the ways by which salmeterol could inhibit 
cytotoxicity may also involve inhibition of p38,  a member of the MAP kinase subfamily that 
is involved in regulating cellular responses to inflammation. Furthermore, Whalen and 
Bankhurst. (1990) reported that forskolin (an agent that elevates cAMP levels) inhibited the 
cytotoxicity of human NK cells by inhibiting the effector cell-target cell (NK-K562 tumour 
cell-line conjugation). On the other hand, Loshkin et al. (2006), reported that inhibition of the 
cytotoxic activity of activated NK cells by adenosine was mediated via cAMP-dependent 
activation of the regulatory subunits of PKA I. Regardless of how the cytotoxic activity of 
CD8+ T and NK cells is inhibited, the reduction in the CD8+ T and NK cytotoxicity upon 
catecholamine release coincides with a rapid mobilisation of CD8+ T and NK cells into 
peripheral circulation possibly via multiple mechanisms including shear stress due to a 
substantial increase in peripheral blood flow or downregulation of adhesion molecule 
expression (Nagao et al., 2000; Timmons and Cieslak, 2008). It has also been reported that 
during prolonged exercise (more than 3 hours) the counts of circulating NK cells may return 
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to pre-exercise levels (Gannon et al., 1997; Timmons and Cieslak, 2008) or can even drop 
below pre-exercise levels possibly due to the entry of cells at sites of muscle damage (Gannon 
et al., 1997; Timmons and Cieslak, 2008).  
 
Since epinephrine mostly affect a specific subpopulation of CD8+ T and NK cells, the non-
significant effects of catecholamines in our study could be due to the use of whole populations 
(PBMCs) that might not show the whole picture and thus we would need to isolate CD8+ T 
and NK cells subsets separately to see significant results. In addition, it was planned to 
incorporate CMV-specific T cells to analyse migration (Chapter 4) and killing (Chapter 5), 
however due to the relatively small changes adding small numbers of these cells was regarded 
unrealistic. Furthermore, it should be pointed out that specific populations of memory T cells 
and NK cells would be affected more than others. Most cell researchers define memory cells 
on the basis of their surface markers and not on function. Indeed, it is just now being 
understood that memory cells may be a more diverse population that had been considered, and 
that only relatively few of these cells may have been aroused by exposure to foreign antigens 
(Younes et al., 2011). Recent studies have shown that in response to high lymphocytic 
choriomeningitis virus (LCMV) infection it were naive cells that responded more efficiently 
compared to the memory population (West et al., 2011). Interestingly, NK cells can also be 
divided in to distinct population based on licensing, i.e. whether or not they have been primed 
by HLA ligands (Yokoyama, 1998). Orr et al. (2010) reported that in normal mice, a 
significant number of phenotypically mature NK cells lack the inhibitory receptors to 
recognise self-MHC class I, rendering them hyporesponsive and unable to acutely reject MHC 
class I deficient bone marrow. Similarly, the expression of the inhibitory KIRs recognising 
self-HLA receptors on the surface of human NK cells render them more responsive than NK 
cells that lack self-reacting inhibitory KIRs following in vitro stimulation with antibodies 
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against their activating receptors (Orr et al., 2010). Since licensing is governed by HLA 
genotype of each individual, this could account for the differences in the studies of NK 
migration and killing (Chapter 5).  
The question raised by the current studies is what is the biological meaning of catecholamine-
induced immune changes? 
Upon epinephrine release during psychological stress, exercise, trauma, heat, shock, these 
subpopulations of cytotoxic effectors cells mobilise in circulation in order to build up an acute 
defense system to allow efficient surveillance of tissues and rapid accumulation at sites of 
injury and infection  (Bouchama et al., 1992; Dimitrov et al., 2010; Karandikar et al., 2002; 
Simpson et al., 2007). However, these catecholamines also appear to inhibit cytotoxic effector 
cells’ functional capabilities including IFN-γ production and cytotoxicity.  
At least two possible mechanisms are suggested by these data. One that the increase in the 
number of CD8+ T and NK cells in circulation could also be a compensatory mechanism to 
account for the loss of cytotoxicity in the effector cells and thus a reduced ability to defend 
against pathogens, or that as memory CD8+ T cells and NK cells are full of toxic effector 
molecules migration into the blood must be mediated by decreased function.  
6.4 Summary and Future Research 
The studies presented in this thesis provided evidence that catecholamines decrease the 
cytotoxic activity of CD8+ T and NK cells, and by inhibition of IFN-γ production on CD4+ T 
and CD8+ T cells. The highest inhibition was observed with the IFN-y producing CD8+ T 
cells, possibly as result of higher β2AR expressed on the surface of these cells. The effect of 
catecholamines on the CD8+ T and NK cell cytotoxicity was also assessed using a novel 
assay that directly measures degranulation, and thus functional capacity, of the responding 
CD8+ T and NK cells per se (Alter et al., 2004; Betts et al., 2003). We concluded that 
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catecholamines decrease the percentage of CD107a on both CD8+ T and NK cells possibly 
involving the downregulation of the NKG2D activating receptor expressed on effector CD8+ 
T and NK cells. It is also reported that the cytotoxic CD8+ T and NK cells lose their 
preference to adhere to VCAM-1 coated microslide or endothelial cells upon treatment with 
higher concentrations of salmeterol. While the studies presented in this thesis brought to light 
a number of new facts, several fundamental questions remain to be resolved. 
Future research activities should determine the cellular mechanisms of catecholamine induced 
lymphocytosis. Questions such as what are the exact migration pathways of the affected cell 
population after catecholamine administration; need to be analysed and answered. Emphasis 
should be given on specific adhesion molecules required for leukocytes-endothelial cell 
interaction as well as on the mechanisms of modification of adhesion such as the adhesion 
structure. The intracellular mechanism of how catecholamines modify the adhesion and signal 
transduction pathways of CD8+ T and NK cells need also to be elucidate. 
Another fundamental question is perhaps the clinical relevance of stressed induced leukocytes 
mobilisation. While, several suggestions have been proposed, these remain largely 
speculative. Furthermore, it would be interesting to know whether responses of the immune 
system to catecholamines could be used as predictors for future development of disease.   
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APPENDIX 
Table A.1: List of adhesion receptors involved in leukocytes recirculation and their 
counter ligands expressed on the endothelium. 
Lymphocytes Endothelium Function 
L-Selectin GlyCAM-1 
MadCAM-1 
tethering/rolling 
CLA, SL-1 E-selectin tethering/rolling 
PSGL-1 P-selectin tethering/rolling 
CD44 hyaluronate tethering/rolling 
αLβ2 (LFA-1) ICAM-1,-2, -3 firm adhesion 
α4β1 (VLA-4) VCAM-1 rolling and firm adhesion 
α4β7(LPAM-1), 
CD49d/CD- 
MadCAM, VCAM-1 rolling and firm adhesion 
CD31 CD31 transmigration 
   
GlyCAM: glycosylation cell adhesion molecule; MadCAM: mucosal addressin cell adhesion 
molecule; CLA: cutaneous leukocyte antigen; SL-1: E-selectin monospecific ligand; PSGL: 
P-selectin glycoprotein ligand; LFA: leukocyte functional associated antigen; ICAM: 
intracellular cell adhesion molecule; VLA: very late antigen 4 and VCAM: vascular cell 
adhesion molecule. Adapted from (Fabbri et al., 1999; Springer, 1995).  
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Table A.2: Properties of the selectin family 
Family 
molecule - 
Selectin 
Selectin 
Expression 
Ligand/counter 
receptor 
Ligand 
Expression 
Function 
E-selectin 
(CD62E) 
(ELAM-1) 
 
 
 
 
 
 
 
 
 
P-selectin 
(CD62P) 
(PADGEM, 
GMP140) 
 
 
 
 
 
 
 
L-selectin 
(CD62L) 
(LAM-1, 
MEL-14) 
Cytokine-
activated 
endothelium 
 
 
 
 
 
 
 
 
 
Weibel-palade 
bodies of 
endothelial cells 
 
α-granules of 
platelets 
 
 
 
 
 
All circulating 
leukocytes 
except effector 
and memory 
subgroups 
Sialylated 
fucosylated 
lactosamines 
(i.e., sLeX, 
sLeA), Lselectin, 
PSGL-1 
ESL-1  
CLA 
 
 
 
 
Sialylated 
fucosylated 
lactosamines 
(i.e., sLeX, 
sLeA), 
L-selectin 
PSGL-1 
CD24 
 
 
 
GlyCAM-1 
CD34  
PNAd, 
MAdCAM-1 
Leukocytes  
 
Skin 
homing T 
cell 
 
 
 
 
 
 
 
Leukocytes 
 
 
 
 
 
 
 
 
 
 
HEV in 
peripheral 
lymphoid 
tissues, 
mucosal 
and 
mesenteric 
tissues 
Leukocyte 
localization at 
sites of 
inflammation 
 
 
 
Leukocytes 
homing to the 
skin 
 
 
Leukocyte 
localization at 
sites of 
inflammation 
 
 
 
 
 
 
 
Homing of 
lymphocytes to 
lymphoid 
tissues (i.e. 
peripheral 
lymph nodes) 
 
Leukocyte 
localization at 
sites of 
inflammation 
PSGL-1: P-selectin glycolipid ligand-1; ESL-1: E-selectin ligand-1; CLA-cutaneous 
lymphocyte antigen; GlyCAM-1: glycosylation-dependent cell adhesion molecule-1; PNAd: 
peripheral node addressin; HEV: high endothelial venules and MAdCAM-1: mucosal 
addressin cell adhesion molecule-1.Adapted from (Butcher and Picker, 1996; Crockett-
Torabi, 1998; Mackay, 1993; Penberthy et al., 1997; Springer, 1995). 
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Table A.3: Properties of the integrin family 
Family 
molecule - 
Integrin 
Leukocyte 
Expression 
Ligand/counter 
receptor 
Ligand 
Distribution 
α1β1  (VLA-1) 
 
α2β1   (VLA-2) 
 
 
α4β1   (VLA-4) 
 
 
 
α5β1   (VLA-5) 
 
 
α6β1   (VLA-6) 
 
 
α9β1   (VLA-9) 
 
 
 
 
αLβ2 (LFA-1) 
 
 
 
 
αMβ2 (MAC-1) 
 
 
 
 
 
αVβ3 
 
α4β7 
 
 
Activated T cells 
 
PMN 
 
 
Lymphocytes 
 
 
 
PMN and 
memory T cells 
 
PMN and 
lymphocytes 
 
PMN 
 
 
 
 
All leukocytes 
 
 
 
 
PMN 
 
 
 
 
 
PMN 
 
Lymphocytes 
LN-1, CN 
 
LN-1, CN 
 
 
VCAM-1, 
MAdCAM-1, FN 
 
 
VCAM-1, FN 
 
 
LN 
 
 
VCAM-1, 
osteopontin 
 
 
 
ICAM-1, ICAM-2, 
ICAM-3, ICAM-4, 
ICAM-5, JAM-1 
 
 
ICAM-1, ICAM-2, 
ICAM-3,  iC3b, 
fibrinogen 
 
 
 
PECAM-1, FN 
 
MAdCAM-1, 
VCAM-1, 
fibronectin 
ECM 
 
ECM 
 
 
ECM, activated EC, 
HEV 
 
 
ECM, activated EC 
 
 
ECM 
 
 
Activated EC, ECM, 
bone marrow 
stroma, osteoblasts, 
mesothelium 
 
PMN, monocytes, 
macrophages, EC, 
platelets 
 
 
Lymphoid cells, 
monocytes, 
macrophages, 
neutrophils 
 
 
EC, PMN 
 
HEV, lamina 
propria, spleen 
VLA: very late antigen; MAC-1: macrophage-1 antigen; PMN: neutrophils; LN: laminin; CN: 
collagen; FN: fibronectin; MAdCAM-1: mucosal addressin cell adhesion molecule-1; 
VCAM: vascular cell adhesion molecule; ICAM: intercellular cell adhesion molecule; JAM: 
junctional adhesion molecule; PECAM-1: platelet-endothelial cell adhesion molecule-1; 
ECM: extracellular matrix; EC: endothelial cells and HEV: high endothelial venules. Adapted 
from (Larson and Springer, 1990; Luscinskas et al., 1995; Ostermann et al., 2002; Springer, 
1994, 1995). 
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Table A.4: CC- chemokines 
Chemokines Cellular 
Distribution 
Chemokine 
Receptor 
Function 
MCP-1, 3 and 4 
 
 
 
 
 
Eotaxin-1, 2, and 
3; RANTES; 
MCP-2, 3, and 4, 
HCC-2, MIP-5 
 
TARC, MDC-1 
 
 
 
 
 
RANTES,    
MIP-1α, MIP-1β, 
MCP-2 
 
 
 
SLC, ELC,    
MIP-3β 
 
 
 
 
 
I-309 
 
 
TECK 
M 
 
 
 
 
 
Eo, Bs, T 
 
 
 
 
T, P 
 
 
 
 
 
T, M, MØ, DC 
 
 
 
 
 
T, B, DC 
 
 
 
 
 
 
M, Thymus 
 
 
T, Thymus 
CCR2 
 
 
 
 
 
CCR3 
 
 
 
 
CCR4 
 
 
 
 
 
CCR5 
 
 
 
 
 
CCR7 
 
 
 
 
 
 
CCR8 
 
 
CCR9 
 
 
 
Migration of 
memory T cell in 
inflammation; 
Migration of (TH1) 
effector T cells;  
 
Migration of (TH2) 
effector T cells 
 
 
 
Migration of 
memory T cell to the 
skin; 
Migration of (TH2) 
effector T cells 
 
Migration of 
memory T cell in 
inflammation; 
Migration of (TH1) 
effector T cells 
 
Naïve T cell 
migration to lymph 
nodes and Peyers 
patches; Migration of 
memory T cells to 
lymphoid tissues 
 
Migration of (TH2) 
effector T cells 
 
Migration of 
memory T cells to 
the gut; Migration of 
pro-thymocytes to 
thymus 
MCP: macrophage chemoattractant protein; RANTES: regulated on activation of normal T 
cell expressed and secreted; HCC: human CC chemokine; MIP: macrophage inhibitory 
protein; TARCC: thymus and activation regulated chemokine; MDC: macrophage derived 
chemokine; TECK: thymus expressed chemokine; M: monocyte/macrophage; Eo: eosinophil: 
Bs: basophil; T: T-lymphocyte; P: platelet; MØ: macrophage; DC:dendritic cell; and  B: B-
lymphocyte.Adapted from (Moser and Loetscher, 2001; Moser et al., 2004; Murdoch and 
Finn, 2000; von Andrian and Mackay, 2000). 
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Table A.5: CXC- chemokines 
Chemokines Cellular 
Distribution 
Chemokine 
Receptor 
Function 
 
CXCR1 
 
 
 
 
CXCR2 
 
 
 
 
CXCR3 
 
 
 
 
CXCR4 
 
N, M, T, NK, Bs, 
Ms, En 
 
N, M, T, NK, MS, 
As, Nn, Ms, En 
 
 
 
Activated T,  
 
 
 
 
Myeloid, T, B, Ep, 
En, DC 
 
Interleukin-8,    
GCP-2 
                
Interleukin-8, Groα, 
Groβ, Groγ, Nap-2, 
GCP-2, ENA-78 
IP-10, Mig, I-TAC,  
 
 
 
 
 
SDF-1α 
 
 
 
 
 
 
Recruitment of 
neutrophils in 
inflammation 
 
 
Recruitment of 
neutrophils in 
inflammation 
 
Migration of (TH1)  
effector T cells 
 
 
 
 
Migration of naïve T 
cells within 
lymphoid tissues, 
Migration of (TH2) 
effector T cells, 
Neutrophils homing 
to bone marrow 
N: neutrophil; M: monocyte/macrophage; T: T-lymphocyte; NK: natural killer cell;  Bs: 
basophil; Ms: mast cell: En: endothelial cell; As: astrocyte; Nn: neurone; B: B-lymphocyte; 
Ep: epithelial cell; DC: dendritic cell; GCP-2: granulocyte chemotactic protein-2; GRO: 
melanoma growth-stimulating activity; Nap-2: neutrophil-activating peptide-2; ENA78: 
epithelial derived neutrophil attractant-78 amino acids; IP-10: interferon-γ-inducible protein 
10; Mig: monokine induced by interferon-γ; ITAC: interferon-inducible T cell alpha 1 and 
SDF-1α: stromal-derived factor 1α.        Adapted from (Engelhardt et al., 1998; Moser et al., 
2004; Murdoch and Finn, 2000; von Andrian and Mackay, 2000). 
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Table A.6:  Regulation of NK function by cytokines  
Cytokines                                                             Effect on NK cells 
 
IL-15 
 
IL-2 
 
IL-12 
 
 
IFNα/β 
 
IFN-γ 
 
 
IL-1α, β 
 
IGIF 
IL-10 
 
TGF-β 
 
NK cell proliferation and differentiation; 
major mediator of NK cell homeostasis. 
Potent immunoregulator of NK cells; 
supports survival and proliferation; may 
aid local immunity to infections by 
stabilizing or inducing cytotoxic granules. 
Stimulates the production of IFN-γ; 
induces cytotoxicity; induces expression of  
MIP-1α when in synergism with IL-15; 
stabilizes or induces cytotoxic granules, 
Induces NK cytotoxic activity and 
proliferation in vivo; inhibits IL-12 
production. 
Major source of NK cell production; 
eliminates viral infected cells, stressed 
cells and tumour cells; promotes 
maturation of DCs by NKs; facilitates Th1 
response; induces blastogenesis of NK 
cells in vivo. 
Stimulates production of IFN-γ. 
Induces cytotoxicity; stimulates IFN-γ 
production when in synergism with IL-12. 
Inhibits production of IL-12 and IFN-γ; 
downmodulates NK cell responses. 
Stops proliferation and cytotoxicity; 
Inhibits production of IFN-γ and IL-12. 
 
Adapted from (Anfossi et al., 2006; Biron et al., 1999; Colucci et al., 2003; Conigliaro et al., 
2011; Cooper et al., 2001; Lodoen and Lanier, 2006; Martin-Fontecha et al., 2004; Qian et al., 
2011; Suzui et al., 2004; Vivier et al., 2008) 
 
 
241 
 
Table A.7:  Regulation of NK function by chemokines 
Chemokines                                                        Effect on NK cells 
 
MIP1-α 
 
 
MIP-1β 
 
MCP-1, 2, 3 
 
RANTES 
 
 
Induces chemotaxis in culture and 
following in    vivo infection. 
 
Induces chemotaxis in culture. 
 
Induces chemotaxis in culture. 
 
Induces chemotaxis in culture. 
 
 
 
 
 (Ranson et al, 2003; Reviewed by Colucci et al, 2003; Reviewed by Cooper et al, 2001; 
Natuk and Welsh, 1987; Reviewed by Vivier et al, 2008; Biron et al, 1999; Mariel Levy et al, 
2010; Lodoen and Lanier, 2006; Conigliaro et al, 2011; Suzui et al, 2004; Yang et al, 2011; 
Loza et al, 2002, Anfossi et al 2006; Martin-Fontecha et al, 2004; Qian et al, 2011). 
